1
|
p4036+ p4361+ p4413+p4639+p4749+p5666+p28422 (PSA)
|
Protein
|
Humans
|
Upregulated in PCa: [p4036; p4361; p4413; p4639; p4749; p28422 (PSA)] Downregulated in PCa: [p5666]
|
Diagnostic
|
Prostate Cancer or Prostatic intraepithelial neoplasia Vs Benign Prostatic Hyperplasia or Normal Prostate
|
NA
|
Tissue
|
12171882
|
2
|
p4036
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
NA
|
Tissue
|
12171882
|
3
|
p4361
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
NA
|
Tissue
|
12171882
|
4
|
p4639
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
NA
|
Tissue
|
12171882
|
5
|
p4749
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
NA
|
Tissue
|
12171882
|
6
|
p4036+p4361
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
NA
|
Tissue
|
12171882
|
7
|
p4036+p4639
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
NA
|
Tissue
|
12171882
|
8
|
p4361+p4639
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
NA
|
Tissue
|
12171882
|
9
|
p4036+p4749
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
NA
|
Tissue
|
12171882
|
10
|
p4361+p4749
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
NA
|
Tissue
|
12171882
|
11
|
p4639+p4749
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
NA
|
Tissue
|
12171882
|
12
|
p4036+p4361+p4639
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
NA
|
Tissue
|
12171882
|
13
|
p4036+p4361+p4749
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
NA
|
Tissue
|
12171882
|
19
|
XLKD1/LYVE1
|
mRNA
|
Humans
|
Downregulated in PCa(atleast 2 fold)
|
Diagnostic
|
Normal Prostate vs Prostate Cancer
|
p<0.05
|
Tissue
|
14654526
|
20
|
CGA
|
mRNA
|
Humans
|
Downregulated in PCa(atleast 2 fold)
|
Diagnostic
|
Normal Prostate vs Prostate Cancer
|
p<0.05
|
Tissue
|
14654526
|
21
|
F2R/PAR1
|
mRNA
|
Humans
|
Downregulated in PCa(atleast 2 fold)
|
Diagnostic
|
Normal Prostate vs Prostate Cancer
|
p<0.05
|
Tissue
|
14654526
|
22
|
BCL-G
|
mRNA
|
Humans
|
Downregulated in PCa(atleast 2 fold)
|
Diagnostic
|
Normal Prostate vs Prostate Cancer
|
p<0.05
|
Tissue
|
14654526
|
29
|
Alpha Methylacyl Coenzyme A Racemase (AMACR)
|
mRNA
|
Humans
|
Upregulated in Localised Prostate Cancer (3.1 fold)
|
Diagnostic
|
Benign Prostate vs Localised Prostate Cancer
|
p<0.001
|
Tissue
|
11926890
|
30
|
Alpha Methylacyl Coenzyme A Racemase (AMACR)
|
mRNA
|
Humans
|
Upregulated in Metastatic Prostate Cancer (1.67 fold)
|
Diagnostic
|
Benign Prostate vs Metastatic Prostate Cancer
|
p<0.004
|
Tissue
|
11926890
|
31
|
Alpha Methylacyl Coenzyme A Racemase (AMACR)
|
Protein
|
Humans
|
Upregulated in Localised Prostate Cancer [Mean expression Value: (Localised Prostate Cancer: 3.2 vs Normal Prostate: 1.3)]
|
Diagnostic
|
Benign Prostate vs Localised Prostate Cancer
|
p<0.001
|
Tissue
|
11926890
|
32
|
Triiodothyronine
|
Protein
|
Humans
|
Upregulated in Prostate Cancer (Control: 72 ±24.9; PCa: 83.9 ±18.1)
|
Diagnostic
|
Normal Prostate vs Localised Prostate Cancer
|
p = 0.048
|
Serum
|
12441933
|
33
|
Triiodothyronine
|
Protein
|
Humans
|
Upregulated in Prostate Cancer (PCa: 83.9 ±18.1 vs BPH: 94.4±12.3)
|
Diagnostic
|
Localised Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p = 0.013
|
Serum
|
12441933
|
36
|
Lycopene
|
Protein
|
Humans
|
Downregulated (41% fold)
|
Diagnostic
|
Normal vs Cancerous
|
p<0.05
|
Serum
|
12497123
|
37
|
Lycopene
|
Protein
|
Humans
|
Downregulated (36% fold)
|
Diagnostic
|
Normal vs Cancerous
|
p<0.05
|
Tissue
|
12497123
|
43
|
Fatty Acid Synthase (FAS)
|
mRNA
|
Humans
|
Upregulated in PCa (3 fold) [Mean Value: PCa:158 Vs Normal: 53]
|
Diagnostic
|
Prostate Cancer Vs Normal Adjacent
|
p<0.00000029
|
Tissue
|
12939396
|
45
|
Fatty Acid Synthase (FAS) Intensity
|
Protein
|
Humans
|
Upregulated in Metastatic PCa (12 fold) [Mean Value: GS7 :149.2 Vs Metastatic: 1960.8]
|
Diagnostic
|
Prostate Cancer Vs Normal Adjacent
|
p<0.00000000857
|
Tissue
|
12939396
|
46
|
alpha-Methylacyl Coenzyme A Racemase (AMACR)
|
Protein
|
Humans
|
Upregulated in PCa (Prostate Cancer: 3.14 Vs Benign Prostate: 1.3)
|
Diagnostic
|
Benign Prostate Vs Localised Prostate Cancer
|
p<0.00001
|
Tissue
|
14982837
|
47
|
alpha-Methylacyl Coenzyme A Racemase (AMACR)
|
Protein
|
Humans
|
Upregulated in PCa (Prostate Cancer: 21.6 Vs Benign Prostate: 7.3)
|
Diagnostic
|
Benign Prostate Vs Localised Prostate Cancer
|
p<0.05
|
Tissue
|
14982837
|
50
|
GalNAc-T3+PSMA+Hepsin+DD3
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs benign prostatic hyperplasia
|
NA
|
Tissue
|
15609297
|
51
|
PSMA+Hepsin+DD3
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs benign prostatic hyperplasia
|
NA
|
Tissue
|
15609297
|
52
|
GalNAc-T3+Hepsin+DD3
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs benign prostatic hyperplasia
|
NA
|
Tissue
|
15609297
|
53
|
GalNAc-T3,+Hepsin+PSMA
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs benign prostatic hyperplasia
|
NA
|
Tissue
|
15609297
|
54
|
GalNAc-T3+PSMA+DD3
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs benign prostatic hyperplasia
|
NA
|
Tissue
|
15609297
|
55
|
DDR/PCA3
|
mRNA
|
Humans
|
Upregulated (140 fold)
|
Diagnostic
|
Prostate Cancer Vs benign prostatic hyperplasia
|
p=0.007
|
Tissue
|
15609297
|
56
|
HEPSIN
|
mRNA
|
Humans
|
Upregulated (21 fold)
|
Diagnostic
|
Prostate Cancer Vs benign prostatic hyperplasia
|
p=0.049
|
Tissue
|
15609297
|
57
|
PSMA
|
mRNA
|
Humans
|
Upregulated (66 fold)
|
Diagnostic
|
Prostate Cancer Vs benign prostatic hyperplasia
|
p=0.047
|
Tissue
|
15609297
|
58
|
GalNAc-T3
|
mRNA
|
Humans
|
Upregulated (4.6 fold)
|
Diagnostic
|
Prostate Cancer Vs benign prostatic hyperplasia
|
p=0.005
|
Tissue
|
15609297
|
59
|
Kallikrein 4 (KLK4/hK4)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Benign prostatic hyperplasia Vs Prostate Cancer
|
p<0.05
|
Tissue
|
16172196
|
64
|
Heat Shock Protein (Hsp70)
|
Protein
|
Mice
|
Upregulated in PCa (2 fold)
|
Diagnostic
|
Wild-type mouse dorsal prostate Vs Transgenic Adenocarcinoma Mouse Prostate (TRAMP) dorsal prostate
|
p<0.05
|
Tissue
|
15666362
|
65
|
Proliferating cell nuclear antigen (PCNA)
|
Protein
|
Mice
|
Upregulated in PCa (1.44 fold)
|
Diagnostic
|
Wild-type mouse dorsal prostate Vs Transgenic Adenocarcinoma Mouse Prostate (TRAMP) dorsal prostate
|
p<0.05
|
Tissue
|
15666362
|
66
|
Apoliprotein A-1
|
Protein
|
Mice
|
Upregulated in PCa (1.65 fold)
|
Diagnostic
|
Wild-type mouse dorsal prostate Vs Transgenic Adenocarcinoma Mouse Prostate (TRAMP) dorsal prostate
|
p<0.05
|
Tissue
|
15666362
|
67
|
Phospholipase C
|
Protein
|
Mice
|
Upregulated in PCa (1.95 fold)
|
Diagnostic
|
Wild-type mouse dorsal prostate Vs Transgenic Adenocarcinoma Mouse Prostate (TRAMP) dorsal prostate
|
p<0.05
|
Tissue
|
15666362
|
68
|
Glucose regulated protein (GRP 58)
|
Protein
|
Mice
|
Upregulatd in PCa (2 fold)
|
Diagnostic
|
Wild-type mouse dorsal prostate Vs Transgenic Adenocarcinoma Mouse Prostate (TRAMP) dorsal prostate
|
p<0.05
|
Tissue
|
15666362
|
69
|
Enolase 1, Non-Neuron
|
Protein
|
Mice
|
Upregulatd in PCa (1.8 fold)
|
Diagnostic
|
Wild-type mouse dorsal prostate Vs Transgenic Adenocarcinoma Mouse Prostate (TRAMP) dorsal prostate
|
p<0.05
|
Tissue
|
15666362
|
70
|
AMACR (o-methylacyl-CoA racemaÌŠse)
|
mRNA
|
Humans
|
Upregulated in PCa (3.3 fold)
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
71
|
SIM2 (single-minded homolog 2)
|
mRNA
|
Humans
|
Upregulated in PCa (2.3 fold)
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
72
|
EST (similar to cDS4 retroviral related polyprotein)
|
mRNA
|
Humans
|
Upregulated in PCa (2.3 fold)
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
73
|
EST (weakly similar to protease)
|
mRNA
|
Humans
|
Upregulated in PCa (2.2 fold)
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
74
|
TRGV9 (Tcell receptory variable 9)
|
mRNA
|
Humans
|
Upregulated in PCa (2.1 fold)
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
75
|
EST (AGR2 anterior gradient 2 homolog)
|
mRNA
|
Humans
|
Upregulated in PCa (2.1 fold)
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
76
|
HPN (hepsin transmembrane protease, serine I)
|
mRNA
|
Humans
|
Upregulated in PCa (2.0 fold)
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
77
|
KCNA5 (potassium voltage-gated channel),
|
mRNA
|
Humans
|
Upregulated in PCa (2.0 fold)
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
78
|
TM4SF13 (transmembrane 4 superfamily member 13)
|
mRNA
|
Humans
|
Upregulated in PCa (2.0 fold)
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
79
|
SOX9 (SRY sex determining region Y-box 9)
|
mRNA
|
Humans
|
Upregulated in PCa (2.0 fold)
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
80
|
SOX4 (SRY sex determining region Y-box 4)
|
mRNA
|
Humans
|
Upregulated in PCa (1.9 fold)
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
81
|
SLC26A2 (solute carrier family 26 member 2)
|
mRNA
|
Humans
|
Upregulated in PCa (1.9 fold)
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
82
|
SYNP02 (synaptopodin)
|
mRNA
|
Humans
|
Downregulated in PCa (4.2 fold )
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
83
|
SLC18A2 (solute carrier family 18 member 2)
|
mRNA
|
Humans
|
Downregulated in PCa (3.0 fold )
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
84
|
CALD1 (caldesmon 1)
|
mRNA
|
Humans
|
Downregulated in PCa (2.8 fold )
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
85
|
MRE11A (meiotic recombination 11 homologue A)
|
mRNA
|
Humans
|
Downregulated in PCa (2.8 fold )
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
86
|
KRT15 (keratin 15)
|
mRNA
|
Humans
|
Downregulated in PCa (2.7 fold )
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
87
|
ACTG2 (actin gamma 2 smooth muscle, enteric)
|
mRNA
|
Humans
|
Downregulated in PCa (2.5 fold)
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
88
|
DSIPI (delta sleep inducing peptide, immunoreactor)
|
mRNA
|
Humans
|
Downregulated in PCa (2.5 fold)
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
89
|
SLC18A2 (solute carrier family 18 member 2)
|
mRNA
|
Humans
|
Downregulated in PCa (2.5 fold )
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
90
|
MME [membrane metallo-endopeptidase]
|
mRNA
|
Humans
|
Downregulated in PCa (2.4 fold )
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
91
|
KRT17 (similar to keratin 17)
|
mRNA
|
Humans
|
Downregulated in PCa (2.4 fold )
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
92
|
LY96 (lymphocyte antigen 96)
|
mRNA
|
Humans
|
Downregulated in PCa (2.4 fold )
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
93
|
SYNP02 (synaptopodin)
|
mRNA
|
Humans
|
Downregulated in PCa (2.4 fold )
|
Diagnostic
|
Malignant Vs Benign Tissue
|
p<0.05
|
Tissue
|
15645116
|
94
|
E-cadherin
|
Protein
|
Humans
|
Upregulated in Localised PCa (BPH: 7.26; Localised PCa: 9.46)
|
Diagnostic
|
Benign Prostatic Hyperplasia (BPH) Vs Localised PCa
|
p=0.011
|
Serum
|
15870707
|
97
|
Thymosin b15 (Tb15)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Untreated Prostate Cancer Vs Controls
|
p<0.001
|
Urine
|
15666387
|
98
|
Thymosin b15 (Tb15)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
ADT treated Prostate Cancer Vs Controls
|
p=0.001
|
Urine
|
15666387
|
99
|
Ghrelin
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Benign Prostatic Hypertrophy Vs Prostate Cancer
|
p<0.05
|
Tissue
|
16322288
|
100
|
Preproghrelin
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Benign Prostatic Hypertrophy Vs Prostate Cancer
|
p<0.05
|
Tissue
|
16322288
|
101
|
bromo domain containing protein 2 (BRD2),+eukaryotic translation initiation factor 4 gamma 1 (EIF4G1)+ribosomal protein L22 (RPL22)+ribosomal protein L13a (RPL13a)+17 other autoantibodies
|
mRNA
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p<0.05
|
Serum
|
16177248
|
107
|
18 proteins with Mass (Da) M3700 + M3904 + M3978 + M4300 + M5085 + M5923 + M6250 + M6569+ M6652 + M7121 + M7782 +M7850 + M7991 + M95031+ M5265 +M15878 + M16003 + M16068
|
Protein
|
Humans
|
Downregulated in PCa: [M3700 + M3904 + M3978 + M4300 + M5085 + M5923 + M6250 + M6569+ M6652 + M7121 + M7782 +M7850 + M7991 + M95031Upregulated in PCa: [M5265 +M15878 + M16003 + M16068]
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p<0.01
|
Serum
|
16372118
|
108
|
FPA
|
Protein
|
Humans
|
Downregulated (0.58 fold)
|
Diagnostic
|
Normal vs Prostate Cancer
|
p=0.000108
|
Serum
|
16395409
|
109
|
Fibrogen alpha
|
Protein
|
Humans
|
Downregulated (0.33 fold)
|
Diagnostic
|
Normal vs Prostate Cancer
|
p=0.00000000000763
|
Serum
|
16395409
|
110
|
inter-α-trypsin inhibitor heavy chain H4 (ITIH4)
|
Protein
|
Humans
|
Upregulated (121 fold)
|
Diagnostic
|
Normal vs Prostate Cancer
|
p=0.0000108
|
Serum
|
16395409
|
111
|
Clusterin Beta
|
Protein
|
Humans
|
Upregulated (251 fold)
|
Diagnostic
|
Normal vs Prostate Cancer
|
p=0.00000000481
|
Serum
|
16395409
|
112
|
factor X111a
|
Protein
|
Humans
|
Upregulated (2.84 fold)
|
Diagnostic
|
Normal vs Prostate Cancer
|
p=0.0000000143
|
Serum
|
16395409
|
113
|
PCaP Polypeptide Panel (PCAPP)
|
Protein
|
Humans
|
Differentially Expressed in Prostate Cancer
|
Diagnostic
|
Prostate Cancer Vs Healthy Controls
|
p<0.05
|
Urine
|
19759844
|
116
|
PP2A
|
mRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Benign Prostatic Hyperplasia (BPH) vs Prostate Cancer (PCa)
|
p=0.0073
|
Tissue
|
17977648
|
123
|
Neuropeptide Y (NPY)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Benign Prostate Vs Prostate Cancer
|
p<0.0001
|
Tissue
|
16614113
|
124
|
Neuropeptide Y (NPY)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
HGPIN vs PCa
|
p=0.0108
|
Tissue
|
16614113
|
128
|
Macrophage Inhibitory Cytokine-1 (MIC-1)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Benign Prostate Vs Prostate Cancer
|
p<0.0001
|
Tissue
|
16614113
|
129
|
Macrophage Inhibitory Cytokine-1 (MIC-1)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
HGPIN vs PCa
|
p<0.0001
|
Tissue
|
16614113
|
131
|
PTGS2
|
Other
|
Humans
|
Upregulated in PCa [(Mean Values) PCa: 85.95; BPH: 25.26]
|
Diagnostic
|
Benign Prostatic Hyperplasia (BPH) vs Prostate Cancer (PCa)
|
P<0.0001
|
Serum
|
17764114
|
132
|
PTGS2
|
Other
|
Humans
|
Upregulated in PCa [(Mean Values) PCa: 85.95; Healthy Individuals: 10.88]
|
Diagnostic
|
Prostate Cancer (PCa) Vs Healthy Individuals
|
P<0.0001
|
Serum
|
17764114
|
136
|
Fusion Status of (TMPRSS2-ERG)+PCA3
|
mRNA
|
Humans
|
Fused/ Upregulated in PCa
|
Diagnostic
|
Positive Vs Negative Biopsies for PCa
|
NA
|
Urine
|
17785564
|
137
|
β-2-Microglobulin
|
Protein
|
Humans
|
Upregulated in Metastatic Prostate Cancer (Controls: 1.9± 0.6; Metastatic Castrate PCa: 2.7 ± 1.1)
|
Diagnostic
|
Controls Vs Metastatic Castrate Prostate Cancer
|
p<0.05
|
Serum
|
17404077
|
138
|
CCNE2+CDC6+FBP1+HOXC6+MKI67+MYBL2+PTTG1+DTL+UBE2C+WNT5A+ALCAM+AZGP1+CCK+MYLK+PPAP2B+PROK1
|
mRNA
|
Humans
|
Upregulated GEX score in PCa Patients (PCa: 7.38 ± 0.35 Vs Non Cancer: 7.2±0.16)
|
Diagnostic
|
No Cancer Vs Prostate Cancer
|
p=0.0013
|
Tissue
|
17459658
|
140
|
PARP
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Benign Vs Cancerous Tissue in Native Japanese
|
p=0.02
|
Tissue
|
15491717
|
141
|
BCL-2
|
Protein
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Benign Vs Cancerous Tissue in Native Japanese
|
p=0.01
|
Tissue
|
15491717
|
142
|
EGFR
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Benign Vs Cancerous Tissue in Native Japanese
|
p=0.01
|
Tissue
|
15491717
|
143
|
BAD
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Benign Vs Cancerous Tissue in Native Japanese
|
p=0.01
|
Tissue
|
15491717
|
144
|
H3
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Benign Vs Cancerous Tissue in Native Japanese
|
p=0.01
|
Tissue
|
15491717
|
145
|
Lipoxygenase
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Benign Vs Cancerous Tissue in Native Japanese
|
p=0.01
|
Tissue
|
15491717
|
146
|
p27
|
Protein
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Benign Vs Cancerous Tissue in Native Japanese
|
p=0.01
|
Tissue
|
15491717
|
147
|
Racemase 3
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Benign Vs Cancerous Tissue in Native Japanese
|
p=0.01
|
Tissue
|
15491717
|
148
|
Ki-67
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Benign Vs Cancerous Tissue in Native Japanese
|
p=0.01
|
Tissue
|
15491717
|
149
|
PARP
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Benign Vs Cancerous Tissue in Japanese American
|
p=0.01
|
Tissue
|
15491717
|
150
|
BCL-2
|
Protein
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Benign Vs Cancerous Tissue in Japanese American
|
p=0.01
|
Tissue
|
15491717
|
151
|
EGFR
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Benign Vs Cancerous Tissue in Japanese American
|
p=0.01
|
Tissue
|
15491717
|
152
|
BAD
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Benign Vs Cancerous Tissue in Japanese American
|
p=0.01
|
Tissue
|
15491717
|
153
|
Lipoxygenase
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Benign Vs Cancerous Tissue in Japanese American
|
p=0.01
|
Tissue
|
15491717
|
154
|
p27
|
Protein
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Benign Vs Cancerous Tissue in Japanese American
|
p=0.01
|
Tissue
|
15491717
|
155
|
Racemase 3
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Benign Vs Cancerous Tissue in Japanese American
|
p=0.01
|
Tissue
|
15491717
|
156
|
Ki-67
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Benign Vs Cancerous Tissue in Japanese American
|
p=0.01
|
Tissue
|
15491717
|
157
|
Lipoxygenase
|
Protein
|
Humans
|
Downregulated (in JA compared to NJ)
|
Diagnostic
|
Cancerous Tissue in Japanese American (JA) Vs Native Japanese (NJ)
|
p=0.01
|
Tissue
|
15491717
|
158
|
Caspase-3
|
Protein
|
Humans
|
Downregulated (in JA compared to NJ)
|
Diagnostic
|
Cancerous Tissue in Japanese American (JA) Vs Native Japanese (NJ)
|
p=0.01
|
Tissue
|
15491717
|
159
|
AMACR (α-methylacyl-CoA racemåse) [AMACR 2094, 2097, 2098, 2095]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
2.12E-08
|
Tissue
|
16618727
|
160
|
PYCR1 (Pyroline 5 - Carboxylate reductase1)
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
8.58E-10
|
Tissue
|
16618727
|
161
|
MYO6 (Myosin VI) [MYO6-0041]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
1.15E-08
|
Tissue
|
16618727
|
162
|
SMPDL3B (Sphingomyelinase like phosphodiesterase 3B) [SMPDL3B 2030]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
2.32E-08
|
Tissue
|
16618727
|
163
|
NOX4 (NADPH oxidase 4) [NOX4 1355]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
1.57E-07
|
Tissue
|
16618727
|
164
|
FASN (Fatty Acid Synthase) [FASN 1432,1433, 1435]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
4.78E-05
|
Tissue
|
16618727
|
165
|
CACNA1D (Voltage-dep. L-type Calcium Channel Alpha 1D Subunit) [CACNA1D 2040, 2039]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
3.32E-06
|
Tissue
|
16618727
|
166
|
FBP1 (Fructose 1,6 Bisphosphatase 1) [FBP1 0807]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
1.46E-07
|
Tissue
|
16618727
|
167
|
IMPDH2 (Inosine-5′-monophosphate dehydrogenase 2) [IMPDH2 0144,0145]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
1.68E-05
|
Tissue
|
16618727
|
168
|
ABCC4 (Multidrug Resistance-Associated Protein 4) [ABCD4 2013]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
1.09E-05
|
Tissue
|
16618727
|
169
|
GART (Phosphoribosylglycinamide Formyltransferase) [GART 0310, 0307]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
1.57E-05
|
Tissue
|
16618727
|
170
|
CLN3 (ceroid lipofuscinosis, neuronal 3, juvenile) [CLN3 1132]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
1.50E-05
|
Tissue
|
16618727
|
171
|
DHPS (Deoxyhypusine Synthase) [DHPS 2028]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
1.68E-05
|
Tissue
|
16618727
|
172
|
BIRC5 (Baculoviral IAP Repeat Containing 5 (survivin)) [BIRC5 0847]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
1.73E-05
|
Tissue
|
16618727
|
173
|
REPS2 (RALBP1 Associated Eps Domain Containing 2) [REPS2 0732, 0733]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
2.18E-05
|
Tissue
|
16618727
|
174
|
RPS2 (40S Ribosomal Protein S2) [RPS2-0809]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.051607
|
Tissue
|
16618727
|
175
|
TMSNB (Thymosin, Beta, identified in neuroblastoma cells) [TMSNB 0227]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
2.34E-05
|
Tissue
|
16618727
|
176
|
EPB41 (Erythrocyte Membrane Protein Band 4.1) [EPB41 1096,1092]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
2.69E-05
|
Tissue
|
16618727
|
177
|
GCNT1 (Core 2 Beta1,6 N-Acetylglucosaminyltransferase-I) [GCNT1 0981, 0982,0985]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
8.15E-05
|
Tissue
|
16618727
|
178
|
LYPLA1 (Lysophospholipase 1) [LYPLA1 0862, 0860]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.006744
|
Tissue
|
16618727
|
179
|
RET1 (Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret) [RET1 0252 0250]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.008659
|
Tissue
|
16618727
|
180
|
HSPD1 (Heat Shock 60kDa Protein 1 (Chaperonin)) [HSPD1 0152, 0154]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.033554
|
Tissue
|
16618727
|
181
|
MAPT (Microtubule Associated Protein Tau) [MAPT 1060]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.000885
|
Tissue
|
16618727
|
182
|
C7ORF24 (Chromosome 7 Open Reading Frame 24) [C7ORF24 0.001028]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.001028
|
Tissue
|
16618727
|
183
|
ERBB3 (Erb-B2 Receptor Tyrosine Kinase 3) [ERBB3 1431]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.001238
|
Tissue
|
16618727
|
184
|
PLA2G2A (Phospholipase A2 Group IIA) [PLA2G2A 1380]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.001569
|
Tissue
|
16618727
|
185
|
NME1 (Nucleoside Diphosphate Kinase A) [NME1 0827]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.001945
|
Tissue
|
16618727
|
186
|
CDK7 (Cyclin Dependent Kinase 7) [CDK7 0899]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.002319
|
Tissue
|
16618727
|
187
|
MMP9 (Matrix Metallopeptidase 9) [MMP9 1185]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.00262
|
Tissue
|
16618727
|
188
|
BGN (Biglycan) [BGN 1274]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.002956
|
Tissue
|
16618727
|
189
|
PPIB (Peptidylprolyl Isomerase B (Cyclophilin B)) [PPIB 0969]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.006963
|
Tissue
|
16618727
|
190
|
IQGAP2 (IQ Motif Containing GTPase Activating Protein 2) [IQGAP2 0234]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.010253
|
Tissue
|
16618727
|
191
|
DKFZP564B167 (DKFZP564B167 Protein) [DKFZP564B167 0717]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.015526
|
Tissue
|
16618727
|
192
|
TMEPAI (Transmembrane Prostate Androgen- Induced Protein) [TMEPAI 2074]
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.023696
|
Tissue
|
16618727
|
193
|
STAC (SH3 And Cysteine Rich Domain) [STAC 1045, 1044, 1047]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
4.42E-07
|
Tissue
|
16618727
|
194
|
FGFR2 (Fibroblast Growth Factor Receptor 2) [FGFR2 0101,0095,0100,0106, 0107, 0097]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
1.42E-07
|
Tissue
|
16618727
|
195
|
CDC42BPA (CDC42 Binding Protein Kinase Alpha) [CDC42BPA 1051]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
1.56E-08
|
Tissue
|
16618727
|
196
|
KRT15 (keratin 15) [KRT15 1335, 1333, 1334,1341]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
1.60E-06
|
Tissue
|
16618727
|
197
|
TRIM29 (Tripartite Motif Containing 29) [TRIM29 1353, 1348, 1346]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
4.38E-06
|
Tissue
|
16618727
|
198
|
CES1 (Carboxylesterase ) [CES1 0942, 0937]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
1.43E-05
|
Tissue
|
16618727
|
199
|
CLU (Clusterin) [CLU 0196, 0192, 0191]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.000272
|
Tissue
|
16618727
|
200
|
ALDH1A2 (Aldehyde Dehydrogenase 1A2) [ALDH1A2 0004,0001, 0006]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.000266
|
Tissue
|
16618727
|
201
|
DRR1 (Collagen and Wnt5a regulated receptor tyrosin kinase) [DRR1 - 0753]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
1.88E-07
|
Tissue
|
16618727
|
202
|
ROBO1 (Roundabout, Axon Guidance Receptor, Homolog 1) [ROBO1 1419]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
2.26E-07
|
Tissue
|
16618727
|
203
|
LTBP4 (Latent TFG Beta Binding Protein 4) [LTBP4 0752, 0747, 0742, 1519, 1518, 0745, 0748, 0746]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.002361
|
Tissue
|
16618727
|
204
|
PGR (Progesterone Receptor) [PGR 1161, 1162]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
3.77E-06
|
Tissue
|
16618727
|
205
|
EDNRB (Endothelin Receptor Type B) [EDNRB 1187]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
1.88E-06
|
Tissue
|
16618727
|
206
|
ANGPT1 (Angiopoietin 1) [ANGPT1 1032, 1031]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
3.72E-05
|
Tissue
|
16618727
|
207
|
IGF1 (Insulin like Growth Factor 1 Somatomedin C) [IGF1 0025]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
3.77E-06
|
Tissue
|
16618727
|
208
|
COL6A2 (Collagen, Type VI, Alpha 2) [COL6A2 1489]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
8.16E-06
|
Tissue
|
16618727
|
209
|
PTGDS (Prostaglandin D2 Synthase 21kDa) [PTGDS 0787]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
1.09E-05
|
Tissue
|
16618727
|
210
|
ANGPTL2 (Angiopoietin-related Protein 2) [ANGPTL2 0950]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
1.20E-05
|
Tissue
|
16618727
|
211
|
VCL (Vinculin) [VCL 1534, 0933, 0936]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.011744
|
Tissue
|
16618727
|
212
|
GSTP1 (Glutathione S-transferase P) [GSTP1 0927, 0923]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.030854
|
Tissue
|
16618727
|
213
|
SAT (Spermidine/Spermine N1-acetyltransferase) [SAT 0840, 0842]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.052888
|
Tissue
|
16618727
|
214
|
TGFB2 (Transforming Growth Factor, Beta 2) [TGFB2 0085]
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Cancerous Tissue Vs Normal Tissue
|
0.095398
|
Tissue
|
16618727
|
220
|
VEGF (Vascular Endothelial Growth Factor)
|
Protein
|
Humans
|
Downregulated in Prostate Cancer
|
Diagnostic
|
Cancerous Vs Normal Patients
|
p=0.01
|
Serum
|
17932343
|
221
|
Resistin
|
Protein
|
Humans
|
Downregulated in Prostate Cancer
|
Diagnostic
|
Cancerous Vs Normal Patients
|
p=0.04
|
Serum
|
17932343
|
222
|
IL-1Ra (Interleukin 1Ra)
|
Protein
|
Humans
|
Downregulated in Prostate Cancer
|
Diagnostic
|
Cancerous Vs Normal Patients
|
p=0.03
|
Serum
|
17932343
|
223
|
MMP-3 (Matrix Metalloproteinase-3)
|
Protein
|
Humans
|
Downregulated in Prostate Cancer
|
Diagnostic
|
Cancerous Vs Normal Patients
|
p=0.01
|
Serum
|
17932343
|
224
|
PAI-1(active) (Plasminogen Activator Inhibitor)
|
Protein
|
Humans
|
Downregulated in Prostate Cancer
|
Diagnostic
|
Cancerous Vs Normal Patients
|
p=0.01
|
Serum
|
17932343
|
225
|
AFP (α- Fetoprotein)
|
Protein
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Cancerous Vs Normal Patients
|
p=0.02
|
Serum
|
17932343
|
226
|
Kallikrein-8
|
Protein
|
Humans
|
Downregulated in Prostate Cancer
|
Diagnostic
|
Cancerous Vs Normal Patients
|
p=0.02
|
Serum
|
17932343
|
227
|
PSA
|
Protein
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Cancerous Vs Normal Patients
|
p=0.0001
|
Serum
|
17932343
|
228
|
G-CSF (Granulocyte Colony-Stimulating Factor)
|
Protein
|
Humans
|
Downregulated in Prostate Cancer
|
Diagnostic
|
Cancerous Vs Normal Patients
|
p=0.005
|
Serum
|
17932343
|
229
|
ENC1 + GJB1
|
mRNA
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Benign Prostate Vs Prostate Cancer
|
p<0.0005
|
Tissue
|
17460773
|
230
|
MYO6 + AMACR
|
mRNA
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Benign Prostate Vs Prostate Cancer
|
p<0.0005
|
Tissue
|
17460773
|
231
|
TSPAN13 + PRKCBP1
|
mRNA
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Benign Prostate Vs Prostate Cancer
|
p<0.0005
|
Tissue
|
17460773
|
232
|
C20ORF74 + DAPK1
|
mRNA
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Benign Prostate Vs Prostate Cancer
|
p<0.0005
|
Tissue
|
17460773
|
233
|
IMAGE:396839 + ENC1
|
mRNA
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Benign Prostate Vs Prostate Cancer
|
p<0.0005
|
Tissue
|
17460773
|
239
|
Anterior Gradient 2 Homolog AGR2
|
Protein
|
Humans
|
Upregulatated in PCa (3.8 fold)
|
Diagnostic
|
Normal Vs Prostate Cancer
|
p=0.0021
|
Serum
|
18061988
|
240
|
YKL- 40
|
Protein
|
Humans
|
Upregulated in PCa (PPC: 188.01 Vs BPH: 73.54 ± 9.25)
|
Diagnostic
|
Benign Prostatic Hyperplasia vs Primary Prostate Cancer
|
p<0.001
|
Serum
|
18190830
|
241
|
Chitotriosidase
|
Protein
|
Humans
|
Upregulated in PCa (PCa: 91.33 ± 8.32 Vs BPH: 69.72 ±8.69)
|
Diagnostic
|
Normal (Control) Vs Cancer (High Gleason Grade)
|
p<0.05
|
Serum
|
18190830
|
242
|
CXCL12
|
Protein
|
Humans
|
Upregulated in Biopsy Positive Patients
|
Diagnostic
|
Biopsy Negative Patients And Biopsy Positive Patients for Prostate Cancer
|
p=0.05
|
Serum
|
18196514
|
243
|
SPINK1
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Normal Vs Prostate Cancer
|
p=0.0002
|
Urine
|
18245462
|
244
|
GOLPH2
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Normal Vs Cancer
|
p=0.0002
|
Urine
|
18245462
|
245
|
PCA3
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Normal Vs Cancer
|
p=0.001
|
Urine
|
18245462
|
246
|
SPINK1, PCA3, GOLPH2, TMPRSS2:ERG
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Normal Vs Cancer
|
p=1.91E-11
|
Urine
|
18245462
|
247
|
SPINK1, PCA3, GOLPH2, TMPRSS2:ERG
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Normal Vs Cancer
|
p=1.91E-11
|
Urine
|
18245462
|
253
|
AMACR (Alpha-methylacyl-coA racemase )
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
High Grade Prostatic Intraepithelial Neoplasia Vs Prostate Cancer
|
p=0.0044
|
Tissue
|
18343427
|
256
|
TOP2A
|
mRNA
|
Humans
|
Upregulated in PCa (≥2 fold)
|
Diagnostic
|
Prostate Cancer Vs Nonneoplastic Sample
|
p<0.05
|
Tissue
|
18347174
|
257
|
ERG
|
mRNA
|
Humans
|
Upregulated in PCa (≥2 fold)
|
Diagnostic
|
Prostate Cancer Vs Nonneoplastic Sample
|
p<0.05
|
Tissue
|
18347174
|
263
|
Methylation Status of NKX2-5
|
mRNA
|
Humans
|
Hypermethylated (2.7% normal vs 14% in Cancerous condition)
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.05
|
Tissue
|
18446232
|
264
|
Methylation Status of CALSTN1
|
mRNA
|
Humans
|
Hypermethylated (2.5% normal vs 12.1% in Cancerous condition)
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.05
|
Tissue
|
18446232
|
265
|
Methylation Status of SPOCK2
|
mRNA
|
Humans
|
Hypermethylated (7.5% normal vs 15.2% in Cancerous condition)
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.05
|
Tissue
|
18446232
|
266
|
Methylation Status of NSE1
|
mRNA
|
Humans
|
Hypermethylated (10.3% normal vs 20.5% in Cancerous condition)
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.05
|
Tissue
|
18446232
|
267
|
Methylation Status of SLC16A12
|
mRNA
|
Humans
|
Hypermethylated (9% normal vs 22% in Cancerous condition)
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.05
|
Tissue
|
18446232
|
268
|
Methylation Status of FOXN4
|
mRNA
|
Humans
|
Hypermethylated (2.4% normal vs 4.3% in Cancerous condition)
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.05
|
Tissue
|
18446232
|
269
|
Methylation Status of GALR2
|
mRNA
|
Humans
|
Hypermethylated (2% normal vs 4.3% in Cancerous condition)
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.05
|
Tissue
|
18446232
|
270
|
Methylation Status of DPYS
|
mRNA
|
Humans
|
Hypermethylated (24.2% normal vs 42.71% in Cancerous condition)
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.05
|
Tissue
|
18446232
|
271
|
Methylation Status of (DPYS or NKX2-5)
|
mRNA
|
Humans
|
Hypermethylated in Prostate Cancer
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.05
|
Tissue
|
18446232
|
272
|
Methylation Status of (CALSTN1 or DYPS)
|
mRNA
|
Humans
|
Hypermethylated in Prostate Cancer
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.05
|
Tissue
|
18446232
|
273
|
Methylation Status of (NSE1 or DPYS)
|
mRNA
|
Humans
|
Hypermethylated in Prostate Cancer
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.05
|
Tissue
|
18446232
|
274
|
Methylation Status of (NSE1 or SPOCK2)
|
mRNA
|
Humans
|
Hypermethylated in Prostate Cancer
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.05
|
Tissue
|
18446232
|
275
|
Methylation Status of (SLC16A12 or DPYS)
|
mRNA
|
Humans
|
Hypermethylated in Prostate Cancer
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.05
|
Tissue
|
18446232
|
280
|
Golgi phosphoprotein 2 (GOLPH2)
|
mRNA
|
Humans
|
Upregulated in Prostate Cancer(3.04 fold)
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.001
|
Tissue
|
18543251
|
281
|
Golgi phosphoprotein 2 (GOLPH2)
|
Protein
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.01
|
Tissue
|
18543251
|
282
|
Golgi phosphoprotein 2 (GOLPH2)
|
Protein
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
prostate cancer Vs normal prostate epithelium
|
p<0.001
|
Tissue
|
18543251
|
283
|
Myosin VI (MYO6)
|
mRNA
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Tumor and adjacent normal prostate tissues
|
NA
|
Tissue
|
18543251
|
284
|
%[-2]proPSA
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Cancer
|
p=0.001
|
Serum
|
18550118
|
285
|
PSA+BPSA+%fPSA+%[-2] proPSA+[-2]proPSA/BPSA
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Cancer
|
p<0.05
|
Serum
|
18550118
|
286
|
%fPSA
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Cancer
|
p=0.008
|
Serum
|
18550118
|
287
|
40S ribosomal protein S25
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 2.13 ±0.44)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
288
|
40S ribosomal protein S7
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 5.24 ±0.66)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
289
|
α-1-antitrypsin precursor (α-1protease inhibitor)
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 3.19 ±0.97)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
290
|
Cellular nucleic acid-binding protein (CNBP) (Zinc finger protein 9)
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 2.33 ±0.79)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
291
|
Chondroitin sulfate proteoglycan 2 (Versican) variant (Fragment)
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 2.28 ±0.58)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
292
|
Chromobox protein homologue 1 (Heterochromatin protein 1 homologue β)
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 3.36 ±0.50)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
293
|
Cofilin-1 (Cofilin, nonmuscle isoform) (18 kDa phosphoprotein) (p18)
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 3.29 ± 1.2)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
294
|
Complement component 1 Q subcomponent-binding protein (p33)
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 4.55 ± 1.70)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
295
|
Elongation factor 1-R 2 (Elongation factor 1 A-2) (Statin S1)
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 2.68 ±0.73)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
296
|
Ezrin (p81) (Cytovillin) (Villin-2)
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 2.26 ±0.0.49)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
297
|
FASN variant protein (Fragment)
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 2.78 ±0.91)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
298
|
FK506-binding protein 4 (Peptidyl-prolyl cis-trans isomerase) (Rotamase)
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 2.46 ±0.29)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
299
|
Glutamate carboxypeptidase 2 (Folate hydrolase 1) (Prostate- specific membrane antigen)
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 2.82 ±0.95)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
300
|
Glutathione peroxidase 3 precursor
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 2.19 ±0.57)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
301
|
Glutathione S-transferase ω-1
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 2.36 ±0.58)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
302
|
Heat shock protein HSP90-β
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 3.2 ±0.61)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
303
|
Histone cluster 1, H1e
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 3.5 ±0.82)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
304
|
Histone H1.2 (Histone H1d)
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 2.98 ±1.07)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
305
|
Lactoylglutathione lyase (Aldoketomutase) (Glyoxalase I)
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 2.06 ±0.56)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
306
|
α-methylacyl-CoA racemase (AMAC)
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 2.51 ±0.62)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
307
|
Nucleophosmin (NPM) (Nucleolar phosphoprotein B23) (Numatrin)
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 2.6 ±1.01)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
308
|
Periostin, osteoblast specific factor
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 3.38 ± 1.59)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
309
|
Prostaglandin E synthase 3 (Telomerase-binding protein p23) (Hsp90 co-chaperone) (Progesterone receptor complex p23)
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 3.14 ±0.56)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
310
|
Proteasome subunit alpha type 5 (Multicatalytic endopeptidase complex ?-chain)
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 2.07 ±1.70)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
311
|
Protein mago nashi homologue 2
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 2.18 ±0.43)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
312
|
Protein-glutamine γ-glutamyltransferase 4 (Prostate transglutaminase) (Prostate-specific transglutaminase)
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 3.45 ±1.00)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
313
|
Thioredoxin domain-containing protein 4 precursor
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 2.54 ±0.45)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
314
|
Ubiquinol-cytochrome c reductase complex 11 kDa protein
|
Protein
|
Humans
|
Upregulated (Mean Ratio: 2.90 ±0.59)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
315
|
14-3-3 protein β/α
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.52 ±0.1)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
316
|
Androgen receptor-associated protein of 55 kDa (ARA 55)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.38 ±0.11)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
317
|
α-parvin (Calponin-like integrin-linked kinase-binding protein) (CH-ILKBP)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.53 ±0.08)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
318
|
Angiotensin-converting enzyme, somatic isoform (precursor) (CD143 antigen)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.32 ±0.09)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
319
|
Ankyrin repeat domain-containing protein 25 (SRC-1-interacting protein)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.46 ±0.11)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
320
|
BCL2-associated athanogene 3 variant (Fragment)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.32 ±0.11)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
321
|
CD44 antigen precursor (Phagocytic glycoprotein I) (Hyaluronate receptor) (Epican)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.23 ±0.07)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
322
|
Cell surface glycoprotein MUC18 precursor (Melanoma cell adhesion molecule) (CD146 antigen)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.49 ±0.08)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
323
|
Ciliary dynein heavy chain 10 (Axonemal beta dynein heavy chain 10) (Fragment)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.35 ±0.05)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
324
|
Collagen α-1(V) chain precursor
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.41 ±0.19)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
325
|
Collagen α-1(VI) chain precursor
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.43 ±0.15)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
326
|
Flotillin-1
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.33 ±0.10)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
327
|
G antigen family C member 1 (Prostate-associated gene 4 protein)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.25 ±0.09)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
328
|
γ-synuclein (Persyn) (Breast cancer-specific gene 1 protein) (Synoretin)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.18 ±0.07)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
329
|
Glutathione S-transferase μ-1
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.42 ±0.09)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
330
|
Glutathione S-transferase π-1
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.29 ±0.10)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
331
|
Hsc70-interacting protein (Hip) (Putative tumor suppressor ST13) (Progesterone receptor-associated p48 protein)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.33 ±0.11)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
332
|
Insulin-degrading enzyme (Insulysin) (Insulinase) (Insulin protease)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.38 ±0.12)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
333
|
Insulin-like growth factor-binding protein 7 precursor (IGFBP-7) (Prostacyclin-stimulating factor) (PGI2-stimulating factor)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.42 ±0.10)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
334
|
Kallikrein-11 precursor (Hippostasin)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.41 ±0.09)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
335
|
Keratin, type I cytoskeletal 17 (Cytokeratin-17)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.38 ±0.14)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
336
|
Leiomodin-1 (64 kDa autoantigen 1D)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.21 ±0.07)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
337
|
Microtubule-associated protein 1B (MAP 1B)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.46 ±0.11)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
338
|
Olfactomedin-like protein 1 precursor
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.33 ±0.09)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
339
|
Phosphoglucomutase-like protein 5 (Aciculin)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.47 ±0.10)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
340
|
Platelet-activating factor acetylhydrolase IB subunit α
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.42 ±0.09)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
341
|
Prostatic acid phosphatase [Precursor]
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.42 ±0.14)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
342
|
Ras-related protein R-Ras (p23)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.31 ±0.10)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
343
|
Retinol binding protein I, cellular
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.28 ±0.12)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
344
|
Selenium binding protein 1 (SELENBP1 protein)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.36 ±0.11)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
345
|
TFIIH basal transcription factor complex helicase XPB subunit (DNA-repair protein complementing XP-B)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.32 ±0.13)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
346
|
Ubiquitin carboxyl-terminal hydrolase isozyme L1 (Ubiquitin thioesterase L1
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.38 ±0.12)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
347
|
Vinculin (Metavinculin)
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.46 ±0.12)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
348
|
Zinc-α-2-glycoprotein precursor
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.43 ±0.13)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
349
|
Zyxin
|
Protein
|
Humans
|
Downregulated (Mean Ratio: 0.45 ±0.13)
|
Diagnostic
|
Prostate cancer Vs Benign Prostatic Hyperplasia
|
p≤0.01
|
Tissue
|
18553995
|
363
|
Lactate
|
Metabolites
|
Humans
|
Upregulated (Benign: 0.61 ± 0.28 Vs Cancerous: 1.59 ± 0.61)
|
Diagnostic
|
Benign Vs Malignant
|
p<0.0001
|
Tissue
|
18727052
|
364
|
Alanine
|
Metabolites
|
Humans
|
Upregulated (Benign: 0.14 ± 0.06 Vs Cancerous: 0.26 ± 0.07)
|
Diagnostic
|
Benign Vs Malignant
|
p<0.0001
|
Tissue
|
18727052
|
378
|
Methylation Status of RASSF1
|
Methylation
|
Humans
|
Hypermethylated in Prostate Cancer
|
Diagnostic
|
Benign vs. PCA
|
p<0.05
|
Expressed Prostatic Secretion
|
18948370
|
379
|
TMPRSS2:ERG
|
mRNA
|
Humans
|
Fused in Prostate Cancer
|
Diagnostic
|
Benign vs. PCA
|
p<0.05
|
Expressed Prostatic Secretion
|
18948370
|
380
|
Serum PSA + DRE + Methylation Status of RARB
|
mRNA
|
Humans
|
Hypermethylated in Prostate Cancer
|
Diagnostic
|
Benign vs. PCA
|
p<0.06
|
Expressed Prostatic Secretion
|
18948370
|
381
|
Serum PSA + DRE + Methylation Status of (GSTP1, APC, RARB, and RASSF1)
|
mRNA
|
Humans
|
GSTP1, APC, RARB, and RASSF1 Hypermethylated in Prostate Cancer
|
Diagnostic
|
Benign vs. PCA
|
p<0.01
|
Expressed Prostatic Secretion
|
18948370
|
382
|
Serum PSA + DRE + Methylation Status of RASSF1
|
mRNA
|
Humans
|
RASSF1 Hypermethylated in Prostate Cancer
|
Diagnostic
|
Benign vs. PCA
|
p< 0.05
|
Expressed Prostatic Secretion
|
18948370
|
383
|
Serum PSA + DRE + PCA3
|
mRNA
|
Humans
|
NA
|
Diagnostic
|
Benign vs. PCA
|
p<0.01
|
Expressed Prostatic Secretion
|
18948370
|
384
|
Serum PSA + DRE + TMPRSS:ERG
|
mRNA
|
Humans
|
NA
|
Diagnostic
|
Benign vs. PCA
|
p<0.001
|
Expressed Prostatic Secretion
|
18948370
|
386
|
Serum PSA + DRE + Methylation Status of GSTP1
|
mRNA
|
Humans
|
Hypermethylated in Prostate Cancer
|
Diagnostic
|
(Benign Samples + Gleason sums < 7) Vs ≥ 7
|
p<0.05
|
Expressed Prostatic Secretion
|
18948370
|
387
|
Serum PSA + DRE + Methylation Status of APC
|
mRNA
|
Humans
|
Hypermethylated in Prostate Cancer
|
Diagnostic
|
(Benign Samples + Gleason sums < 7) Vs ≥ 7
|
p<0.01
|
Expressed Prostatic Secretion
|
18948370
|
388
|
Serum PSA + DRE + Methylation Status of RARB
|
mRNA
|
Humans
|
Hypermethylated in Prostate Cancer
|
Diagnostic
|
(Benign Samples + Gleason sums < 7) Vs ≥ 7
|
p<0.01
|
Expressed Prostatic Secretion
|
18948370
|
389
|
Serum PSA + DRE + Methylation Status of RASSF1
|
mRNA
|
Humans
|
Hypermethylated in Prostate Cancer
|
Diagnostic
|
(Benign Samples + Gleason sums < 7) Vs ≥ 7
|
p<0.05
|
Expressed Prostatic Secretion
|
18948370
|
390
|
Serum PSA + DRE + Methylation Status of (GSTP1, APC, RARB, and RASSF1)
|
mRNA
|
Humans
|
GSTP1, APC, RARB, and RASSF1 Hypermethylated in Prostate Cancer
|
Diagnostic
|
(Benign Samples + Gleason sums < 7) Vs ≥ 7
|
p<0.05
|
Expressed Prostatic Secretion
|
18948370
|
391
|
Serum PSA + DRE + PCA3
|
mRNA
|
Humans
|
NA
|
Diagnostic
|
(Benign Samples + Gleason sums < 7) Vs ≥ 7
|
p<0.01
|
Expressed Prostatic Secretion
|
18948370
|
392
|
Serum PSA + DRE + TMPRSS2:ERG
|
mRNA
|
Humans
|
Fused in Prostate Cancer
|
Diagnostic
|
(Benign Samples + Gleason sums < 7) Vs ≥ 7
|
p<0.001
|
Expressed Prostatic Secretion
|
18948370
|
393
|
Ornithine Decarboxylase (ODC) + Ornithine Decarboxylase antizyme (OAZ) +Adenosylmethionine Decarboxylase (AdoMetDC)+ Spermidine/Spermine N(1)-acetyltransferase (SSAT)+ histone H3 (H3)+ growth arrest specific gene (GAS1)+glyceraldehyde 3-phosphate dehydrogenase (GAPDH) + Clusterin (CLU)
|
mRNA
|
Humans
|
Downgregulated in PCa: (GAS1,SSAT, CLU, OAZ, GAPDH); Upregulated in PCa (H3, ODC)
|
Diagnostic
|
Benign Vs Prostate Cancer
|
Clusterin: p<0.01
|
Tissue
|
18974881
|
400
|
Ki-67
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Localized prostate cancer Vs benign prostate
|
p<0.01
|
Tissue
|
19050681
|
401
|
p53
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Localized prostate cancer Vs benign prostate
|
p<0.01
|
Tissue
|
19050681
|
402
|
BCL-2
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Localized prostate cancer Vs benign prostate
|
p<0.01
|
Tissue
|
19050681
|
414
|
4-OHE1(E2)-1-N7Gua
|
Metabolites
|
Humans
|
Upregulated (PCA median: 0.7pmol/ml vs Control median: 0.3pmol/ml)
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p=0.0004
|
Urine
|
18816637
|
415
|
4-OHE1-1-N3Ade
|
Metabolites
|
Humans
|
Upregulated (PCA median: 0.4pmol/ml vs Control median: 0.2pmol/ml)
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p=0.056
|
Urine
|
18816637
|
416
|
2-OHE1-6-N3Ade
|
Metabolites
|
Humans
|
Upregulated (PCA median: 0.2pmol/ml vs Control median: 0pmol/ml)
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p=0.0014
|
Urine
|
18816637
|
430
|
TMPRSS2
|
mRNA
|
Humans
|
Upregulated in PCa: (Normal: 0.26 ± 0.04 vs PCa: 3.91 ± 0.78)
|
Diagnostic
|
prostate cancer Vs Adjacent Normal
|
p=0.001
|
Tissue
|
19242826
|
434
|
KLK11
|
mRNA
|
Humans
|
Upregulated in PCa: (Normal: 0.49 ± 0.07 vs PCa: 3.63 ± 0.42)
|
Diagnostic
|
prostate cancer Vs Adjacent Normal
|
p=0.003
|
Tissue
|
19242826
|
438
|
Methylation Status of: Chromosome 20 open reading frame 103 (C20orf103); Homeobox D9 (HOXD9); Nuclear receptor subfamily, group A, member 2 (NR5A2); Distal-less homeobox 5 (DLX5); Iroquois homeobox 1 (IRX1); Spastic paraplegia 20 (SPG20); Transcription factor AP-2 alpha (TFAP2A); Wilms tumor 1 (WT1); SIX homeobox 6 (SIX6); Homeobox D4 (HOXD4) ; Transcription factor 7-like 1 (TCF7L1); Sonic hedgehog homolog (SHH); Protocadherin, gamma subfamily C,5 (PCDHG5); Methionine aminopeptidase 1D (MAP1D); Runt-related transcription factor 1 (RUNX1)
|
Methylation
|
Humans
|
Hypermethylated in PCa: [Chromosome 20 open reading frame 103 (C20orf103) (3.7 fold); Homeobox D9 (HOXD9) (3.2 fold); Nuclear receptor subfamily, group A, member 2 (NR5A2) (3.1 fold); Distal-less homeobox 5 (DLX5) (3.7 fold); Iroquois homeobox 1 (IRX1) (3.0 fold); Spastic paraplegia 20 (SPG20) (3.0 fold); Transcription factor AP-2 alpha (TFAP2A) (2.9 fold); Wilms tumor 1 (WT1) (2.9 fold); SIX homeobox 6 (SIX6) (2.8 fold); Homeobox D4 (HOXD4) (2.7 fold) ; Transcription factor 7-like 1 (TCF7L1) (2.6 fold); Sonic hedgehog homolog (SHH) (2.5 fold) ; Protocadherin , gamma subfamily C,5 (PCDHG5) (2.4 fold); Methionine aminopeptidase 1D (MAP1D) (2.3 fold); Runt-related transcription factor 1 (RUNX1) (2.3 fold);]
|
Diagnostic
|
Cancer Vs Non Cancer
|
p<0.05
|
Tissue
|
19283074
|
444
|
Differential display 3 (DD3/PCA3)
|
mRNA
|
Humans
|
Upregulated in PCa (37 fold)
|
Diagnostic
|
Benign prostatic hyperplasia (BPH) Vs prostate cancer (PCa)
|
p=0.0001
|
Urine
|
19489685
|
445
|
Urinary PSA
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Benign prostatic hyperplasia (BPH) Vs prostate cancer (PCa)
|
p=0.0001
|
Urine
|
19489685
|
446
|
DD3 +PSA
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Benign prostatic hyperplasia (BPH) Vs prostate cancer (PCa)
|
p<0.0001
|
Urine
|
19489685
|
458
|
Prostate specific antigen (PSA), Prostate Specific Membrane Antigen (PSMA), Platelet Factor-4 (PF-4), and Interleukin-6 (IL-6)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Female Controls
|
NA
|
Serum
|
19775154
|
459
|
IGF1
|
Protein
|
Humans
|
Higher concentrations in patients with increased risk of prostate cancer
|
Diagnostic
|
NA
|
p=0.049
|
NA
|
19491931
|
474
|
CCNB1 (cyclin B1); CENPF (centromere protein F, 350/400 ka (mitosin)); BUB1B (BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast)); CLDN4 (claudin 4); KIAA0101 (KIAA0101); LOC400879 (Hypothetical gene supported by AK096951); SLC39A6 (solute carrier family 39 (zinc transporter), member 6); SOX4 (SRY (sex determining region Y)-box 4); TOP2A (topoisomerase (DNA) II alpha 170 kDa)
|
mRNA
|
Humans
|
Upregulated: CCNB1 (cyclin B1) [1.8 fold]; CENPF (centromere protein F, 350/400 ka (mitosin)) [1.4 fold]; BUB1B (BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast)) [1.4 fold]; CLDN4 (claudin 4) [2.4 fold]; KIAA0101 (KIAA0101) [1.6 fold]; LOC400879 (Hypothetical gene supported by AK096951) [1.7 fold]; SLC39A6 (solute carrier family 39 (zinc transporter), member 6) [1.6 fold]; SOX4 (SRY (sex determining region Y)-box 4) [1.8 fold]; TOP2A (topoisomerase (DNA) II alpha 170 kDa) [1.7 fold]
|
Diagnostic
|
Tumor Vs Adjacent To Tumor
|
p=0.05
|
Tissue
|
19652763
|
475
|
ABLIM3 (actin binding LIM protein family, member 3); AOX1 (aldehyde oxidase 1); CES1 (carboxylesterase 1 (monocyte/macrophage serine esterase 1)); DSCR1 (Down syndrome critical region gene 1); GLRX (glutaredoxin (thioltransferase)); IGFBP4 (insulin-like growth factor binding protein 4); MT1B (metallothionein 1B); MT1E (metallothionein 1E); MT1F (metallothionein 1F); MT1H (metallothionein 1H); C1QB (complement component 1, q subcomponent, B chain); CYB5R3 (cytochrome b5 reductase 3); DARC (Duffy blood group, chemokine receptor); DUSP3 (dual specifi city phosphatase 3 (vaccinia virus phosphatase VH1−related)); F13A1 (coagulation factor XIII, A1 polypeptide); FEZ1 (fasciculation and elongation protein zeta 1 (zygin I)); G0S2 (G0/G1switch 2); GAS6 (growth arrest-specifi c 6); IFITM2 (interferon induced transmembrane protein 2 (1–8D)); ITGA1 (integrin, alpha 1); MAP4 (microtubule-associated protein 4); MT1A (metallothionein 1A); MT2A (metallothionein 2A); PCMT1 (protein-L-isoaspartate (D-aspartate) O-methyltransferase); PROS1 (protein S (alpha)); RBPMS (RNA binding protein with multiple splicing); RDX (Radixin); RNF11 (ring finger protein 11); S100A8 (S100 calcium binding protein A8); SERINC1 (serine incorporator 1); SERPING1 (serpin peptidase inhibitor, clade G (C1 inhibitor), member 1, (angioedema, hereditary)); STOM (stomatin); TGFBR3 (transforming growth factor, beta receptor III); TGM2 (transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase)); WDR47 (WD repeat domain 47)
|
mRNA
|
Humans
|
Downregulated: ABLIM3 (actin binding LIM protein family, member 3) [1.6 fold]; AOX1 (aldehyde oxidase 1) [2.6 fold]; CES1 (carboxylesterase 1 (monocyte/macrophage serine esterase 1)) [1.7 fold]; DSCR1 (Down syndrome critical region gene 1) [1.6 fold]; GLRX (glutaredoxin (thioltransferase)) [1.7 fold]; IGFBP4 (insulin-like growth factor binding protein 4) [2.5 fold]; MT1B (metallothionein 1B) [2.3 fold]; MT1E (metallothionein 1E) [1.9 fold]; MT1F (metallothionein 1F) [2.3 fold]; MT1H (metallothionein 1H) [2.4 fold]; C1QB (complement component 1, q subcomponent, B chain) [1.4 fold]; CYB5R3 (cytochrome b5 reductase 3) [1.4 fold]; DARC (Duffy blood group, chemokine receptor) [2.9 fold]; DUSP3 (dual specifi city phosphatase 3 (vaccinia virus phosphatase VH1−related)) [1.4 fold]; F13A1 (coagulation factor XIII, A1 polypeptide) [2.1 fold]; FEZ1 (fasciculation and elongation protein zeta 1 (zygin I)) [1.6 fold]; G0S2 (G0/G1switch 2) [2.2 fold]; GAS6 (growth arrest-specifi c 6) [2 fold]; IFITM2 (interferon induced transmembrane protein 2 (1–8D)) [2 fold]; ITGA1 (integrin, alpha 1) [1.4 fold]; MAP4 (microtubule-associated protein 4) [1.6 fold]; MT1A (metallothionein 1A) [2.6 fold]; MT2A (metallothionein 2A) [2.5 fold]; PCMT1 (protein-L-isoaspartate (D-aspartate) O-methyltransferase) [1.3 fold]; PROS1 (protein S (alpha)) [1.7 fold]; RBPMS (RNA binding protein with multiple splicing) [2.4 fold]; RDX (Radixin) [1.4 fold]; RNF11 (ring finger protein 11) [1.4 fold]; S100A8 (S100 calcium binding protein A8) [2.3 fold]; SERINC1 (serine incorporator 1) [1.5 fold]; SERPING1 (serpin peptidase inhibitor, clade G (C1 inhibitor), member 1, (angioedema, hereditary)) [2.2 fold]; STOM (stomatin) [1.8 fold]; TGFBR3 (transforming growth factor, beta receptor III) [1.7 fold]; TGM2 (transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase)) [1.8 fold]; WDR47 (WD repeat domain 47) [1.5 fold]
|
Diagnostic
|
Tumor Vs Adjacent To Tumor
|
p=0.05
|
Tissue
|
19652763
|
478
|
Clusterin and Clusterin Density
|
Protein
|
Humans
|
Upregulated: Clusterin [(BPH: 94.2 ± 38.7) Vs (PCA: 137.2 ± 36.6 )]; Clusterin Density [(BPH: 3.2 ± 2.2 ) Vs (PCA: 5.5 ± 2.6 )]
|
Diagnostic
|
Benign Prostatic Hyperplasia Vs Prostate Cancer
|
p<0.001
|
Serum
|
19854485
|
482
|
PSA
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Tumor
|
p<0.05
|
Serum
|
20632177
|
483
|
MMP-2
|
Protein
|
Humans
|
Upregulated and Hypermethylated (PCa: 684.65 ± 129.36; Normal: 609.63 ± 172.58)
|
Diagnostic
|
Prostate Cancer Vs No Tumor
|
p=0.038
|
Serum
|
20632177
|
484
|
PSA+MMP-2+ AMACR + Methylation Status of (GSTP1 or RASSF1A)
|
Protein + DNA
|
Humans
|
Upregulated and Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Tumor
|
p=0.036
|
Urine and Serum
|
20632177
|
485
|
Methylation Status of GSTP1 or RASSF1A
|
Methylation
|
Humans
|
HyperMethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Tumor
|
p<0.05
|
Urine
|
20632177
|
486
|
PSGR (Prostate-Specific G-protein Coupled Receptor)
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Benign Vs Prostate Cancer
|
p=0.008
|
Urine
|
20672322
|
487
|
PCA3 (Prostate Cancer Gene 3)
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Benign Vs Prostate Cancer
|
p<0.001
|
Urine
|
20672322
|
488
|
PSGR + PCA3
|
mRNA
|
Humans
|
Upregulated
|
Diagnostic
|
Benign Vs Prostate Cancer
|
NA
|
Urine
|
20672322
|
489
|
PCA3 (Prostate Cancer Gene 3)
|
mRNA
|
Humans
|
Upregulated in Positive Biopsy
|
Diagnostic
|
Positive PCa Biopsy Vs Negative PCa Biopsy
|
p <0.0001
|
Urine
|
20850153
|
490
|
Age+ Family History+ PCA3 + %fPSA+ Prostate Volume+ sPSA
|
mRNA
|
Humans
|
Upregulated in Positive Biopsy
|
Diagnostic
|
Positive PCa Biopsy Vs Negative PCa Biopsy
|
p <0.0001
|
Urine
|
20850153
|
491
|
Age+ Family History+ PCA3 + %fPSA+ Prostate Volume+ sPSA
|
mRNA
|
Humans
|
Upregulated in Positive Biopsy
|
Diagnostic
|
Positive PCa Biopsy Vs Negative PCa Biopsy
|
p <0.0001
|
Urine
|
20850153
|
494
|
transglutaminase 2 isoform a; TPM1 protein; FTH1 protein; S100 calcium binding protein A9; splicing factor, arginine/ serine-rich 1 isoform 1; chromatin modifying protein 4B;
|
Protein
|
Humans
|
Upregulated ratio in Localised PCA: transglutaminase 2 isoform a [2.03]; TPM1 protein [4.18]; FTH1 protein [2.28]; S100 calcium binding protein A9 [3.81]; splicing factor, arginine/ serine-rich 1 isoform 1 [2.07]; chromatin modifying protein 4B [2.16];
|
Diagnostic
|
Localized PCa and BPH
|
p<0.05
|
Tissue
|
19894759
|
495
|
keratin 5; mutant desmin; histone cluster 2, H2bf;
|
Protein
|
Humans
|
Downregulated ratio in Localised PCA: keratin 5 [2.08]; mutant desmin [2.03]; histone cluster 2, H2bf [2.02];
|
Diagnostic
|
Localized PCa and BPH
|
p<0.05
|
Tissue
|
19894759
|
497
|
e-FABP5
|
Protein
|
Humans
|
Upregulated in Localised PCA
|
Diagnostic
|
Localized PCa and BPH
|
p<0.01
|
Serum
|
19894759
|
507
|
TRPM8 (transient receptor potential member 8)
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Tumors Vs patient matched non-tumor
|
NA
|
Tissue
|
20043080
|
508
|
TRPM8 (transient receptor potential member 8)
|
mRNA
|
Humans
|
Upregulated in PCa (ratio = 1.94±0.256)
|
Diagnostic
|
Tumors Vs patient matched non-tumor
|
p<0.01
|
Tissue
|
20043080
|
509
|
TRPM8 (transient receptor potential member 8)
|
mRNA
|
Humans
|
Upregulated in Metastatis (Metastatis: 1.81±0.153; Healthy: 1.0 ± 0.132)
|
Diagnostic
|
Healthy Vs Metastatic
|
p<0.001
|
Blood
|
20043080
|
510
|
TRPM8 (transient receptor potential member 8)
|
mRNA
|
Humans
|
Upregulated in Metastatis
|
Diagnostic
|
Healthy Vs Metastatic
|
p<0.0001
|
Urine
|
20043080
|
515
|
p2PSA ([-2]isoform of proenzyme prostate specific antigen)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Sample
|
p = 0.0006
|
Serum
|
20171670
|
516
|
%fPSA
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Sample
|
p=0.02
|
Serum
|
20171670
|
517
|
prostate specific antigen
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Sample
|
NA
|
Serum
|
20171670
|
518
|
Prostate Health Index (phi)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Sample
|
NA
|
Serum
|
20171670
|
520
|
CB:SA ratio: (cathepsin B/stefin A)
|
Protein
|
Humans
|
Upregulated in Cancer: (BPH Geometric Mean : 1.448 Vs Cancer Geometric Mean : 2.990)
|
Diagnostic
|
benign prostatic hyperplasia Vs Prostate Cancer
|
p=0.0001
|
Tissue
|
20392989
|
521
|
CB:SA ratio: (cathepsin B/stefin A)
|
Protein
|
Humans
|
Upregulated in Cancer (Gleason Score 6): (BPH Geometric Mean : 1.448 Vs GS6 Geometric Mean : 3.452)
|
Diagnostic
|
benign prostatic hyperplasia Vs Prostate Cancer (Gleason Score 6)
|
p=0.0003
|
Tissue
|
20392989
|
522
|
CB:SA ratio: (cathepsin B/stefin A)
|
Protein
|
Humans
|
Upregulated in Cancer (Gleason Score 7): (BPH Geometric Mean : 1.448 Vs GS7: Geometric Mean : 2.756)
|
Diagnostic
|
benign prostatic hyperplasia Vs Prostate Cancer (Gleason Score 7)
|
p=0.0052
|
Tissue
|
20392989
|
529
|
miRNA-375
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Tumor Vs Normal
|
p<0.001
|
Tissue
|
20473869
|
530
|
miRNA-141
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Tumor Vs Normal
|
p<0.001
|
Tissue
|
20473869
|
531
|
KLK15 (kallikrein-related peptidase)
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Adjacent
|
p = 0.045
|
Tissue
|
20473923
|
533
|
PSA (G/G Genotype)
|
Mutation
|
Humans
|
Increases risk with G/G Genotype compared with the G/A And A/A genotype
|
Diagnostic
|
Cancer Vs Controls
|
p<0.05
|
Blood
|
20632874
|
534
|
AR: (Short CAG)
|
Mutation
|
Humans
|
Increased Risk with shorter CAG Repeats
|
Diagnostic
|
Cancer Vs Controls
|
p = 0.007
|
Blood
|
20632874
|
535
|
PSA and AR (G/G and Short CAG)
|
Mutation
|
Humans
|
Increased Risk of Prostate Cancer
|
Diagnostic
|
Cancer Vs Controls
|
p = 0.0418
|
Blood
|
20632874
|
538
|
SPATA19
|
mRNA
|
Humans
|
Upregulated in PCa (Increased Prostate cancer risk with High expression)
|
Diagnostic
|
Benign Prostatic Hyperplasia Vs Prostate Cancer
|
p<0.0001
|
Tissue
|
20682177
|
539
|
LEMD1
|
mRNA
|
Humans
|
Upregulated in PCa (Increased Prostate cancer risk with High expression)
|
Diagnostic
|
Benign Prostatic Hyperplasia Vs Prostate Cancer
|
p=0.012
|
Tissue
|
20682177
|
543
|
PCA3
|
mRNA
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Cancer Vs No Malignancy (PSA Range: 4-10)
|
Univariate: p=0; Multivariate: p=0.02
|
Urine
|
20957673
|
544
|
TMPRSS2: ERG
|
mRNA
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Cancer Vs No Malignancy (PSA Range: 4-10)
|
Univariate: p=0.002; Multivariate: p=0.028
|
Urine
|
20957673
|
545
|
Annexin A3
|
Protein
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Cancer Vs No Malignancy (PSA Range: 4-10)
|
Univariate: p=0; Multivariate: p=0.027
|
Urine
|
20957673
|
546
|
Sarcosine
|
Metabolites
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Cancer Vs No Malignancy (PSA Range: 4-10)
|
Univariate: p=0.011; Multivariate: p=0.015
|
Urine
|
20957673
|
547
|
PCA3
|
mRNA
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Cancer Vs No Malignancy
|
Univariate: p=0; Multivariate: p=0.02
|
Urine
|
20957673
|
548
|
TMPRSS2: ERG
|
mRNA
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Cancer Vs No Malignancy
|
Univariate: p=0.002; Multivariate: p=0.028
|
Urine
|
20957673
|
549
|
Annexin A3
|
Protein
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Cancer Vs No Malignancy
|
Univariate: p=0.002; Multivariate: p=0.027
|
Urine
|
20957673
|
550
|
Sarcosine
|
Metabolites
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Cancer Vs No Malignancy
|
Univariate: p=0.011; Multivariate: p=0.015
|
Urine
|
20957673
|
551
|
Total sialic acid
|
Metabolites
|
Humans
|
Upregulated (mg/dL): (Controls: 6.25±3.49) Vs (Prostate Cancer: 15.1±4.83)
|
Diagnostic
|
Control Vs Cancer
|
p<0.001
|
Serum
|
20973404
|
552
|
Total sialic acid
|
Metabolites
|
Humans
|
Upregulated (mg/dL): (BPH: 7.24±4.56) Vs (Prostate Cancer: 15.1±4.83)
|
Diagnostic
|
BPH Vs Cancer
|
p<0.001
|
Serum
|
20973404
|
553
|
Cathepsin D
|
Protein
|
Humans
|
Upregulated (pmol/mL): (Controls: 4.85±1.35) Vs (Prostate Cancer: 9.2±1.75)
|
Diagnostic
|
Control Vs Cancer
|
p<0.001
|
Serum
|
20973404
|
554
|
Cathepsin D
|
Protein
|
Humans
|
Upregulated (pmol/mL): (BPH: 5.11±1.17) Vs (Prostate Cancer: 9.2±1.75)
|
Diagnostic
|
BPH Vs Cancer
|
p<0.001
|
Serum
|
20973404
|
555
|
Fructose-bisphosphate aldolase A; Isocitrate dehydrogenase; Citrate synthase; L-Lactate dehydrogenase A; ATP synthase gamma chain; Alpha-enolase; Phosphoglycerate mutase 1; Malate dehydrogenase; Core protein II; Transketolase; 60 kDa heat shock protein; Flotillin 1; 26S protease regulatory subunit 8; Annexin A2;
|
Protein
|
Humans
|
Upregulated (with Regulation Coefficient): Fructose-bisphosphate aldolase A [1.15]; Isocitrate dehydrogenase [1.09]; Citrate synthase [1.18]; L-Lactate dehydrogenase A [1.40]; ATP synthase gamma chain [1.28]; Alpha-enolase [1.48]; Phosphoglycerate mutase 1 [1.56]; Malate dehydrogenase [1.64]; Core protein II [1.19]; Transketolase [1.31]; 60 kDa heat shock protein [1.83]; Flotillin 1 [1.07]; 26S protease regulatory subunit 8 [1.14]; Annexin A2 [1.29];
|
Diagnostic
|
Gleason 6 Vs Benign Prostate
|
p<0.05
|
Tissue
|
20977276
|
556
|
Lamin A; Cytokeratin-1; Mimecan; Prostatic acid phosphatase; Prostate-specific antigen;
|
Protein
|
Humans
|
Downregulated (with Regulation Coefficient): Lamin A [-1.52]; Cytokeratin-1 [-1.09]; Mimecan [-1.08]; Prostatic acid phosphatase [-2.85]; Prostate-specific antigen [-1.15];
|
Diagnostic
|
Gleason 6 Vs Benign Prostate
|
p<0.05
|
Tissue
|
20977276
|
559
|
HSP60
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Gleason 6 Vs Benign Prostate
|
p<0.05
|
Tissue
|
20977276
|
561
|
C8orf4; TMC5; PDLIM5; JAG1; HOXA9; C4A; STEAP4; HLA-DMB; COL12A1; DHRS8; C10orf137; SLC7A1; PDZRN3; F3; ACER3; POLB; PXDN; PROM2; GUCY1A3; SOX4;
|
mRNA
|
Humans
|
Upregulated (Fold Change): [C8orf4 (5.14 fold); TMC5 (4.83 fold) ; PDLIM5 (4.51 fold); JAG1 (4.36 fold); HOXA9 (4.25 fold) ; C4A (3.98 fold); STEAP4 (3.92 fold); HLA-DMB (3.85fold); COL12A1 (3.81 fold); DHRS8 (3.81 fold); C10orf137 (3.62 fold); SLC7A1 (3.44 fold); PDZRN3 (3.30 fold); F3 (3.26 fold) ; ACER3 (3.17fold); POLB (3.16 fold); PXDN (3.12 fold); PROM2 (3.11 fold); GUCY1A3 (3.10 fold); SOX4 (3.02 fold);]
|
Diagnostic
|
High BMI Tumor Vs High BMI Normal
|
p<0.05
|
Tissue
|
21060327
|
562
|
ACADL; PHLDA2; GPD1; L; NTAN1; LOC389048; SFN; HSRG1; PAK1IP1; EBP; ANPEP; ANTXR2; COL4A6; LOC400880; RHOU; GREB1; FLJ30428; C3orf14; ZNF532; SCD; PTN; SC4MOL; MAF; NPAL3; CYP3A5; NOV; ALOX15B; LOC399959; VGL-3; INSIG1; Rcan3; Poteg; P704P; EFS;
|
mRNA
|
Humans
|
Downregulated (Fold Change): [ACADL (0.33 fold); PHLDA2 (0.33 fold); GPD1L (0.33 fold); NTAN1 (0.33 fold); LOC389048 (0.32 fold); SFN (0.32 fold); HSRG1 (0.32 fold); PAK1IP1 (0.32 fold); EBP (0.31 fold); ANPEP (0.31 fold); ANTXR2 (0.29 fold); COL4A6 (0.29 fold); LOC400880 (0.29 fold); RHOU (0.29 fold); GREB1 (0.28 fold); FLJ30428 (0.27 fold); C3orf14 (0.27 fold); ZNF532 (0.26 fold); SCD (0.25 fold); PTN (0.24 fold); SC4MOL (0.24 fold); MAF (0.22 fold); NPAL3 (0.22 fold); CYP3A5 (0.21 fold); NOV (0.20 fold); ALOX15B (0.17 fold); LOC399959 (0.17 fold); VGL-3 (0.16 fold); INSIG1 (0.16 fold); Rcan3 (0.15 fold); Poteg (0.14 fold); P704P (0.13 fold); EFS (0.13 fold)]
|
Diagnostic
|
High BMI Tumor Vs High BMI Normal
|
p<0.05
|
Tissue
|
21060327
|
563
|
freePSA (free prostate specific antigen)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Control Vs Cancer
|
p<0.05
|
Serum
|
21074193
|
564
|
[-2]proPSA ([-2]proenzyme prostate specific antigen)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Control Vs Cancer
|
p<0.05
|
Serum
|
21074193
|
565
|
%fPSA (%free prostate specific antigen)
|
Protein
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Control Vs Cancer
|
p<0.05
|
Serum
|
21074193
|
566
|
DKK1 (Dickkopf-1)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Control Vs Cancer
|
p<0.05
|
Serum
|
21074193
|
567
|
NEM (neuroendocrine marker)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Control Vs Cancer
|
p<0.05
|
Serum
|
21074193
|
568
|
Prostate Health Index (phi)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Control Vs Cancer
|
p<0.05
|
Serum
|
21074193
|
570
|
miR-874, -1274a, -1207-5p, -93, and -106a
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Healthy Vs Prostate Cancer
|
miR-874 p<0.00; miR-1274a p<0.001; miR-1207-5p p<0.001; miR-93 p<0.001; miR-106a p<0.001
|
Serum
|
21098088
|
571
|
miR- 223, -26b, -30c, and -24
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Healthy Vs Prostate Cancer
|
miR-30c p= 0.01; miR-26b p<0.001; miR-223 p<0.001; miR-24 p= 0.005;
|
Serum
|
21098088
|
572
|
miR-106a, miR-93 and -1274a; miR-451; miR-1207-5p; miR-874
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Healthy Vs High Risk (CAPRA>5)
|
miR-106a p<0.001, miR-93 p<0.001; miR-1274a p<0.001; miR-451 p= 0.02; miR-1207-5p p<0.001; miR-874 p= 0.003
|
Serum
|
21098088
|
573
|
miR-223; miR-24;
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Healthy Vs High Risk (CAPRA>5)
|
miR-223 p= 0.002; miR-24 p=0.02
|
Serum
|
21098088
|
574
|
Apolipoprotein A-IV + Serum amyloid P-component + Gluthathione peroxidase 3
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
BPH vs Prostate Cancer
|
NA
|
Serum
|
21166384
|
577
|
Apolipoprotein A-IV + Serum amyloid P-component + Gluthathione peroxidase 3
|
Protein
|
Humans
|
Upregulated
|
Diagnostic
|
BPH vs Prostate Cancer
|
NA
|
Serum
|
21166384
|
580
|
Methylation Status of [A4GALT; ADAM8; ALOX15B; BIK; CCK; CRCP; CTSC; CXCL2; CXCL3; CYBA; EIF4B; GSTM1 ; GSTM2; IGF2; LTF; MCAM; PDCD1; PDPN; PKMYT1; PPP1R3C; RAB32; RFTN1; SERPINB1; SLC16A5; SOCS1; TIMP3; TNF]
|
Methylation
|
Humans
|
HyperMethylated in PCa ( Positive Fold change): [A4GALT(2.0 fold) ; ADAM8(3.9 fold); ALOX15B(5.1fold, 2.7 fold); BIK(2.6 fold); CCK(9.3 fold); CRCP(2.1fold); CTSC(3.7 fold); CXCL2(3.2 fold); CXCL3(3.0fold); CYBA(3.8 fold); EIF4B(3.5 fold); GSTM1 (20.5 fold); GSTM2(4.1 fold); IGF2(4.2 fold); LTF(2.1 fold); MCAM(2.7 fold); PDCD1(3.2 fold); PDPN(4.5 fold); PKMYT1(2.9 fold); PPP1R3C(8.2 fold) ; RAB32(3.3 fold); RFTN1(5.5 fold); SERPINB1(2.4 fold); SLC16A5(17.2fold, 4.2 fold); SOCS1(2.6 fold); TIMP3(2.2 fold); TNF(2.0 fold)]
|
Diagnostic
|
Tumor Vs Tumor Adjacent
|
p=0.013
|
Tissue
|
21237555
|
581
|
Methylation Status of [ALDH1A3; NR4A2; PF4; RELB; SOCS1; TNFRSF1B; ZBTB11; ZNF365]
|
Methylation
|
Humans
|
HypoMethylated in PCa: ( Negative Fold change): [ALDH1A3(2.6 fold); NR4A2(2.5 fold); PF4(3.4 fold); RELB(2.1 fold); SOCS1(8.2 fold); TNFRSF1B(3.0 fold); ZBTB11(2.9 fold); ZNF365(5.0 fold)]
|
Diagnostic
|
Tumor Vs Tumor Adjacent
|
p=0.013
|
Tissue
|
21237555
|
582
|
GSTP1, BCL2, ADCY4, CACNA1G, LOC63928, and D4S234E
|
mRNA
|
Humans
|
Downregulated
|
Diagnostic
|
Tumor Vs Tumor Adjacent
|
p<0.05
|
Tissue
|
21237555
|
587
|
Tropomyosin β chain fibroblast and epithelia, Keratin type II cytoskeletal 8 Cytokeratin 8 K, 14-3-3 protein γ protein kinase C inhibitor p, Protein disulfide isomerase precursor PDI EC 5, Keratin type I cytoskeletal 19 Cytokeratin 19, Actin muscle type A2, Desmin, α1 antitrypsin precursor, Tubulin β2 chain, 78 kDa glucose regulated protein prec GRP 78, Rho GDP dissociation inhibitor 1, Creatine kinase B chain EC 2 7 3 2 B CK, Fibrinogen γ chain precursor, Heat shock cognate 71 kDa protein, Stress 70 protein mitochondrial precursor 75 kD, Heat shock 70 kDa protein 1 HSP70 1a, Enoyl CoA hydratase mitochprecursor EC 4, Prohibitin, Apolipoprotein A I precursor Apo AI, ATP synthase β chain mitochondrial precursor, Small nuclear ribonucleoprotein 200 kDa helicas, Glycerol 3 phosphate acyltransferase EC 2 3 1 15, Keratin type I cytoskeletal 18 Cytokeratin 18, Serum albumin precursor, Annexin A4 Lipocortin IV Endonexin, Serum albumin precursor, 60 kDa heat shock protein mitochondrial precursor.
|
Protein
|
Humans
|
Differentially Expressed
|
Diagnostic
|
BPH Vs Prostate Cancer
|
p<0.05
|
Tissue
|
21305254
|
596
|
Engrailed-2 (EN2)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Biopsy Positive Vs Biopsy Negative
|
p<0.05
|
Tissue
|
21364037
|
597
|
Engrailed-2 (EN2)
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p<0.05
|
Cell Lines
|
21364037
|
598
|
Engrailed-2 (EN2)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p<0.0001
|
Urine
|
21364037
|
599
|
vascular endothelial growth factor (VEGF)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
BPH Vs Prostate Cancer
|
p<0.001
|
Tissue
|
21367627
|
600
|
matrix metalloproteinase-9 (MMP-9)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
BPH Vs Prostate Cancer
|
p=0.004
|
Tissue
|
21367627
|
607
|
let-7a; miR-101; miR-106a; miR-106b; miR-1274; miR-141; miR-17; miR-182; miR-1826; miR-200b; miR-200c; miR-20a; miR-20b; miR-21; miR-375; miR-720; miR-768-3p; miR-93
|
miRNA
|
Humans
|
Upregulated in PCa(Fold Change): let-7a(1.53 fold) ; miR-101(1.13 fold) ; miR-106a(2.41 fold); miR-106b(1.70 fold); miR-1274(1.87 fold); miR-141(1.44 fold); miR-17(2.69 fold); miR-182(2.39 fold) ; miR-1826(1.73 fold) ; miR-200b( 1.54 fold) ; miR-200c( 2.92 fold); miR-20a(2.67 fold); miR-20b(2.81 fold); miR-21( 1.40 fold); miR-375(3.90 fold) ; miR-720(1.41 fold); miR-768-3p(1.67 fold); miR-93(2.52 fold)
|
Diagnostic
|
Prostate Cancer Vs Normal
|
p<0.001
|
Tissue
|
21400514
|
608
|
miR-136-star; miR-145; miR-214; miR-221; miR-222; miR-302d-star; miR-378-star
|
miRNA
|
Humans
|
Downregulated in PCa (Fold Change): miR-136-star(1.18 fold) ; miR-145(1.44 fold); miR-214(1.74 fold); miR-221(2.16 fold) ; miR-222(2.91 fold) ; miR-302d-star(1.13 fold); miR-378-star(1.30 fold)
|
Diagnostic
|
Prostate Cancer Vs Normal
|
p<0.001
|
Tissue
|
21400514
|
609
|
miRNA- 375; miRNA-143; miRNA-145 (Individual assesment)
|
miRNA
|
Humans
|
Upregulated in PCa: miRNA-375; Downregulated in PCa: miRNA-143, miRNA 145
|
Diagnostic
|
Prostate Cancer Vs Normal
|
miRNA- 375 (p=0.002) ; miRNA-143 (p=0.001); miRNA-145 (p<0.0001);
|
Tissue
|
21400514
|
610
|
miRNA- 375 + miRNA-143+ miRNA-145 (Combined assesment)
|
miRNA
|
Humans
|
Upregulated in PCa: miRNA-375; Downregulated in PCa: miRNA-143, miRNA 146
|
Diagnostic
|
Prostate Cancer Vs Normal
|
p<0.0001
|
Tissue
|
21400514
|
611
|
miRNA- 375; miRNA-143; miRNA-145 (Individual assesment)
|
miRNA
|
Humans
|
Upregulated in PCa: miRNA-375; Downregulated in PCa: miRNA-143, miRNA 147
|
Diagnostic
|
Prostate Cancer Vs Normal
|
miRNA- 375 (p=0.005) ; miRNA-143 (p=0.005); miRNA-145 (p<0.0001);
|
Tissue
|
21400514
|
612
|
miRNA- 375 + miRNA-143+ miRNA-145 (Combined assesment)
|
miRNA
|
Humans
|
Upregulated in PCa: miRNA-375; Downregulated in PCa: miRNA-143, miRNA 148
|
Diagnostic
|
Prostate Cancer Vs Normal
|
p<0.0001
|
Tissue
|
21400514
|
613
|
miRNA- 375; miRNA-143; miRNA-145 (Individual assesment)
|
miRNA
|
Humans
|
Upregulated in PCa: miRNA-375; Downregulated in PCa: miRNA-143, miRNA 149
|
Diagnostic
|
Prostate Cancer Vs Normal
|
miRNA- 375 (p<0.0001) ; miRNA-143 (p<0.0001); miRNA-145 (p<0.0001);
|
Tissue
|
21400514
|
614
|
miRNA- 375 + miRNA-143+ miRNA-145 (Combined assesment)
|
miRNA
|
Humans
|
Upregulated in PCa: miRNA-375; Downregulated in PCa: miRNA-143, miRNA 150
|
Diagnostic
|
Prostate Cancer Vs Normal
|
p<0.0001
|
Tissue
|
21400514
|
615
|
Mutation Status of TNFSF10 (SNP: rs3774315 (A/G))
|
Mutation
|
Humans
|
Associated with Disease Aggressiveness
|
Diagnostic
|
More Aggressive Vs Controls
|
Discovery Set: 0.0000734; Testing Set: p=0.03
|
Blood
|
21467234
|
616
|
Mutation Status of FBXO34 (SNP: rs8015211 (T/C))
|
Mutation
|
Humans
|
Associated with Disease Aggressiveness
|
Diagnostic
|
More Aggressive Vs Controls
|
Discovery Set: p= 0.0000164
|
Blood
|
21467234
|
617
|
Mutation Status of FBXO34 (SNP: rs12433615 (A/G))
|
Mutation
|
Humans
|
Associated with Disease Aggressiveness
|
Diagnostic
|
More Aggressive Vs Controls
|
Discovery Set: p= 0.0000406
|
Blood
|
21467234
|
618
|
Mutation Status of FBXO34 (SNP: rs1188069 (T/G))
|
Mutation
|
Humans
|
Associated with Disease Aggressiveness
|
Diagnostic
|
More Aggressive Vs Controls
|
Discovery Set: p= 0.0000638
|
Blood
|
21467234
|
619
|
Mutation Status of FBXO34 (SNP: rs2341883 (A/G))
|
Mutation
|
Humans
|
Associated with Disease Aggressiveness
|
Diagnostic
|
More Aggressive Vs Controls
|
Discovery Set: p= 0.0000638 ; Testing Set: 0.01
|
Blood
|
21467234
|
620
|
Mutation Status of HERC2 (SNP: rs6497287 (T/C))
|
Mutation
|
Humans
|
Associated with Disease Aggressiveness
|
Diagnostic
|
More Aggressive Vs Controls
|
Discovery Set: p= 0.000052 ; Test Set: p=0.004
|
Blood
|
21467234
|
621
|
Mutation Status of WWOX (SNP: rs11150069 (C/A))
|
Mutation
|
Humans
|
Associated with Disease Aggressiveness
|
Diagnostic
|
More Aggressive Vs Controls
|
Discovery Set: p= 0.00000943
|
Blood
|
21467234
|
622
|
Mutation Status of WWOX (SNP: rs4628973 (A/G))
|
Mutation
|
Humans
|
Associated with Disease Aggressiveness
|
Diagnostic
|
More Aggressive Vs Controls
|
Discovery Set: p= 0.000000462
|
Blood
|
21467234
|
623
|
Mutation Status of IL1RAPL1 (SNP: rs225061 (G/T))
|
Mutation
|
Humans
|
Associated with Disease Aggressiveness
|
Diagnostic
|
More Aggressive Vs Controls
|
Discovery Set: p= 0.000971
|
Blood
|
21467234
|
624
|
Mutation Status of TNFSF10 (SNP: rs3774315 (A/G))
|
Mutation
|
Humans
|
Associated with Disease Aggressiveness
|
Diagnostic
|
Less Aggressive Vs Controls
|
Discovery Set: 0.0000734; Testing Set: p=0.002
|
Blood
|
21467234
|
625
|
Mutation Status of FBXO34 (SNP: rs2341883 (A/G))
|
Mutation
|
Humans
|
Associated with Disease Aggressiveness
|
Diagnostic
|
Less Aggressive Vs Controls
|
Discovery Set: p= 0.0000638 ; Testing Set: 0.01
|
Blood
|
21467234
|
626
|
fPSA
|
Protein
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p=0.024
|
Serum
|
21482022
|
627
|
%fPSA
|
Protein
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p=0.008
|
Serum
|
21482022
|
628
|
PSA Density
|
Protein
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p=0.001
|
Serum
|
21482022
|
629
|
%p2PSA
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p < 0.001
|
Serum
|
21482022
|
630
|
Prostat Health Index (phi)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p < 0.001
|
Serum
|
21482022
|
631
|
Base Model (Age+ Prostate Volume + tPSA+ fPSA)
|
Protein
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs Controls
|
Not significant
|
Serum
|
21482022
|
632
|
Base Model + %p2PSA
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p < 0.001
|
Serum
|
21482022
|
633
|
Base Model + phi
|
Protein
|
Humans
|
Upregulated in PCa (phi)
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p < 0.001
|
Serum
|
21482022
|
634
|
NY-ESO-1 + XAGE-1b + SSX-2,4 + AMACR + p90 + LEDGF + PSA Index
|
Protein
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Prostate Cancer Vs BPH
|
LEDGF, p90, SSX-2, 4, XAGE-1b: p<0.001; NY-ESO-1: p=0.029; AMACR: NS
|
Serum
|
21504557
|
635
|
PSA
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs BPH
|
p<0.05
|
Serum
|
21504557
|
636
|
40S ribosomal protein S8; Heterogeneous nuclear ribonucleoprotein H; 78 kDa glucose-regulated protein; Cytochrome c oxidase polypeptide VIc; Cytochrome c oxidase subunit 5B, mitochondrial ATP synthase subunit beta, mitochondrial Stress-70 protein, mitochondrial Biglycan; Elongation factor Tu mitochondrial; Ubiquitin-like modifier-activating enzyme 1; Protein disulfide-isomerase A4; Heterochromatin protein 1-binding protein 3; Tumor protein D52 Prohibitin-2; Protein disulfide-isomerase; EH domain-containing protein 2; 60 kDa heat shock protein mitochondrial; Nucleophosmin Periostin; Sorbitol dehydrogenase
|
Protein
|
Humans
|
Upregulated in PCA(Fold Change) :
|
Diagnostic
|
Prostate Cancer Vs BPH
|
p<0.05
|
Tissue
|
21504578
|
637
|
Desmin; Serum deprivation-response protein 3; Sorbin and SH3 domain-containing protein 1; Vimentin; Calponin-1; Heat shock protein beta-1; Actin, gamma-enteric smooth muscle; Protein kinase C delta-binding protein; Collagen alpha-1(VI) chain Laminin subunit gamma-1; Sorbin and SH3 domain-containing protein 2; Tenascin; Zyxin; Talin-1; Collagen alpha-1(I) chain; Vinculin; Mimecan; Lipoma-preferred partner; Neuroblast differentiation-associated protein AHNAK; Decorin; Basement membrane-specific heparan sulfate proteoglycan core protein; Phosphatidylethanolamine-binding protein 1
|
Protein
|
Humans
|
Downregulated in PCA(Fold Change):
|
Diagnostic
|
Prostate Cancer Vs BPH
|
p<0.05
|
Tissue
|
21504578
|
638
|
Neuroblast differentiation-associated protein AHNAK; Glutamate dehydrogenase 1, mitochondrial; Protein disulfide-isomerase A4; Cytochrome c oxidase subunit 5B, mitochondrial; Collagen alpha-3(VI) chain; Heterogeneous nuclear ribonucleoprotein H; 10 kDa heat shock protein, mitochondrial; Elongation factor Tu, mitochondrial; 78 kDa glucose-regulated protein; Myosin-9; Protein disulfide-isomerase; Biglycan; Nucleoside diphosphate kinase B; 60 kDa heat shock protein, mitochondrial; Periostin; 60S ribosomal protein L10a Nucleophosmin; Asporin; Sorbitol dehydrogenase;
|
Protein
|
Humans
|
Upregulated in PCA(Fold Change) :
|
Diagnostic
|
Prostate Cancer Vs BPH with Local PIN
|
p<0.05
|
Tissue
|
21504578
|
639
|
Desmin; Myosin regulatory light polypeptide 9; Serum deprivation-response protein 3; Sorbin and SH3 domain- containing protein 1; Tropomyosin alpha-1 chain; Protein kinase C delta-binding protein; Calponin-1; Vinculin; Prostatic acid phosphatase; Zyxin; Fibrinogen alpha chain; Histone H1.0; Talin-1; Protein disulfide-isomerase A3;
|
Protein
|
Humans
|
Downregulated in PCA(Fold Change):
|
Diagnostic
|
Prostate Cancer Vs BPH with Local PIN
|
p<0.05
|
Tissue
|
21504578
|
640
|
Periostin
|
Protein
|
Humans
|
Upregulated in PCA
|
Diagnostic
|
Prostate Cancer Vs BPH with Local PIN
|
p<0.01
|
Tissue
|
21504578
|
644
|
PSMA
|
mRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign
|
p=0.016
|
Urine
|
21520154
|
645
|
PSGR
|
mRNA
|
Humans
|
Upregulted in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign
|
p<0.001
|
Urine
|
21520154
|
646
|
PCA3
|
mRNA
|
Humans
|
Upregulted in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign
|
p=0.018
|
Urine
|
21520154
|
647
|
PSMA + PSGR + PCA3
|
mRNA
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Prostate Cancer Vs Benign
|
NA
|
Urine
|
21520154
|
648
|
PSMA + PSGR + PCA3 + PSA
|
mRNA
|
Humans
|
Differentially Expressed
|
Diagnostic
|
(Prostate Cancer Vs Benign) with PSA in range 4-10ng/ml
|
NA
|
Urine
|
21520154
|
649
|
PSMA
|
mRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
(Prostate Cancer Vs Benign) with PSA in range 4-10ng/ml
|
p=0.003
|
Urine
|
21520154
|
650
|
PSGR
|
mRNA
|
Humans
|
Upregulted in PCa
|
Diagnostic
|
(Prostate Cancer Vs Benign) with PSA in range 4-10ng/ml
|
p= 0.009
|
Urine
|
21520154
|
651
|
PCA3
|
mRNA
|
Humans
|
Upregulted in PCa
|
Diagnostic
|
(Prostate Cancer Vs Benign) with PSA in range 4-10ng/ml
|
p=0.025
|
Urine
|
21520154
|
652
|
PSMA + PSGR + PCA3
|
mRNA
|
Humans
|
Differentially Expressed
|
Diagnostic
|
(Prostate Cancer Vs Benign) with PSA in range 4-10ng/ml
|
NA
|
Urine
|
21520154
|
658
|
PCA3
|
mRNA
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Prostate Cancer Vs No Prostate cancer
|
p=0.001
|
Urine
|
21600800
|
659
|
PSA
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate cancer
|
p=0.019
|
Urine
|
21600800
|
660
|
TMPRSS2:ERG
|
mRNA
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Prostate Cancer Vs No Prostate cancer
|
p=0.001
|
Urine
|
21600800
|
661
|
PSA +PCA3 + TMPRSS2:ERG
|
mRNA
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Prostate Cancer Vs No Prostate cancer
|
NA
|
Urine
|
21600800
|
662
|
TMPRSS2:ERG+ PCA3
|
mRNA
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Prostate Cancer Vs No Prostate cancer
|
NA
|
Urine
|
21600800
|
663
|
Propenoic acid+ Pyrimidine+ Dihyroxybutanoic acid+Creatinine+ Purine+ Glucopyranoside+ Ribofuranoside+Xylonic acid=Xylopyranose
|
Metabolites
|
Humans
|
Upregulated in PCA: (Propenoic acid, Dihyroxybutanoic acid, Creatinine and Xylonic acid); Downregulated in PCA: (Pyrimidine, Creatinine, Purine, Glucopyranoside, Ribofuranoside, Xylopyranose)
|
Diagnostic
|
Prostate Cancer Vs Healthy Men
|
p<0.05
|
Urine
|
21626193
|
664
|
Dihyroxybutanoic acid + Pyrimidine + Xylonic acid + Xylopyranose + Ribofuranoside
|
Metabolites
|
Humans
|
Upregulated in PCA: (Dihyroxybutanoic acid, Xylonic acid); Downregulated in PCA: (Pyrimidine, Xylopyranose, Ribofuranoside)
|
Diagnostic
|
PCa Vs Non Cancerous (healthy+BPH)
|
p<0.05
|
Urine
|
21626193
|
673
|
Androgen Receptor
|
mRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Tumor Vs Normal Tissues
|
p=0.018
|
Tissue
|
21667031
|
685
|
miR-96; miR-182; miR-32; miR-221; miR-25; miR-93; miR-182*; miR-106b; miR-183; miR-153; miR-602; miR-455-5p; miR-205 miR-183*; miR-425; miR-375; miR-193b; miR-30e*; miR-95; miR-378; miR-455-3p; miR-133a; miR-873; miR-222; miR-21; miR-142-3p; miR-575 ;miR-130b; miR-339-3p; miR-149; miR-338-3p; miR-19a; miR-148a; miR-146b-5p; miR-125a-5p; miR-27b; miR-10b*; miR-141; miR-7; miR-505; miR-30c-1*; miR-145*; miR-145; miR-125b; miR-99a; miR-378*; miR-583; miR-221*; miR-20a; miR-124; miR-103; miR-542-5p; miR-193b*; miR-940
|
miRNA
|
Humans
|
Differentially Expressed (Fold Change): [miR-96 (2.12 fold); miR-182 (2.02 fold); miR-32 (2.01 fold); miR-221 (2.27 fold); miR-25 (1.53 fold); miR-93 (1.61 fold); miR-182* (2.25 fold); miR-106b (1.56 fold); miR-183 (2.18 fold); miR-153 (2.74 fold); miR-602 (1.57 fold); miR-455-5p (2.01 fold); miR-205 (6.29 fold); miR-183* (1.8 fold); miR-425 (1.66 fold); miR-375 (1.72 fold); miR-193b (1.58 fold); miR-30e* (1.32 fold); miR-95 (378 fold); miR-378 (1.65 fold); miR-455-3p (2.12 fold); miR-133a (2.19 fold); miR-873 (2.3 fold); miR-222 (2.17 fold); miR-21 (1.71 fold); miR-142 -3p (1.65 fold); miR-575 (1.7 fold) ;miR-130b (1.62 fold); miR-339-3p (1.19 fold); miR-149 (1.82 fold); miR-338-3p (1.96 fold); miR-19a (1.4 fold); miR-148a (1.63 fold); miR-146b-5p (1.68 fold); miR-125a-5p (1.41 fold); miR-27b (1.27 fold); miR-10b* (1.94 fold); miR-141 (1.42 fold); miR-7 (1.76 fold); miR-505 (1.33 fold); miR-30c-1* (1.41 fold); miR-145* (2.01 fold); miR-145 (2.01 fold); miR-125b (1.37 fold); miR-99a (1.34 fold); miR-378* (1.97 fold); miR-583 (1.82 fold); miR-221* (2.1 fold); miR-20a (1.4 fold); miR-124 (1.67 fold); miR-103 (1.21 fold); miR-542-5p (1.77 fold); miR-193b* (1.68 fold); miR-941 (1.52 fold)]
|
Diagnostic
|
Prostate Cancer (PCa)Vs Normal Adjacent Prostate (NAP)
|
p= 0.0046
|
Tissue
|
21765474
|
686
|
miR-96; miR-182; miR-32; miR-221; miR-25; miR-93; miR-182*; miR-106b; miR-183; miR-153; miR-602; miR-455-5p; miR-205 miR-183*; miR-425; miR-375; miR-193b; miR-30e*; miR-95; miR-378; miR-455-3p; miR-133a; miR-873; miR-222; miR-21; miR-142-3p; miR-575 ;miR-130b; miR-339-3p; miR-149; miR-338-3p; miR-19a; miR-148a; miR-146b-5p; miR-125a-5p; miR-27b; miR-10b*; miR-141; miR-7; miR-505; miR-30c-1*; miR-145*; miR-145; miR-125b; miR-99a; miR-378*; miR-583; miR-221*; miR-20a; miR-124; miR-103; miR-542-5p; miR-193b*; miR-941
|
miRNA
|
Humans
|
Differentially Expressed (Fold Change): [miR-96 (2.12 fold); miR-182 (2.02 fold); miR-32 (2.01 fold); miR-221 (2.27 fold); miR-25 (1.53 fold); miR-93 (1.61 fold); miR-182* (2.25 fold); miR-106b (1.56 fold); miR-183 (2.18 fold); miR-153 (2.74 fold); miR-602 (1.57 fold); miR-455-5p (2.01 fold); miR-205 (6.29 fold); miR-183* (1.8 fold); miR-425 (1.66 fold); miR-375 (1.72 fold); miR-193b (1.58 fold); miR-30e* (1.32 fold); miR-95 (378 fold); miR-378 (1.65 fold); miR-455-3p (2.12 fold); miR-133a (2.19 fold); miR-873 (2.3 fold); miR-222 (2.17 fold); miR-21 (1.71 fold); miR-142 -3p (1.65 fold); miR-575 (1.7 fold) ;miR-130b (1.62 fold); miR-339-3p (1.19 fold); miR-149 (1.82 fold); miR-338-3p (1.96 fold); miR-19a (1.4 fold); miR-148a (1.63 fold); miR-146b-5p (1.68 fold); miR-125a-5p (1.41 fold); miR-27b (1.27 fold); miR-10b* (1.94 fold); miR-141 (1.42 fold); miR-7 (1.76 fold); miR-505 (1.33 fold); miR-30c-1* (1.41 fold); miR-145* (2.01 fold); miR-145 (2.01 fold); miR-125b (1.37 fold); miR-99a (1.34 fold); miR-378* (1.97 fold); miR-583 (1.82 fold); miR-221* (2.1 fold); miR-20a (1.4 fold); miR-124 (1.67 fold); miR-103 (1.21 fold); miR-542-5p (1.77 fold); miR-193b* (1.68 fold); miR-941 (1.52 fold)]
|
Diagnostic
|
Prostate Cancer (PCa)Vs Normal Adjacent Prostate (NAP)
|
p= 0.0046
|
Tissue
|
21765474
|
688
|
PCA3
|
mRNA
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Prostate Cancer Vs Non- Prostate Cancer
|
p<0.001
|
Urine
|
21788966
|
689
|
PCA3
|
mRNA
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Prostate Cancer Vs Non- Prostate Cancer
|
p=0.04
|
Urine
|
21788966
|
690
|
AMACR
|
mRNA
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Prostate Cancer Vs Non- Prostate Cancer
|
p=0.04
|
Urine
|
21788966
|
691
|
Multiplex Model (PCA3+ AMACR+ SPINK1+ EZH2+ GOLM1+ TRPM8 + MSMB + Serum PSA)
|
mRNA
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Prostate Cancer Vs Non- Prostate Cancer
|
p<0.001
|
Urine
|
21788966
|
692
|
Quadriplex Model (TRPM8 + MSMB+ PCA3+ AMACR)
|
mRNA
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Prostate Cancer Vs Non- Prostate Cancer
|
p<0.001
|
Urine
|
21788966
|
693
|
Triplex Model (TRPM8 + MSMB+AMACR)
|
mRNA
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Prostate Cancer Vs Non- Prostate Cancer
|
p<0.001
|
Urine
|
21788966
|
694
|
Duplex Model (TRPM8 + MSMB)
|
mRNA
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Prostate Cancer Vs Non- Prostate Cancer
|
p=0.01
|
Urine
|
21788966
|
705
|
PCA3
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Controls
|
NA
|
Blood
|
21832279
|
706
|
α2-macroglobulin (α2M)
|
Protein
|
Humans
|
Upregulated (Healthy: 151.7±25.30 Vs without α2M deficiency: 252.45±125.07)
|
Diagnostic
|
healthy controls vs. PCa patients without α2M deficiency;
|
p<0.01
|
Serum
|
21894431
|
707
|
C-reactive protein (CRP)
|
Protein
|
Humans
|
Upregulated (Healthy: 109.58±89.66 Vs without α2M deficiency: 1534.6±1482.8)
|
Diagnostic
|
healthy controls vs. PCa patients without α2M deficiency;
|
p<0.01
|
Serum
|
21894431
|
708
|
serum amyloid A (SAA)
|
Protein
|
Humans
|
Upregulated (Healthy: 9.96±4.16 Vs without α2M deficiency: 54.7±44.5)
|
Diagnostic
|
healthy controls vs. PCa patients without α2M deficiency;
|
p<0.01
|
Serum
|
21894431
|
709
|
interleukin-6 (IL-6)
|
Protein
|
Humans
|
Upregulated (Healthy: 7.58±6.0 Vs without α2M deficiency: 46.50±40.65)
|
Diagnostic
|
healthy controls vs. PCa patients without α2M deficiency;
|
p<0.01
|
Serum
|
21894431
|
710
|
α1 anti-chymotripsin (α1AT)
|
Protein
|
Humans
|
Upregulated (Healthy: 122±28.0 Vs without α2M deficiency: 293.76±68.51)
|
Diagnostic
|
healthy controls vs. PCa patients without α2M deficiency;
|
p<0.05
|
Serum
|
21894431
|
711
|
α1 acid glycoprotein (α1AG)
|
Protein
|
Humans
|
Upregulated (Healthy: 67.5±25.5 Vs without α2M deficiency: 102±39.36)
|
Diagnostic
|
healthy controls vs. PCa patients without α2M deficiency;
|
p<0.05
|
Serum
|
21894431
|
712
|
Ceruloplasmin (CP)
|
Protein
|
Humans
|
Upregulated (Healthy: 29.0±8.0 Vs without α2M deficiency: 37.74±10.93)
|
Diagnostic
|
healthy controls vs. PCa patients without α2M deficiency;
|
p<0.05
|
Serum
|
21894431
|
717
|
α1 anti-chymotripsin (α1AT)
|
Protein
|
Humans
|
Upregulated (Healthy: 122±28.0 Vs with α2M deficiency: 293.76±68.51)
|
Diagnostic
|
Healthy controls vs. PCa patients with α2M deficiency
|
p<0.05
|
Serum
|
21894431
|
718
|
α1 acid glycoprotein (α1AG)
|
Protein
|
Humans
|
Upregulated (Healthy: 67.5±25.5 Vs with α2M deficiency: 100.8±38.90)
|
Diagnostic
|
Healthy controls vs. PCa patients with α2M deficiency
|
p<0.05
|
Serum
|
21894431
|
719
|
Ceruloplasmin (CP)
|
Protein
|
Humans
|
Upregulated (Healthy: 29.0±8.0 Vs without α2M deficiency: 37.6±10.89)
|
Diagnostic
|
Healthy controls vs. PCa patients with α2M deficiency
|
p<0.05
|
Serum
|
21894431
|
721
|
Methylation Status of APC
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
negative histology followed by a positive biopsy less than 24 months later
|
NA
|
Tissue
|
19755651
|
722
|
Methylation Status of RAR-2β
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
negative histology followed by a positive biopsy less than 24 months later
|
NA
|
Tissue
|
19755651
|
723
|
Methylation Status of GST-Pi
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
negative histology followed by a positive biopsy less than 24 months later
|
NA
|
Tissue
|
19755651
|
724
|
Mutation Status of PER1, SNP: rs885747
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs More Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
725
|
Mutation Status of PER1, SNP rs2289591 - T/T Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs More Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
726
|
Mutation Status of PER1, SNP: rs885747 - G/T + T/T Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs More Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
727
|
Mutation Status of PER2, SNP: rs7602358: T/G phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Less Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
728
|
Mutation Status of PER2, SNP: rs7602358: T/G+G/G phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Less Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
729
|
Mutation Status of PER3,SNP: rs1012477: C/G phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Less Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
730
|
Mutation Status of PER3,SNP: rs1012477: C/G + C/C phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Less Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
731
|
Mutation Status of CSNK1E SNP: rs1534891: T/T phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Cancer
|
p<0.05
|
Blood
|
19934327
|
732
|
Mutation Status of CSNK1E SNP: rs1534891: T/T phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Less Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
733
|
Mutation Status of CRY1 SNP: rs12315175 ; C/C Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Less Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
734
|
Mutation Status of ARNTL, SNP: rs795022; G/A Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Cancer
|
p<0.05
|
Blood
|
19934327
|
735
|
Mutation Status of ARNTL, SNP: rs795022; G/A+A/A Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Cancer
|
p<0.05
|
Blood
|
19934327
|
736
|
Mutation Status of ARNTL, SNP: rs795022; G/A Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Less Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
737
|
Mutation Status of ARNTL, SNP: rs795022; G/A+A/A Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Less Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
738
|
Mutation Status of CLOCK, SNP: rs11133373, G/G Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs More Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
739
|
Mutation Status of CLOCK, SNP: rs11133373, G/G + C/G Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs More Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
740
|
Mutation Status of NPAS2, SNP: rs1369481, G/A Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Cancer
|
p<0.05
|
Blood
|
19934327
|
741
|
Mutation Status of NPAS2, SNP: rs1369481, G/A+A/APhenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Cancer
|
p<0.05
|
Blood
|
19934327
|
742
|
Mutation Status of NPAS2, SNP: rs1369481, G/A Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Less Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
743
|
Mutation Status of NPAS2, SNP: rs1369481, G/A+A/APhenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Less Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
744
|
Mutation Status of NPAS2, SNP: rs895521 G/A Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Cancer
|
p<0.05
|
Blood
|
19934327
|
745
|
Mutation Status of NPAS2, SNP: rs1369481, G/A+A/APhenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Cancer
|
p<0.05
|
Blood
|
19934327
|
746
|
Mutation Status of NPAS2, SNP: rs1369481, G/A+A/APhenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs More Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
747
|
Mutation Status of NPAS2, SNP: rs1369481, T/C Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Cancer
|
p<0.05
|
Blood
|
19934327
|
748
|
Mutation Status of NPAS2, SNP: rs1369481, T/C + CC Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Cancer
|
p<0.05
|
Blood
|
19934327
|
749
|
Mutation Status of NPAS2, SNP: rs1369481, T/C Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Less Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
750
|
Mutation Status of NPAS2, SNP: rs1369481, C/C Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Less Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
751
|
Mutation Status of NPAS2, SNP: rs1369481, T/C+C/C Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Less Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
760
|
OPNa (osteopontin -a )
|
mRNA
|
Humans
|
Upregulated in Cancerous Conditions (PCA: Median: 62.43; BPH: Median: 0.20)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.05
|
Tissue
|
21963599
|
761
|
OPNb (osteopontin -b )
|
mRNA
|
Humans
|
Upregulated in Cancerous Conditions (PCA: Median: 43.47; BPH: Median: 0.50)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.05
|
Tissue
|
21963599
|
762
|
OPNc (osteopontin -c )
|
mRNA
|
Humans
|
Upregulated in Cancerous Conditions (PCA: Median: 200.36; BPH: Median: 0.0)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.05
|
Tissue
|
21963599
|
763
|
tPSA
|
mRNA
|
Humans
|
Upregulated in Cancerous Conditions (PCA: Median: 7.51; BPH: Median: 4.15)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.05
|
Serum
|
21963599
|
764
|
OPNa+OPNb+OPNc
|
mRNA
|
Humans
|
Upregulated in Cancerous Conditions
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.05
|
Tissue
|
21963599
|
765
|
OPNa+OPNb+OPNc+PSA
|
mRNA
|
Humans
|
Upregulated in Cancerous Conditions
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.05
|
Tissue
|
21963599
|
766
|
OPNc+PSA
|
mRNA
|
Humans
|
Upregulated in Cancerous Conditions
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.05
|
Tissue
|
21963599
|
772
|
Thiobarbituric acid reactive substances (TBARS)
|
Protein
|
Humans
|
Upregulated in PCA
|
Diagnostic
|
Controls Vs Patients
|
p<0.05
|
Plasma
|
21993000
|
773
|
Catalase
|
Protein
|
Humans
|
Downregulated in PCA
|
Diagnostic
|
Controls Vs Patients
|
p<0.05
|
Blood
|
21993000
|
774
|
Superoxide Dismutase
|
Protein
|
Humans
|
Upregulated in PCA
|
Diagnostic
|
Controls Vs Patients
|
p<0.05
|
Blood
|
21993000
|
775
|
Vitamin -C
|
Protein
|
Humans
|
Downregulated in PCA
|
Diagnostic
|
Controls Vs Patients
|
p<0.05
|
Serum
|
21993000
|
776
|
Vitamin -E
|
Protein
|
Humans
|
Downregulated in PCA
|
Diagnostic
|
Controls Vs Patients
|
p<0.05
|
Serum
|
21993000
|
786
|
AMACR+CSTA+HPN+MYO6+LAMB3+ABCC4
|
mRNA
|
Humans
|
Upregulated: [ABCC4, AMACR, HPN and MYO6]; Downregulated: [CSTA and LAMB3]
|
Diagnostic
|
Tumor Vs Normal Tissues
|
p<0.001
|
Tissue
|
22009027
|
787
|
Auto-antibody profile (TTLL12+VAT1L+GGA1+RPIA+NHSL1+NOVA2+MAP2+PRPF38B+SRP14+ HSPH1+ZNF154+ADD1+RASSF7+RBM15+394 other genes)
|
Protein (Auto-antibodies)
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
prostate cancer Vs benign disease
|
p<0.001
|
Serum
|
22012634
|
788
|
TTLL12+VAT1L+GGA1+RPIA+NHSL1+NOVA2+MAP2+PRPF38B+SRP14+ HSPH1+ZNF154+ADD1+RASSF7+RBM15+394 other genes
|
Protein (Auto-antibodies)
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Healthy Men
|
p<0.001
|
Serum
|
22012634
|
789
|
tPSA
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
PCa VS Benign Prostatic Hyperplasia
|
p≤ 0.05
|
Serum
|
22024423
|
790
|
cPSA
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
PCa VS Benign Prostatic Hyperplasia
|
p≤ 0.05
|
Serum
|
22024423
|
791
|
f/tPSA
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
PCa VS Benign Prostatic Hyperplasia
|
p≤ 0.05
|
Serum
|
22024423
|
792
|
c/tPSA
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
PCa VS Benign Prostatic Hyperplasia
|
p≤ 0.05
|
Serum
|
22024423
|
795
|
mmu-mir-24; mmu-mir-141; mmu-mir-182; mmu-mir-184; mmu-mir-215; mmu-mir-298; mmu-mir-320; mmu-mir-346; mmu-mir-375; mmu-mir-887
|
miRNA
|
Mice
|
Upregulated: [mmu-mir-24; mmu-mir-141; mmu-mir-182; mmu-mir-184; mmu-mir-298; mmu-mir-320; mmu-mir-346; mmu-mir-375; mmu-mir-887]; Downregulated: [mmu-mir-215]
|
Diagnostic
|
TRAMP and wild-type (WT) littermate control mice
|
p≤ 0.05
|
Serum
|
22052531
|
796
|
hsa-mir-141; hsa-mir-298; hsa-mir-375
|
miRNA
|
Humans
|
Upregulated in PCa [hsa-mir-141; hsa-mir-298; hsa-mir-375]
|
Diagnostic
|
Normal Vs Primary Tumor
|
p≤ 0.05
|
Serum
|
22052531
|
797
|
hsa-mir-141; hsa-mir-298; hsa-mir-346; hsa-mir-375
|
miRNA
|
Humans
|
Upregulated in PCa [hsa-mir-141; hsa-mir-298; hsa-mir-346 ; hsa-mir-375]
|
Diagnostic
|
Normal Vs Metastatic Tumor
|
p≤ 0.05
|
Serum
|
22052531
|
822
|
TDRD1
|
mRNA
|
Humans
|
Upregulated in Prostate cancer
|
Diagnostic
|
Benign Vs Tumor
|
p<0.05
|
Tissue
|
22142399
|
824
|
CRISP3
|
mRNA
|
Humans
|
Upregulated in Prostate cancer
|
Diagnostic
|
Benign Vs Tumor
|
p<0.05
|
Tissue
|
22142399
|
825
|
CRISP3
|
mRNA
|
Humans
|
Upregulated in TMPRSS2-ERG gene fusion (37 fold) compared to benign samples, normal and fusion-negative tumor samples (FC = 1.2)
|
Diagnostic
|
Benign Vs TMPRSS2-ERG gene fusion Vs non-fusion
|
TMPRSS2-ERG positive tumors compared to normal tissue (p = 2.2*10-12), normal and fusion-negative tumor samples (p = 0.03)
|
Tissue
|
22142399
|
826
|
CRISP3, AMACR , OR51E2, SPRR2F , TDRD1, F5, ACSM1, C20orf74, GOLM1 , MYC, CACNA1D, SFRP4, TRIB1, GDF15, LRRN1, FOLH1 , PRR16, LUZP2, RRM2, ERG, COL1A1, DNAH5, ZNF417 , SPON2, RICS, HIPK2 , ACACA , TUG1, COQ6 , LARP1, NETO2, FLJ20184, FASN, NEDD4L, LOC286161, MAOA, XPO6, ABCC4, RAB3B, TMEM45B, IMPDH2, DAPK1, LOC100131821 , C19orf48, KIAA1244 , GPI , HIVEP1, NAALADL2, C11orf92, THBS4, MYO6, BAMBI, ZNF462, SPOCK1, REPS2, SGEF, TBC1D16, TRIM36, LBH, AGPAT3, CAMKK2, GCNT1, F2R, BAT2L , LRIG1, GLYATL1 , DDX21, PLA1A, TMEFF2, SLC7A1, KIAA0368, PCDHB13 , UGT2B10 , EEF2 , C10orf137 , MICAL2, BGN, BICC1 , EIF4A1 , STX19, CHD6, ASPN, PTPN13, RAB3IP, ZNF146, BCOR, SH3RF1, TMTC4, ZDHHC9, MS4A8B, UTRN, DIP2B, UAP1, C4A , HDLBP, KIF5C, PMEPA1, GRPR , ZNF217, HUWE1, ZNF417 , AAK1 , CCDC6, BRD2, CRKRS, TP53INP1, ABCA1 , H2BFS , LIG3, PHF12, FAM117B, MED13L, TMEM2, PLA2G7, DICER1, SRRM2, BAGE2 , USP54, MYH10, SLC36A1, SLC7A11, LOC651907 , CREB3L1, ATP13A5 , ATP2B1, ANKRD34B, BAZ2A, C10orf12, POSTN, CALR3 , ZNF828, CS, ERGIC1, BXDC1, EIF4G1, PRKCSH, ABHD2, SIM2, NUFIP2, SPP1, RPL9P11 , HSN2 , JAG1, TPX2, MOSC1, TMEM161B , C4orf18 , BAT2L, DDAH1, NOLC1, ANKRD17, LOC100130958 , CMTM4, APOF, GALNT7, SETD5, HIST1H3B, TSPAN13, EPCAM, MLL, ADAR, EGR1, DNAJC10, MLEC, SEL1L, HYOU1, COL1A2, PSD3, MYO10 , ENC1 , BAT2D1, DDI2 , KDM2A , ENO1, C20orf191 , EP300, ALDH1A3, FAM119A , SLC27A2, C9orf91, TKT, NCL , ABHD2, STK33, ACTG2, IGJ, SLC26A4, SLC39A2, ZNF701 , COCH , BZW1 , CCDC68, PTPLA, VSNL1, GCNT2 , RND3, SCN7A, CYP27A1, CYP3A5 , GJA1, GSTM3, CFL2, C2 , HBB, SPATA6, KRT23, GPR87, MPPED2, HIST1H4C, OGN, LRCH2, C12orf75, NTN4, LOC100188947 , NEFH, SRD5A2, ADAM32, DPT, AZGP1, ACSS3, SLC15A2, PROM1, CACNA2D1, CXCL13, MME, ZNF483, L3MBTL4, APLF , CHRDL1, HIST1H1A, LEPREL1, ARMCX1, ANGPT1, MT1M , DSC3, B3GALT2, SLC22A3, ANO5, MT1G, PCP4, ANXA1 , PLN, EAF2 , ANPEP, TCEAL2 , LTF, PRDM5, LOC100134430 , ATRNL1, KRT15, SPOCK3, PI15, CD177, GDEP, CD38, FLRT3, SLC18A2, AOX1, MSMB, TGM4, OLFM4, SLC14A1, AMY1A
|
mRNA
|
Humans
|
Differentially expressed (Log fold change) [CRISP3 ( 2.93 fold); , AMACR ( 2.85 fold); , OR51E2 ( 2.46 fold); , SPRR2F ( 2.36 fold); , TDRD1 ( 2.31 fold); , F5 ( 2.23 fold); , ACSM1 ( 2.23 fold); , C20orf74 ( 2.05 fold); , GOLM1 ( 2.01 fold); , MYC ( 1.83 fold); , CACNA1D ( 1.73 fold); , SFRP4 ( 1.68 fold); , TRIB1 ( 1.68 fold); , GDF15 ( 1.67 fold); , LRRN1 ( 1.67 fold); , FOLH1 ( 1.66 fold); , PRR16 ( 1.59 fold); , LUZP2 ( 1.58 fold); , RRM2 ( 1.57 fold); , ERG ( 1.57 fold); , COL1A1 ( 1.57 fold); , DNAH5 ( 1.57 fold); , ZNF417 ( 1.56 fold); , SPON2 ( 1.56 fold); , RICS ( 1.55 fold); , HIPK2 ( 1.54 fold); , ACACA ( 1.54 fold); , TUG1 ( 1.51 fold); , COQ6 ( 1.5 fold); , LARP1 ( 1.49 fold); , NETO2 ( 1.49 fold); , FLJ20184 ( 1.48 fold); , FASN ( 1.48 fold); , NEDD4L ( 1.47 fold); , LOC286161 ( 1.46 fold); , MAOA ( 1.45 fold); , XPO6 ( 1.43 fold); , ABCC4 ( 1.43 fold); , RAB3B ( 1.42 fold); , TMEM45B ( 1.42 fold); , IMPDH2 ( 1.39 fold); , DAPK1 ( 1.38 fold); , LOC100131821 ( 1.38 fold); , C19orf48 ( 1.37 fold); , KIAA1244 ( 1.36 fold); , GPI ( 1.35 fold); , HIVEP1 ( 1.34 fold); , NAALADL2 ( 1.34 fold); , C11orf92 ( 1.34 fold); , THBS4 ( 1.33 fold); , MYO6 ( 1.31 fold); , BAMBI ( 1.31 fold); , ZNF462 ( 1.3 fold); , SPOCK1 ( 1.3 fold); , REPS2 ( 1.28 fold); , SGEF ( 1.28 fold); , TBC1D16 ( 1.27 fold); , TRIM36 ( 1.27 fold); , LBH ( 1.26 fold); , AGPAT3 ( 1.26 fold); , CAMKK2 ( 1.25 fold); , GCNT1 ( 1.24 fold); , F2R ( 1.24 fold); , BAT2L ( 1.24 fold); , LRIG1 ( 1.23 fold); , GLYATL1 ( 1.23 fold); , DDX21 ( 1.23 fold); , PLA1A ( 1.22 fold); , TMEFF2 ( 1.22 fold); , SLC7A1 ( 1.22 fold); , KIAA0368 ( 1.22 fold); , PCDHB13 ( 1.21 fold); , UGT2B10 ( 1.21 fold); , EEF2 ( 1.2 fold); , C10orf137 ( 1.2 fold); , MICAL2 ( 1.2 fold); , BGN ( 1.19 fold); , BICC1 ( 1.19 fold); , EIF4A1 ( 1.19 fold); , STX19 ( 1.18 fold); , CHD6 ( 1.18 fold); , ASPN ( 1.18 fold); , PTPN13 ( 1.18 fold); , RAB3IP ( 1.18 fold); , ZNF146 ( 1.18 fold); , BCOR ( 1.17 fold); , SH3RF1 ( 1.17 fold); , TMTC4 ( 1.16 fold); , ZDHHC9 ( 1.16 fold); , MS4A8B ( 1.16 fold); , UTRN ( 1.16 fold); , DIP2B ( 1.15 fold); , UAP1 ( 1.15 fold); , C4A ( 1.15 fold); , HDLBP ( 1.15 fold); , KIF5C ( 1.14 fold); , PMEPA1 ( 1.14 fold); , GRPR ( 1.14 fold); , ZNF217 ( 1.13 fold); , HUWE1 ( 1.13 fold); , ZNF417 ( 1.13 fold); , AAK1 ( 1.13 fold); , CCDC6 ( 1.12 fold); , BRD2 ( 1.12 fold); , CRKRS ( 1.12 fold); , TP53INP1 ( 1.12 fold); , ABCA1 ( 1.12 fold); , H2BFS ( 1.12 fold); , LIG3 ( 1.11 fold); , PHF12 ( 1.11 fold); , FAM117B ( 1.11 fold); , MED13L ( 1.11 fold); , TMEM2 ( 1.11 fold); , PLA2G7 ( 1.11 fold); , DICER1 ( 1.11 fold); , SRRM2 ( 1.1 fold); , BAGE2 ( 1.1 fold); , USP54 ( 1.1 fold); , MYH10 ( 1.1 fold); , SLC36A1 ( 1.1 fold); , SLC7A11 ( 1.1 fold); , LOC651907 ( 1.1 fold); , CREB3L1 ( 1.1 fold); , ATP13A5 ( 1.09 fold); , ATP2B1 ( 1.09 fold); , ANKRD34B ( 1.09 fold); , BAZ2A ( 1.08 fold); , C10orf12 ( 1.08 fold); , POSTN ( 1.08 fold); , CALR3 ( 1.07 fold); , ZNF828 ( 1.07 fold); , CS ( 1.07 fold); , ERGIC1 ( 1.07 fold); , BXDC1 ( 1.07 fold); , EIF4G1 ( 1.06 fold); , PRKCSH ( 1.06 fold); , ABHD2 ( 1.06 fold); , SIM2 ( 1.06 fold); , NUFIP2 ( 1.06 fold); , SPP1 ( 1.06 fold); , RPL9P11 ( 1.06 fold); , HSN2 ( 1.05 fold); , JAG1 ( 1.05 fold); , TPX2 ( 1.05 fold); , MOSC1 ( 1.04 fold); , TMEM161B ( 1.04 fold); , C4orf18 ( 1.04 fold); , BAT2L ( 1.04 fold); , DDAH1 ( 1.04 fold); , NOLC1 ( 1.03 fold); , ANKRD17 ( 1.03 fold); , LOC100130958 ( 1.03 fold); , CMTM4 ( 1.03 fold); , APOF ( 1.03 fold); , GALNT7 ( 1.02 fold); , SETD5 ( 1.02 fold); , HIST1H3B ( 1.02 fold); , TSPAN13 ( 1.02 fold); , EPCAM ( 1.02 fold); , MLL ( 1.02 fold); , ADAR ( 1.02 fold); , EGR1 ( 1.02 fold); , DNAJC10 ( 1.02 fold); , MLEC ( 1.02 fold); , SEL1L ( 1.01 fold); , HYOU1 ( 1.01 fold); , COL1A2 ( 1.01 fold); , PSD3 ( 1.01 fold); , MYO10 ( 1.01 fold); , ENC1 ( 1.01 fold); , BAT2D1 ( 1.01 fold); , DDI2 ( 1.01 fold); , KDM2A ( 1.01 fold); , ENO1 ( 1.01 fold); , C20orf191 ( 1.01 fold); , EP300 ( 1.01 fold); , ALDH1A3 ( 1.01 fold); , FAM119A ( 1.01 fold); , SLC27A2 ( 1.0 fold); , C9orf91 ( 1.0 fold); , TKT ( 1.0 fold); , NCL ( 1.0 fold); , ABHD2 ( 1.0 fold); , STK33 ( -1.0 fold); , ACTG2 ( -1.01 fold); , IGJ ( -1.01 fold); , SLC26A4 ( -1.01 fold); , SLC39A2 ( -1.01 fold); , ZNF701 ( -1.01 fold); , COCH ( -1.02 fold); , BZW1 ( -1.03 fold); , CCDC68 ( -1.03 fold); , PTPLA ( -1.04 fold); , VSNL1 ( -1.04 fold); , GCNT2 ( -1.05 fold); , RND3 ( -1.05 fold); , SCN7A ( -1.05 fold); , CYP27A1 ( -1.05 fold); , CYP3A5 ( -1.05 fold); , GJA1 ( -1.06 fold); , GSTM3 ( -1.07 fold); , CFL2 ( -1.09 fold); , C2 ( -1.09 fold); , HBB ( -1.1 fold); , SPATA6 ( -1.1 fold); , KRT23 ( -1.11 fold); , GPR87 ( -1.11 fold); , MPPED2 ( -1.11 fold); , HIST1H4C ( -1.11 fold); , OGN ( -1.12 fold); , LRCH2 ( -1.12 fold); , C12orf75 ( -1.12 fold); , NTN4 ( -1.12 fold); , LOC100188947 ( -1.12 fold); , NEFH ( -1.13 fold); , SRD5A2 ( -1.15 fold); , ADAM32 ( -1.16 fold); , DPT ( -1.16 fold); , AZGP1 ( -1.16 fold); , ACSS3 ( -1.17 fold); , SLC15A2 ( -1.17 fold); , PROM1 ( -1.18 fold); , CACNA2D1 ( -1.18 fold); , CXCL13 ( -1.18 fold); , MME ( -1.18 fold); , ZNF483 ( -1.19 fold); , L3MBTL4 ( -1.19 fold); , APLF ( -1.21 fold); , CHRDL1 ( -1.21 fold); , HIST1H1A ( -1.23 fold); , LEPREL1 ( -1.25 fold); , ARMCX1 ( -1.25 fold); , ANGPT1 ( -1.26 fold); , MT1M ( -1.27 fold); , DSC3 ( -1.29 fold); , B3GALT2 ( -1.29 fold); , SLC22A3 ( -1.3 fold); , ANO5 ( -1.31 fold); , MT1G ( -1.31 fold); , PCP4 ( -1.32 fold); , ANXA1 ( -1.32 fold); , PLN ( -1.32 fold); , EAF2 ( -1.33 fold); , ANPEP ( -1.35 fold); , TCEAL2 ( -1.39 fold); , LTF ( -1.4 fold); , PRDM5 ( -1.42 fold); , LOC100134430 ( -1.42 fold); , ATRNL1 ( -1.42 fold); , KRT15 ( -1.43 fold); , SPOCK3 ( -1.44 fold); , PI15 ( -1.44 fold); , CD177 ( -1.46 fold); , GDEP ( -1.47 fold); , CD38 ( -1.53 fold); , FLRT3 ( -1.58 fold); , SLC18A2 ( -1.69 fold); , AOX1 ( -1.72 fold); , MSMB ( -1.74 fold); , TGM4 ( -1.76 fold); , OLFM4 ( -1.85 fold); , SLC14A1 ( -1.95 fold); , AMY1A ( -2.11 fold)]
|
Diagnostic
|
Benign Vs Tumor
|
p<0.006857824
|
Tissue
|
22142399
|
827
|
Auto-antibody signature (TARDBP, TLN1, PARK7, LEDGF/ PSIP1, and CALD1)
|
Protein
|
Humans
|
Differentially Expressed
|
Diagnostic
|
prostate cancer Vs benign prostatic hyperplasia
|
p< 0.05
|
Serum
|
22146597
|
828
|
TARDBP; TLN1; ;PARK7; LEDGF/PSIP1; CALD1; p73; PTEN; PXN; PEX10; KLK3; DBN1; NFAT1; B Tubulin; SOS1; HSF4; TOP1; HSPA1A/B;
|
Protein
|
Humans
|
Differentially Expressed
|
Diagnostic
|
prostate cancer Vs benign prostatic hyperplasia
|
p< 0.05
|
Serum
|
22146597
|
829
|
Secreted frizzled-related protein (SFRP)-2
|
Protein
|
Humans
|
Downregulated in Prostate cancer (PCa: 2.28 ± 0.33 Vs Controls: 1.11 ± 0.09)
|
Diagnostic
|
Benign Vs malignant prostate glands
|
p<0.0001
|
Tissue
|
22175903
|
831
|
sPLA2-IIA (Secreted group IIA phospholipase A2)
|
Protein
|
Humans
|
Upregulated in Prostate cancer
|
Diagnostic
|
Controls Vs Prostate Cancer
|
p<0.001
|
Serum
|
22189868
|
832
|
CRP (C- Reactive Protein)
|
Protein
|
Humans
|
Upregulated in Prostate cancer
|
Diagnostic
|
Controls Vs Prostate Cancer
|
p<0.001
|
Serum
|
22189868
|
833
|
APOD; C1QTNF3; CD27; CFB; CFH; CLU; CRABP1; DDAH2; FTL; IGSF8; ITIH4l; LGALS3; LYZ; MGAT5; PECAM1; RBP4; RECK; SELENBP1; SLIT2;
|
mRNA
|
Humans
|
(1.358 fold) Upregulated in PCa [APOD (2.803 fold) ; C1QTNF3 (1.100 fold); CD27 (1.183 fold); CFB (3.231 fold); CFH (1.381 fold); CLU (1.638 fold); CRABP1 (1.477 fold) ; DDAH2 (1.152 fold) ; FTL (1.718 fold); IGSF8 (1.358 fold) ; ITIH4l (1.215 fold) ; LGALS3 (4.121 fold) ; LYZ (2.093 fold) ; MGAT5 (1.112 fold); PECAM1 (2.404 fold) ; RBP4 (1.872 fold); RECK (2.569 fold) ; SELENBP1 (1.327 fold) ; SLIT2 (1.848 fold)]
|
Diagnostic
|
Prostate Cancer Vs Normal controls
|
p<0.001
|
Urine
|
22194848
|
837
|
mir-107; mir-130b; mir-141; mir-181a-2*; mir-2110; mir-301a; mir-326; mir-331-3p; mir-432; mir-574-3p; mir-625;
|
miRNA
|
Humans
|
Upregulated in PCa: [mir-107; mir-130b; mir-141; mir-2110; mir-301a; mir-326; mir-331-3p; mir-432; mir-574-3p; mir-625;] Downregulated in PCa: [miR-181a-2* (2.69 fold)]
|
Diagnostic
|
Normal Vs prostate cancer
|
p<0.001
|
Plasma
|
22240788
|
838
|
mir-107; mir-141; mir-181a-2*; mir-2110; mir-301a; mir-326; mir-432; mir-574-3p; mir-625;
|
miRNA
|
Humans
|
Upregulated in localised PCa: [mir-107; mir-141; mir-2110; mir-301a; mir-326; mir-432; mir-574-3p; mir-625;] Downregulated in localised PCa: [miR-181a-2* (2.69 fold)]
|
Diagnostic
|
Normal Vs localised prostate cancer
|
p<0.001
|
Plasma
|
22240788
|
839
|
mir-582-3p; mir-20a*; mir-375; mir-200b; mir-379; mir-572; mir-513a-5p; mir-577; mir-23a*; mir-1236; mir-609; mir-17*; mir-619; mir-624*; mir-198; mir-130b
|
miRNA
|
Humans
|
Upregulated in metastatic PCa: [mir-582-3p; mir-20a*; mir-375; mir-200b; mir-379; mir-513a-5p; mir-577; mir-23a*; mir-1236; mir-609; mir-17*; mir-619; mir-624*; mir-198; mir-130b] Downregulated in metastatic PCa: [miR-572 (7.39 fold)]
|
Diagnostic
|
metastatic prostate cancer Vs localised prostate cancer
|
p<0.001
|
Plasma
|
22240788
|
840
|
miRNA - 107
|
miRNA
|
Humans
|
Upregulated in Pca
|
Diagnostic
|
Benign Vs Prostate Cancer
|
p=0.001
|
Urine
|
22240788
|
841
|
miRNA - 574-3p
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Benign Vs Prostate Cancer
|
p=0.012
|
Urine
|
22240788
|
843
|
let-7c + let-7e+miR30c+ miR-622+ miR1285
|
miRNA
|
Humans
|
Differentially expressed
|
Diagnostic
|
prostate cancer Vs benign prostatic hyperplasia
|
p<0.001
|
Plasma
|
22298030
|
844
|
let-7c + let-7e+miR30c+ miR-622+ miR1285
|
miRNA
|
Humans
|
Differentially expressed
|
Diagnostic
|
Prostate Cancer Vs Healthy Men
|
p<0.001
|
Plasma
|
22298030
|
845
|
let-7c
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Healthy Men
|
Testing: p<0.001
|
Plasma
|
22298030
|
846
|
let-7e
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Healthy Men
|
Testing: p<0.001
|
Plasma
|
22298030
|
847
|
miR-30c
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Healthy Men
|
Testing: p<0.001
|
Plasma
|
22298030
|
848
|
miR-622
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Healthy Men
|
Testing: p<0.001
|
Plasma
|
22298030
|
849
|
miR-1285
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Healthy Men
|
Testing: p=0.0047
|
Plasma
|
22298030
|
850
|
let-7c
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
prostate cancer Vs benign prostatic hyperplasia
|
Training & Testing: p<0.0001
|
Plasma
|
22298030
|
851
|
let-7e
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
prostate cancer Vs benign prostatic hyperplasia
|
Training: p=0.0029; Testing = p<0.0001
|
Plasma
|
22298030
|
852
|
miR-25
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
prostate cancer Vs benign prostatic hyperplasia
|
Training: p<0.0001; Not significant in validation set
|
Plasma
|
22298030
|
853
|
miR-30c
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
prostate cancer Vs benign prostatic hyperplasia
|
Training: p<0.0001
|
Plasma
|
22298030
|
854
|
miR-346
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
prostate cancer Vs benign prostatic hyperplasia
|
Training: p<0.0001; Not significant in validation set
|
Plasma
|
22298030
|
855
|
miR-622
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
prostate cancer Vs benign prostatic hyperplasia
|
Training: p<0.0001
|
Plasma
|
22298030
|
856
|
miR-940
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
prostate cancer Vs benign prostatic hyperplasia
|
Training: p= 0.0062
|
Plasma
|
22298030
|
857
|
miR-1285
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
prostate cancer Vs benign prostatic hyperplasia
|
Training: p<0.0001
|
Plasma
|
22298030
|
862
|
sphingosine-1-phosphate (S1P)
|
Protein
|
Humans
|
Downregulated in Prostate Cancer (Healthy: 10.36±0.69 ; BPH: 9.39±0.75; PCA: 6.89±0.58)
|
Diagnostic
|
Healthy Controls Vs BPH VS Prostate Cancer
|
p <0.05
|
Plasma
|
22315056
|
865
|
Erythrocyte sphingosine kinase-1 (SphK1)
|
Protein
|
Humans
|
Downregulated in PCa (Healthy: 4.7±0.42; PCa: 2.14±0.17)
|
Diagnostic
|
Prostate Cancer Vs Healthy Men
|
p<0.0001
|
Plasma
|
22315056
|
868
|
Alpha2- macroglobin (α2m); Elongation Factor 1A (EFA1) ; Lumican ; Complement Factor 1 Light Chain; Heparin Cofactor 2; Inter-alpha-trypsin inhbitor heavy chain H2; Serum amyloid P-component; Histidine Rich gylcoprotien; Transthyretin
|
Protein
|
Humans
|
Upregulated: [Alpha2- macroglobin (α2m) (1.4 fold); Elongation Factor 1A (EFA1) (1.2 fold); Lumican (1.1 fold); Downregulated: [Complement Factor 1 Light Chain (1.1 fold); Heparin Cofactor 2 (1.1 fold) ; Inter-alpha-trypsin inhbitor heavy chain H2 (1.1 fold) ; Serum amyloid P-component (1.1 fold); Histidine Rich gylcoprotien (1.3 fold) ; Transthyretin (1.4 fold)]
|
Diagnostic
|
BPH Vs Non Progressing Prostate Cancer
|
p ≤0.01
|
Serum
|
22355332
|
869
|
Beta-2-gylcoprotien 1 + Somatomedin- B
|
Protein
|
Humans
|
Upregulated: [Beta-2-gylcoprotien 1 (1.2 fold)+ Somatomedin- B (1.1 fold)]
|
Diagnostic
|
BPH Vs Non Progressing Prostate Cancer
|
p ≤0.01
|
Serum
|
22355332
|
870
|
Antithrombin III + Inter-alpha-trypsin inhibitor heavy chain H3
|
Protein
|
Humans
|
Downregulated: [Antithrombin III (1.4 fold)+ Inter-alpha-trypsin inhibitor heavy chain H3 (1.7 fold)]
|
Diagnostic
|
BPH Vs Non Progressing Prostate Cancer
|
p ≤0.01
|
Serum
|
22355332
|
871
|
Afamin + Fibronectin 1 + Alpha-2-HS-glycoprotien chain B
|
Protein
|
Humans
|
Upregulated : [Afamin (1.4 fold) + Fibronectin 1 (1.4 fold) + Alpha-2-HS-glycoprotien chain B (1.1 fold)]
|
Diagnostic
|
BPH Vs Non Progressing Prostate Cancer
|
p ≤0.01
|
Serum
|
22355332
|
872
|
cDNA FLJ55673 + cDNA FLJ58564 + Ceruplasmin + Complement C5 + Alpha-1-antichymotrypsin + Complement component C9b + cDNA FLJ54228
|
Protein
|
Humans
|
Downregulated : [cDNA FLJ55673 (1.1 fold)+ cDNA FLJ58564 (1.1 fold)+ Ceruplasmin (1.1 fold) + Complement C5 (1.1 fold) + Alpha-1-antichymotrypsin (1.2 fold) + Complement component C9b (1.2 fold) + cDNA FLJ54228 (1.5 fold)
|
Diagnostic
|
BPH Vs Non Progressing Prostate Cancer
|
p ≤0.01
|
Serum
|
22355332
|
882
|
ANRIL; H19; PCA3; MALAT1; PCGEM1; PTENP1
|
LncRNA
|
Humans
|
Differentially expressed (Median Fold Change): [ANRIL (MFD: −1.17 fold); H19 (MFD: 1.32 fold); PCA3 (MFD: 14.3 fold); MALAT1 (MFD: −1.64 fold); PCGEM1 (MFD: 1.75 fold); PTENP1 (MFD: −1.34 fold);]
|
Diagnostic
|
Primary Vs Normal
|
p<0.01
|
Tissue
|
22371711
|
883
|
ANRIL; H19; PCA3; MALAT1
|
LncRNA
|
Humans
|
Differentially expressed (Median Fold Change): [ANRIL (MFD: 1.49 fold); H19 (MFD: 1.43 fold); PCA3 (MFD: 4.46 fold); MALAT1 (MFD: -3.33 fold)]
|
Diagnostic
|
Metastatic Vs Normal
|
p<0.01
|
Tissue
|
22371711
|
884
|
ANRIL; H19; PCA3; MALAT1; PCGEM1; PTENP1
|
LncRNA
|
Humans
|
Differentially expressed (Median Fold Change): [ANRIL (MFD: 1.33 fold); H19 (MFD: -1.12 fold); PCA3 (MFD: -3.44 fold); MALAT1 (MFD: -2.63 fold); PCGEM1 (MFD: -4 fold); PTENP1 (MFD: 1.50 fold);]
|
Diagnostic
|
Metastatic Vs Primary
|
p<0.04
|
Tissue
|
22371711
|
885
|
miR145; miR221;
|
miRNA
|
Humans
|
Differentially expressed (Median Fold Change): [miR145 (MFD: -7.98 fold); miR221 (MFD: -2.11 fold);]
|
Diagnostic
|
Metastatic Vs Normal
|
p<0.01
|
Tissue
|
22371711
|
886
|
miR143; miR145; miR221;
|
miRNA
|
Humans
|
Differentially expressed (Median Fold Change): [miR143 (MFD: -1.78 fold); miR145 (MFD: -4.77 fold); miR221 (MFD: -1.52 fold);]
|
Diagnostic
|
Metastatic Vs Primary
|
p<0.04
|
Tissue
|
22371711
|
888
|
NK3 homeobox 1 (NKX3-1)
|
Protein
|
Humans
|
Downregulated in Gleason Grade 3
|
Diagnostic
|
Normal Prostate Vs Gleason Grade 3
|
p=0.012
|
Tissue
|
22397815
|
896
|
Ring finger protein 19A (RNF19A)
|
mRNA
|
Humans
|
Upregulated in PCa (>2 fold)
|
Diagnostic
|
Prostate Cancer vs healthy controls
|
p = 0.0066
|
Blood
|
22493721
|
900
|
Transthyretin (TTR)
|
Protein
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Normal Tissue Vs BPH Vs PCa
|
p<0.01
|
Tissue
|
22496929
|
901
|
Clusterin (CLU)
|
Protein
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Normal Tissue Vs BPH Vs PCa
|
p<0.01
|
Tissue
|
22496929
|
902
|
(Table 1)
|
Protein
|
Humans
|
Upregulated in PCa [1.12-2.25]
|
Diagnostic
|
Patients Vs Controls
|
p<0.05
|
Serum
|
22499197
|
907
|
%p2PSA
|
Protein
|
Humans
|
Upreregulated in PCa
|
Diagnostic
|
PCa VS No PCa group; PCa Vs HGPIN group
|
p<0.001
|
Serum
|
22542564
|
908
|
(percent free PSA) % fPSA
|
Protein
|
Humans
|
Downregulated in PCa [No PCa: 19.36 ; PCa: 15.41; HGPIN: 22.23]
|
Diagnostic
|
PCa VS No PCa group; PCa Vs HGPIN group
|
No PCa Vs PCa:p=0.004; PCa Vs HGPIN: p<0.001
|
Serum
|
22542564
|
909
|
Prostate Health Index (phi)
|
Protein
|
Humans
|
Upreregulated in PCa
|
Diagnostic
|
PCa VS No PCa group; PCa Vs HGPIN group
|
p< 0.001
|
Serum
|
22542564
|
910
|
PCA3
|
Protein
|
Humans
|
Upreregulated in PCa
|
Diagnostic
|
PCa VS No PCa group
|
p< 0.001
|
Urine
|
22542564
|
911
|
Minichromosome Maintenance Complex Protein 2 (MCM2) product scores
|
Protein
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Prostate Cancer Vs No Tumor
|
p<0.001
|
Tissue
|
22554381
|
913
|
Ki-67
|
Protein
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Prostate Cancer Vs No Tumor
|
p<0.001
|
Tissue
|
22554381
|
918
|
PCA3
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Cancer (@ first negative biopsy) [Group A]
|
NA
|
Urine
|
22564540
|
919
|
PCA3
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Cancer (@ first negative biopsy) [Group B]
|
NA
|
Urine
|
22564540
|
921
|
Methylation Status Of A0X1; CYBA; EDG3; ELF4; EPB41L3; FLJ12056; FLJ90650; FLT4; GAS6; GRASP; GSTP1; HAAO; HIF3A; HOXC11; LEP; MGC39606; MOBKL2B; RAB34; RARb; RHCG; RND2; SLC34A2; SPATA6; TPM4; ZNF154
|
Methylation
|
Humans
|
Methylated in PCA:
|
Diagnostic
|
Tumor Vs Normal Tissues
|
p<0.0001
|
Tissue
|
22589488
|
925
|
Methylation Status Of HIF3A; HAAO; RARb; GSTP1
|
Methylation
|
Humans
|
Methylated with Systemic Recurrence
|
Diagnostic
|
Tumor Vs Normal Tissues
|
p<0.0182
|
Tissue
|
22589488
|
929
|
Spondin-2 (SPON2)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Healthy Men
|
p=0.001
|
Serum
|
22615945
|
930
|
Triosephosphate isomerase 1 (TPI1); Spondin-2 (SPON-2); Thrombospondin 1, N-Terminal Domain (THBS1); Phosphoglycerate mutase 1 (PGAM1); Syndecan binding protein 1 (ST1); Peroxiredoxin 1 (PRDX1); Nucleophosmin- isoform CRA_c (NPM1)
|
Protein
|
Cell Lines
|
Differentially Expressed in PCA
|
Diagnostic
|
BPH-1, LNCaP Vs C4-2
|
p<0.05
|
Serum
|
22615945
|
931
|
Spondin-2 (SPON2)
|
Protein
|
Humans
|
Upregulated with Gleason Score >=7 and 8
|
Diagnostic
|
Gleason Score (2-6), (7-8) and (9-10)
|
p=0.001
|
Tissue
|
22615945
|
932
|
Modification Status of RNF219
|
cirDNA
|
Humans
|
Highly modified in PCa Patients (Control: 55%
|
Diagnostic
|
PCA VS no history of prostate disease
|
p=3 *10^-41
|
Plasma
|
22619380
|
933
|
Modification Status of RNF220
|
cirDNA
|
Humans
|
Highly modified in PCa Patients (Control: 55%
|
Diagnostic
|
PCA Vs BPH
|
p = 1 *10^-4
|
Plasma
|
22619380
|
934
|
NACA + CCNB1
|
mRNA
|
Humans
|
CCNB1 upregulated in Prostate cancer; NACA Downregulated in Prostate Cancer
|
Diagnostic
|
BPC VS BP
|
p<0.05
|
Tissue
|
22640805
|
935
|
GPR37; SOX4; CCNB1; TOP2A; DLG5; NACA; NR2C2; PDCD5; IDSP1
|
mRNA
|
Humans
|
Upregulated: [GPR37; SOX4; CCNB1; TOP2A;] Downregulated: [DLG5; NACA; NR2C2; PDCD5; IDSP1]
|
Diagnostic
|
BPC (benign prostates containing PCa) VS BP
|
GPR37 (training: 0.018, testing: 0.003); SOX4 (training: 0.03, testing: 0.03); CCNB1 (training: 0.002, testing: 0.007); TOP2A (training: 0.018); DLG5 (training: p< 0.001, testing: 0.004); NACA (p<0.001, testing: 0.003) ; NR2C2 (training: p<0.001, testing: 0.02); PDCD5 (training: p<0.001); IDSP1 (training: p<0.001)
|
Tissue
|
22640805
|
936
|
PCA3
|
mRNA
|
Humans
|
Upregulated (RQ = NP: 7.4 Vs LG = 202)
|
Diagnostic
|
Normal adjacent to Prostate (NP) Vs Low Grade PCa
|
<0.005
|
Tissue
|
22674214
|
937
|
TMPRSS2:ERG Fusion
|
mRNA
|
Humans
|
Upregulated (RQ = NP: 0.6 Vs LG = 11)
|
Diagnostic
|
Normal adjacent to Prostate (NP) Vs Low Grade PCa
|
<0.005
|
Tissue
|
22674214
|
938
|
PCA3 + TMPRSS2:ERG gene fusion
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Normal adjacent to Prostate (NP) Vs Low Grade PCa
|
NA
|
Tissue
|
22674214
|
939
|
TMPRSS2:ERG gene fusion (given that PCA3 test is negative)
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Normal adjacent to Prostate (NP) Vs Low Grade PCa
|
NA
|
Tissue
|
22674214
|
940
|
Apolipoprotein A-II (APOA2); Complement C3 (C3f); Inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4f); Alpha-1 antitrypsin (AAT); High molecular weight kininogen (KNG); Transthyretin (TTR)
|
Protein
|
Humans
|
Downregulated in PCa [Apolipoprotein A-II (APOA2); Complement C3 (C3f); Inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4f); ] Upregulated in PCa [Alpha-1 antitrypsin (AAT); High molecular weight kininogen (KNG); Transthyretin (TTR)]
|
Diagnostic
|
Benign Prostatic Hyperplasia (BPH) Vs Prostate Cancer (PCa)
|
p<0.01
|
Serum
|
22740474
|
946
|
Mutation Status of LEPR (LEPR Gln223Arg)
|
Mutation
|
Humans
|
Increased Risk of PCa
|
Diagnostic
|
LEPR Gln223Arg ( A Vs G mutation) in All patients with Prostate Cancer
|
NA
|
NA
|
22792137
|
947
|
Mutation Status of SPP1 (SPP1-66 T>G)
|
Mutation
|
Humans
|
Increased Risk of PCa
|
Diagnostic
|
SPP1 mutaion (SPP1- 66 T>G) in All patients with Prostate Cancer
|
NA
|
NA
|
22792137
|
948
|
Mutation Status of IGF1R (IGF1R+3174 G>A)
|
Mutation
|
Humans
|
Increased Risk of PCa
|
Diagnostic
|
IGF1R mutation (IGF1R+3174 G>A) in All patients with Prostate Cancer
|
NA
|
NA
|
22792137
|
949
|
Mutation Status of IGFBP3 (IGFBP3-202 A>C)
|
Mutation
|
Humans
|
Increased Risk of PCa
|
Diagnostic
|
IGFBP3 mutation (IGFBP3-202 A>C) in All patients with Prostate Cancer
|
NA
|
NA
|
22792137
|
950
|
Mutation Status of FGF2 (FGF2+223 C>T)
|
Mutation
|
Humans
|
Increased Risk of PCa
|
Diagnostic
|
FGF2 mutation (FGF2+223 C>T) in All patients with Prostate Cancer
|
NA
|
NA
|
22792137
|
951
|
Mutation Status of IL6 (IL6-597 G>A)
|
Mutation
|
Humans
|
Increased Risk of PCa
|
Diagnostic
|
IL6 mutation (IL6-597 G>A) in All patients with Prostate Cancer
|
NA
|
NA
|
22792137
|
961
|
Prostate health index (phi)
|
Protein
|
Humans
|
Upregulated in PCa [No PCa: 36.84 (28.82–46.14) Vs PCa 49.97 (37.75–69.65)]
|
Diagnostic
|
PCa Vs No-PCa
|
<0.001
|
Serum
|
22821756
|
962
|
Prostate Cancer Antigen 3 (PCA3)
|
mRNA
|
Humans
|
Upregulated in PCa [No PCa: 32 (13.5–68) Vs PCa 50 (34–83)]
|
Diagnostic
|
PCa Vs No-PCa
|
p=0.001
|
Urine
|
22821756
|
963
|
PCA3 + phi
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
PCa Vs No-PCa
|
p=0.001
|
Urine + Serum
|
22821756
|
966
|
Osteopontin
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
PCa Vs Controls (Healthy Donors + BPH)
|
p<0.05
|
Serum
|
22870138
|
967
|
Osteopontin
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
PCa Vs BPH VS Healthy Donors
|
p<0.05
|
Plasma
|
22870138
|
973
|
Prostate Specific Antigen (PSA)
|
Protein
|
Humans
|
Upregulated in PCa [Patients: 7.8±3; Controls: 1.9±0.98]
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p<0.001
|
Serum
|
22901185
|
974
|
ACP
|
Protein
|
Humans
|
Upregulated in PCa [Patients: 4.8±1.8; Controls: 3.1±0.6]
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p<0.001
|
Serum
|
22901185
|
975
|
PAP
|
Protein
|
Humans
|
Upregulated in PCa [Patients: 2.0±1.7 Controls: 0.5±0.2]
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p<0.001
|
Serum
|
22901185
|
978
|
ACOT11-001; AOX1-001; C19orf46-002; C8orf84-001; COCH-202; CTA-55I10.1;001; DMD-024; FGF10-002 ;FGFR2-008; FGFR2-016; GABRE-006; GNAL-001; GNAO1-002; HEATR8-006; ISL1-002; NR2F2-202; PCP4-004; PDE5A-005; PDZRN4-202; RSRC2-017; TGM4-001; TSPAN2-001; ABCC4-004; ALK-001; ATP1A1-002; NAMPT-006; NAMPT-007; RP11-627G23.1-004;
|
genes or ncRNA
|
Humans
|
Upregulated: AOX1-001, RSRC2-017, ABCC4-004, ALK-001, ATP1A1-002, NAMPT-006, RP11-627G23.1-004 get upregulated with fold change >1.2; Downregualted: Others get downregulated with Fold Change < 1.0
|
Diagnostic
|
Primary Vs Normal
|
p<0.05
|
Tissue
|
22956952
|
980
|
ACOT11-001; AOX1-001; C19orf46-002; C8orf84-001; COCH-202; CTA-55I10.1;001; DMD-024; FGF10-002 ;FGFR2-008; FGFR2-016; GABRE-006; GNAL-001; GNAO1-002; HEATR8-006; ISL1-002; NR2F2-202; PCP4-004; PDE5A-005; PDZRN4-202; RSRC2-017; TGM4-001; TSPAN2-001;
|
genes or ncRNA
|
Humans
|
Upregulated: C19orf46-002, RSRC2-017 get upregulated with fold change >1.2; Downregualted: Others get downregulated with Fold Change < 1.1
|
Diagnostic
|
Metastatic Vs Normal
|
p<0.05
|
Tissue
|
22956952
|
988
|
Zinc α2-glycoprotein (ZAG)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
PCA VS No PCA group
|
p=0.05
|
Urine
|
23020913
|
989
|
Zinc α2-glycoprotein (ZAG) + PSA
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
PCA VS No PCA group
|
p=0.05
|
Urine + Serum
|
23020913
|
1003
|
CRTAM (cytotoxic and regulatory T cell molecule) + SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)
|
mRNA
|
Humans
|
Downregulated (1.58 fold)
|
Diagnostic
|
Controls Vs High Grade Prostate Cancer (GS 8 and above)
|
p = 0.0000346
|
Blood
|
23071848
|
1004
|
CXCR3 [chemokine (C-X-C motif) receptor 3] + SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)
|
mRNA
|
Humans
|
Downregulated (1.59 fold)
|
Diagnostic
|
Controls Vs High Grade Prostate Cancer (GS 8 and above)
|
p=0.0000338
|
Blood
|
23071848
|
1005
|
FCRL3 (Fc receptor-like 3)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)
|
mRNA
|
Humans
|
Downregulated (1.61 fold)
|
Diagnostic
|
Controls Vs High Grade Prostate Cancer (GS 8 and above)
|
p = 0.00000285
|
Blood
|
23071848
|
1006
|
KIAA1143+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)
|
mRNA
|
Humans
|
Downregulated (1.44 fold)
|
Diagnostic
|
Controls Vs High Grade Prostate Cancer (GS 8 and above)
|
p = 0.000000182
|
Blood
|
23071848
|
1007
|
KLF12 (Kruppel-like factor 12)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)
|
mRNA
|
Humans
|
Downregulated (1.66 fold)
|
Diagnostic
|
Controls Vs High Grade Prostate Cancer (GS 8 and above)
|
p=0.000000816
|
Blood
|
23071848
|
1008
|
TMEM204 (transmembrane protein 204)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)
|
mRNA
|
Humans
|
Downregulated (1.52 fold)
|
Diagnostic
|
Controls Vs High Grade Prostate Cancer (GS 8 and above)
|
p = 0.000084
|
Blood
|
23071848
|
1009
|
Combination of 6 genes duplexes [CRTAM (cytotoxic and regulatory T cell molecule) + SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)] + [CXCR3 [chemokine (C-X-C motif) receptor 3] + SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)] + [FCRL3 (Fc receptor-like 3)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)] + [KIAA1143+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)] + [KLF12 (Kruppel-like factor 12)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)] + [TMEM204 (transmembrane protein 204)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)]
|
mRNA
|
Humans
|
Downregulated (1.52 fold)
|
Diagnostic
|
Controls Vs High Grade Prostate Cancer (GS 8 and above)
|
p = 0.000084
|
Blood
|
23071848
|
1010
|
PSA +CRTAM (cytotoxic and regulatory T cell molecule)+ CXCR3 [chemokine (C-X-C motif) receptor 3]+ FCRL3 (Fc receptor-like 3) + KIAA1143+ KLF12 (Kruppel-like factor 12)+ TMEM204 (transmembrane protein 204)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)
|
mRNA
|
Humans
|
Downregulated (1.52 fold)
|
Diagnostic
|
Controls Vs High Grade Prostate Cancer (GS 8 and above)
|
p = 0.000084
|
Blood
|
23071848
|
1011
|
PSA +CRTAM (cytotoxic and regulatory T cell molecule)+ CXCR3 [chemokine (C-X-C motif) receptor 3]+ FCRL3 (Fc receptor-like 3)+ KIAA1143+ KLF12 (Kruppel-like factor 12)+ TMEM204 (transmembrane protein 204)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)
|
mRNA
|
Humans
|
Downregulated (1.52 fold)
|
Diagnostic
|
Controls Vs High Grade Prostate Cancer (GS 8 and above)
|
p = 0.000084
|
Blood
|
23071848
|
1012
|
Survivn
|
Protein
|
Humans
|
Upregulated in PCA compared to both Healthy controls and BPH
|
Diagnostic
|
(Normal and BPH )VS PCa
|
p<0.001
|
Plasma
|
23091600
|
1013
|
Survivn
|
Protein
|
Humans
|
Upregulated in PCA (150 pg/ml ) compared to both Healthy controls (59.7 pg/ml) and BPH (55 pg/ml)
|
Diagnostic
|
(Normal and BPH )VS PCa
|
p<0.001
|
Serum
|
23091600
|
1014
|
Chromatin Assembly Factor 1 (CAF-1 p60)
|
Protein
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Normal Vs prostate cancer
|
NA
|
Tissue
|
23109837
|
1015
|
NA
|
Methylation
|
Humans
|
Hypermethylation in PCa (Δ Log Intensity): []; Hypomethylated in PCa: (Δ Log intensity): []
|
Diagnostic
|
Pca Tumor Vs Tumor Adjacent
|
NA
|
Tissue
|
23119026
|
1016
|
Aldehyde Oxidase 1 (AOX1)
|
Methylation
|
Humans
|
Hypermethylation in PCa
|
Diagnostic
|
Pca Tumor Vs Tumor Adjacent
|
p = 7.46 x10^-8
|
Tissue
|
23119026
|
1017
|
Spondin 2 (SPON2)
|
Methylation
|
Humans
|
Hypermethylation in PCa
|
Diagnostic
|
Pca Tumor Vs Tumor Adjacent
|
p = 2.1 x10^-14
|
Tissue
|
23119026
|
1018
|
sICAM-1
|
Protein
|
Humans
|
Upregulated in PCa (PCa: 245.2 , Normal: 240.3)
|
Diagnostic
|
PCa Vs Controls
|
p=0.005
|
Plasma
|
23171880
|
1019
|
CRP
|
Protein
|
Humans
|
Upregulated in PCa (PCa: 2.5 , Normal: 2.1)
|
Diagnostic
|
PCa Vs Controls
|
[Odds Ratio: p=0.03]; [Regulation: p = 0.006]
|
Plasma
|
23171880
|
1020
|
PCA3 score >= 25
|
mRNA
|
Humans
|
PCA3 Score upregulated in PCa (No PCa: 24; Pca: 60)
|
Diagnostic
|
PCa Vs No PCA group
|
p<0.001
|
Urine
|
23201468
|
1021
|
TMPRSS2-ERG (v-ets erythroblastosis virus E26 oncogene homolog) >= 10
|
mRNA
|
Humans
|
TMPRSS2-ERG fusion upregulated in PCa (No PCa: 15; Pca: 46)
|
Diagnostic
|
PCa Vs No PCA group
|
p<0.001
|
Urine
|
23201468
|
1027
|
Carbonic Anhydrase I
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
PCA Vs Healthy Controls
|
p = 0.022
|
Plasma
|
23213568
|
1028
|
PSA + Carbonic Anhydrase I
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
PCA Vs Healthy Controls
|
p = 0.022
|
Plasma
|
23213568
|
1029
|
miR-30d
|
miRNA
|
Humans
|
Upregulated in PCa Cell Lines (> 2 fold)
|
Diagnostic
|
Normal Vs Cancerous Prostate Cell Lines
|
p<0.05
|
Cell Lines
|
23231923
|
1030
|
miR-30d
|
miRNA
|
Humans
|
Upregulated in PCa [Normal (6.23 ± 6.06) Vs Cancer (7.95 ± 7.03)]
|
Diagnostic
|
Cancerous Vs Cancer Adjacent from Same patient
|
p = 0.03
|
Tissue
|
23231923
|
1036
|
BMI1
|
Protein
|
Humans
|
Upregulated in PCa: (Normal: 0.81 ± 0.07; PCa stage 2: 1.8 ± 0.08)
|
Diagnostic
|
Normal Vs PCa
|
p< 0.05
|
Tissue
|
23308129
|
1037
|
Aminopeptidase N (APN)
|
Protein
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Non Malignant Tissue
|
p=0.034
|
Tissue
|
23322201
|
1038
|
Alanyl membrane aminopeptidase (ANPEP)
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs Non Malignant Tissue
|
p=0.0023
|
Tissue
|
23322201
|
1039
|
Alanyl membrane aminopeptidase (ANPEP)
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs Non Malignant Tissue
|
p=0.0025
|
Tissue
|
23322201
|
1042
|
Early Growth Response 3 (Egr3)
|
mRNA
|
Humans
|
Upregulated in PCa (5.35 fold)
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
p = 2 x 10^-15
|
Tissue
|
23342084
|
1043
|
Early Growth Response 3 (Egr3)
|
Protein
|
Humans
|
Upregulated in PCa (NSR (number of strong positive pixels ratio):normal prostate: 0.039 ; NSR: prostate cancer: 0.13)
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
p = 0.00047
|
Tissue
|
23342084
|
1044
|
Prostate Specific Membrane Antigen (PSMA)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
p = 0.001
|
Tissue
|
23342084
|
1046
|
Hemoglobin
|
Others
|
Humans
|
NA
|
Diagnostic
|
PC (all stages) vs. non-cancerous conditions
|
p < 0.05
|
Blood
|
23356551
|
1047
|
Prostate Specific Antigen (PSA)
|
Protein
|
Humans
|
NA
|
Diagnostic
|
PC (all stages) vs. non-cancerous conditions
|
p < 0.05
|
Serum
|
23356551
|
1048
|
blood urea nitrogen (BUN)
|
Others
|
Humans
|
NA
|
Diagnostic
|
PC (all stages) vs. non-cancerous conditions
|
p < 0.05
|
Blood
|
23356551
|
1049
|
Prostate biopsy clinical decision rule (PBCDR): (HGB+ Age+ PSA+ RBC+Hematuria+ Creatinine+ Black (Ethnicity) + Albumin+ MCV)
|
Others
|
Humans
|
NA
|
Diagnostic
|
PC (all stages) vs. non-cancerous conditions
|
p < 0.05
|
Tissue
|
23356551
|
1050
|
Prostate biopsy clinical decision rule (PBCDR): (HGB+ RBC+ Creatinine+ PSA+ Age+ MCV+ Black (ethnicity))
|
Others
|
Humans
|
NA
|
Diagnostic
|
PC (stage II, III, IV) vs. other (PC stage I, PIN, BPH, prostatitis)
|
p < 0.05
|
Tissue
|
23356551
|
1051
|
Hemoglobin
|
Others
|
Humans
|
NA
|
Diagnostic
|
PC (stage II, III, IV) vs. other (PC stage I, PIN, BPH, prostatitis)
|
p < 0.001
|
Blood
|
23356551
|
1052
|
Hematuria
|
Others
|
Humans
|
NA
|
Diagnostic
|
PC (stage II, III, IV) vs. other (PC stage I, PIN, BPH, prostatitis)
|
p < 0.05
|
Blood
|
23356551
|
1053
|
RBC
|
Others
|
Humans
|
NA
|
Diagnostic
|
PC (stage II, III, IV) vs. other (PC stage I, PIN, BPH, prostatitis)
|
p < 0.05
|
Blood
|
23356551
|
1054
|
Prostate Specific Antigen (PSA)
|
Protein
|
Humans
|
NA
|
Diagnostic
|
PC (stage II, III, IV) vs. other (PC stage I, PIN, BPH, prostatitis)
|
p < 0.001
|
Serum
|
23356551
|
1065
|
PCA3
|
mRNA
|
Humans
|
Upregulated in Cancerous Conditions (Cancerous: 7.69 Vs Non Cancerous: 7.00)
|
Diagnostic
|
Cancerous Vs Non Cancerous
|
p<0.0005
|
Tissue
|
23391636
|
1066
|
PCA3
|
mRNA
|
Humans
|
Upregulated in Stage pT3/4 (1.9 Median fold difference)
|
Diagnostic
|
Stage pT2 Vs Stage pT3/4
|
p=0.015
|
Tissue
|
23391636
|
1067
|
KLK15
|
mRNA
|
Humans
|
Upregulated in Stage pT3/4 (2.71 Median fold difference)
|
Diagnostic
|
Stage pT2 Vs Stage pT3/4
|
p=0.032
|
Tissue
|
23391636
|
1068
|
AMBP precursor (AMBPf1)
|
Protein
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p=0.005
|
Urine
|
23417432
|
1069
|
AMBP precursor (AMBPf2)
|
Protein
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p=0.004
|
Urine
|
23417432
|
1070
|
Saposin
|
Protein
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p=0.002
|
Urine
|
23417432
|
1071
|
AMBP precursor (AMBPf2)
|
Protein
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p=0.004
|
Urine
|
23417432
|
1072
|
Inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4)
|
Protein
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p=0.006
|
Urine
|
23417432
|
1073
|
Methylation Status of RASSF1A
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.001
|
Tissue
|
23431474
|
1074
|
Methylation Status of APC
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.001
|
Tissue
|
23431474
|
1078
|
ACAT1
|
Protein
|
Humans
|
Upregulated in LNCAP-SF [3-hydroxy-3-methylglutaryl coenzyme A synthase ( HMGCS2 ); ( 9.2394 fold) aldehyde dehydrogenase 1 family, member A3 ( ALDH1A3 ); ( 8.1484 fold) chromosome 6 open reading frame 115 ( C6orf115 ); ( 6.6899 fold) hydroxysteroid (11-beta) dehydrogenase 2 ( HSD11B2 ); ( 5.4227 fold) anterior gradient homolog 2 (Xenopus laevis) ( AGR2 ); ( 5.0377 fold) S100 calcium binding protein P ( S100P ); ( 4.92 fold) dehydrogenase/reductase (SDR family) member 2 ( DHRS2 ); ( 4.5974 fold) monoamine oxidase B ( MAOB ); ( 4.3792 fold) thymidine phosphorylase ( TYMP ); ( 3.8776 fold) monoamine oxidase A ( MAOA ); ( 3.8563 fold) sequestosome 1 ( SQSTM1 ); ( 3.8075 fold) tropomyosin 1 (alpha) ( TPM1 ); ( 3.5117 fold) cathepsin D ( CTSD ); ( 3.3074 fold) growth differentiation factor 15 ( GDF15 ); ( 3.2564 fold) arginase, type II ( ARG2 ); ( 3.2251 fold) glutaminase ( GLS ); ( 3.2099 fold) arylacetamide deacetylase-like 1 ( AADACL1 ); ( 3.1698 fold) aldehyde dehydrogenase 4 family, member A1 ( ALDH4A1 ); ( 3.0362 fold) solute carrier family 12 (potassium/chloride transporters), member 7 ( SLC12A7 ); ( 3.0201 fold) spermatogenesis associated, serine-rich 2-like ( SPATS2L ); ( 2.9743 fold) N-acylsphingosine amidohydrolase (acid ceramidase) 1 ( ASAH1 ); ( 2.9654 fold) calpain 2, (m/II) large subunit ( CAPN2 ); ( 2.9387 fold) acyl-CoA thioesterase 9 ( ACOT9 ); ( 2.9016 fold) keratin 18 ( KRT18 ); ( 2.8839 fold) epoxide hydrolase 1, microsomal (xenobiotic) ( EPHX1 ); ( 2.8828 fold) glutathione S-transferase kappa ( GSTK1 ); ( 2.8356 fold) aldo-keto reductase family 1, member C2 ( AKR1C2 ); ( 2.8239 fold) acyl-CoA synthetase long-chain family member 3 ( ACSL3 ); ( 2.8157 fold) mannosidase, beta A, lysosomal ( MANBA ); ( 2.813 fold) vesicle-associated membrane protein 8 (endobrevin) ( VAMP8 ); ( 2.7515 fold) retinol saturase (all-trans-retinol 13,14-reductase) ( RETSAT ); ( 2.7151 fold) occludin ( OCLN ); ( 2.7082 fold) sulfide dehydrogenase like ( SQRDL ); ( 2.7062 fold) acyl-CoA dehydrogenase, C-2 to C-3 short chain ( ACADS ); ( 2.6711 fold) microtubule associated monoxygenase, calponin and LIM domain containing 1 ( MICAL1 ); ( 2.6382 fold) 3-hydroxyisobutyryl-CoA hydrolase ( HIBCH ); ( 2.5805 fold) abhydrolase domain containing 11 ( ABHD11 ); ( 2.5752 fold) acyl-CoA synthetase long-chain family member 4 ( ACSL4 ); ( 2.5729 fold) superoxide dismutase 2, mitochondrial ( SOD2 ); ( 2.536 fold) fucosidase, alpha-L- 1, tissue ( FUCA1 ); ( 2.5286 fold) sideroflexin 3 ( SFXN3 ); ( 2.5136 fold) carnitine palmitoyltransferase 2 ( CPT2 ); ( 2.5117 fold)
|
Diagnostic
|
Normal Prostate Vs Bone Metastatis
|
p = 0.0001
|
Tissue
|
23443136
|
1082
|
PCA3
|
mRNA
|
Humans
|
Upregulated in Positive Biopsy
|
Diagnostic
|
Positive Vs Negative Biopsy
|
P =0.01
|
Urine
|
23515404
|
1083
|
TMPRSS2:ERG
|
mRNA
|
Humans
|
Upregulated in Positive Biopsy
|
Diagnostic
|
Positive Vs Negative Biopsy
|
P =0.001
|
Urine
|
23515404
|
1085
|
miR-183
|
miRNA
|
Humans
|
Upregulated in PC Cells
|
Diagnostic
|
Prostate Cancer Cell Lines Vs Normal Prostate Cell Lines
|
p<0.05
|
Cell Lines
|
23538390
|
1086
|
miR-183
|
miRNA
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
prostate tumour Vs adjacent normal tissues
|
p<0.05
|
Tissue
|
23538390
|
1089
|
Ribonuclease -L (RNASEL) [Arg462Gln Mutation]
|
Mutation
|
Humans
|
Increased Risk of PCA in African Population
|
Diagnostic
|
Cases Vs Controls
|
p<0.05
|
NA
|
23554651
|
1090
|
Ribonuclease -L (RNASEL) [Arg462Gln Mutation]
|
Mutation
|
Humans
|
Increased Risk of PCA
|
Diagnostic
|
Cases Vs Controls
|
p<0.05
|
NA
|
23554651
|
1115
|
Spermine; Putrescine; Cho; PCho; GPC; PE; Lactate; Alanine; Glucose; Citrate; Succinate; Glutamate; Glutamine; Glycine; Isoleucine; Leucine; Valine;
|
Metabolites
|
Humans
|
Upregulated in Prostate Cancer [Cho; PCho; GPC; PE; Lactate; Alanine; Glutamate; Glutamine; Glycine; Isoleucine; Leucine; Valine;]; Downregulated in Prostate Cancer: [Spermine; Putrescine; Citrate; Creatine;]
|
Diagnostic
|
Normal adjacent samples Vs Cancer samples
|
p<0.05
|
Tissue
|
23626811
|
1116
|
Spermine
|
Metabolites
|
Humans
|
Downregulated in High Grade Prostate Cancer
|
Diagnostic
|
High Grade (GS >=7) Vs Low Grade (GS =6)
|
p = 0.0044
|
Tissue
|
23626811
|
1117
|
Citrate
|
Metabolites
|
Humans
|
Downregulated in High Grade Prostate Cancer
|
Diagnostic
|
High Grade (GS >=7) Vs Low Grade (GS =6)
|
p = 0.000773
|
Tissue
|
23626811
|
1118
|
Citrate
|
Metabolites
|
Humans
|
Downregulated in Gleason Score 7
|
Diagnostic
|
Gleason Score 6 Vs Gleason Score 7
|
p = 0.014
|
Tissue
|
23626811
|
1119
|
Citrate
|
Metabolites
|
Humans
|
Downregulated in Gleason Score 7
|
Diagnostic
|
Gleason Score 6 Vs Gleason Score (8 & 9)
|
p = 0.005
|
Tissue
|
23626811
|
1120
|
Spermine
|
Metabolites
|
Humans
|
Downregulated in Gleason Score 7
|
Diagnostic
|
Gleason Score 6 Vs Gleason Score (8 & 9)
|
p = 0.022
|
Tissue
|
23626811
|
1123
|
miR-24
|
miRNA
|
Mice
|
Upregulated in TRAMP Mice
|
Diagnostic
|
TRansgenic Adenocarcinoma of Mouse Prostate (TRAMP) VS Wild Type (WT) mice
|
p < 0.01
|
Serum
|
23719956
|
1126
|
PCA3; GAS5; PVT1; DANCR; PCAT1; MEG3; PRINS; HOTTIP; EGOT;
|
LncRNA
|
Humans
|
Upregulated in PCa: [PCA3; GAS5; PVT1; DANCR; PCAT1;]lDownregulated in PCa: [MEG3; PRINS; HOTTIP; EGOT;]
|
Diagnostic
|
Tumor Vs Normal Tissues
|
p< 0.05
|
Tissue
|
23728290
|
1127
|
Aminoadipic acid
|
Metabolites
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Malignant Vs Non Malignant
|
p<0.0001
|
Tissue
|
23737455
|
1128
|
Cerebronic acid
|
Metabolites
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Malignant Vs Non Malignant
|
p<0.0001
|
Tissue
|
23737455
|
1129
|
Gluconic acid
|
Metabolites
|
Humans
|
Downregulated in Prostate Cancer
|
Diagnostic
|
Malignant Vs Non Malignant
|
p<0.0001
|
Tissue
|
23737455
|
1130
|
Glycerophosphoethanol-amine
|
Metabolites
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Malignant Vs Non Malignant
|
p<0.0001
|
Tissue
|
23737455
|
1131
|
2-Hydroxybehenic acid
|
Metabolites
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Malignant Vs Non Malignant
|
p<0.0001
|
Tissue
|
23737455
|
1132
|
Isopentenyl pyrophosphate
|
Metabolites
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Malignant Vs Non Malignant
|
p<0.0001
|
Tissue
|
23737455
|
1133
|
Maltotriose
|
Metabolites
|
Humans
|
Downregulated in Prostate Cancer
|
Diagnostic
|
Malignant Vs Non Malignant
|
p<0.0001
|
Tissue
|
23737455
|
1134
|
7-Methylguanine
|
Metabolites
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Malignant Vs Non Malignant
|
p<0.0001
|
Tissue
|
23737455
|
1135
|
Tricosanoic acid
|
Metabolites
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Malignant Vs Non Malignant
|
p<0.0001
|
Tissue
|
23737455
|
1140
|
hsa-miR-10b; hsa-miR-15a; hsa-miR-15b; hsa-miR-16; hsa-miR-18a; hsa-miR-18b; hsa-miR-25; hsa-miR-30c; hsa-miR-32; hsa-miR-34a; hsa-miR-34c-5p; hsa-miR-92a; hsa-miR-181a; hsa-miR-181b; hsa-miR-181c; hsa-miR-184; hsa-miR-122; hsa-miR-124; hsa-miR-125a-5p; hsa-miR-125b; hsa-miR-128a; hsa-miR-133b; hsa-miR-134; hsa-miR-135b; hsa-miR-146b-5p; hsa-miR-148b; hsa-miR-193a-5p; hsa-miR-193b hsa-miR-206; hsa-miR-20b; hsa-miR-214; hsa-miR-215; hsa-miR-301a; hsa-miR-372
|
miRNA
|
Humans
|
Upregulated with fold change > 2
|
Diagnostic
|
prostate tumor Vs normal epithelium
|
p<0.05
|
Tissue
|
23781281
|
1142
|
let-7a; let-7b; let-7c
|
miRNA
|
Humans
|
Downregulated in PCa: [let-7a; let-7b; let-7c]
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.01
|
Tissue
|
23798998
|
1143
|
RFX6 (rs339331)
|
Mutation
|
Humans
|
Reduced Risk of Prostate cancer
|
Diagnostic
|
Cancer Vs Normal
|
p= 0.013
|
Blood
|
23803082
|
1144
|
HPN; CLDN3; AMACR; GOLPH2; TRIB1; LOC729677; GDF15; TARP; MYC; LOC731404; ZFP36; SIM2; CTGF; GJB1; CENPN; EGR2; FBP1; KLF4; LUZP2; C8orf4; PDLIM3; CREB3L1; GCNT1; CTPS; PTP4A3
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.001
|
Tissue
|
23813660
|
1145
|
SLC14A1; LOC642587; TRIM29; CYP3A5; TP73L; SNAI2; PIK3R1; KRT5; NPAL3; FGFR2; CSTA; CAPG; ITGA2; FER1L3; MEIS2; LGALS3BP; GPRC5B; NEFH; GSTM2; S100A16; MME; EVA1; KRT23; ADD3; GSTP1;
|
mRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.001
|
Tissue
|
23813660
|
1146
|
Copy Number Alterations: [PTP4A3; LOC440335; SERPINE1; PKN1; JUNB; GDF15; CLDN4; CLDN3; LOC644844; ZNF511;FOSB; FMOD; ZFP36; RASD1;ODC1; HSD17B6; GADD45G; APOF; TUBB2A; PGC; NR4A1; LOC145837; FOS; FBP1;]
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
NA
|
Tissue
|
23813660
|
1147
|
Copy Number Alterations: [PTP4A3; LOC440335; SERPINE1; PKN1; JUNB; GDF15; CLDN4; CLDN3; LOC644844; ZNF511;FOSB; FMOD; ZFP36; RASD1;ODC1; HSD17B6; GADD45G; APOF; TUBB2A; PGC; NR4A1; LOC145837; FOS; FBP1;]
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Agressive Vs Non Agressive Prostate Cancer
|
NA
|
Tissue
|
23813660
|
1150
|
1,5-anhydroglucitol; 10-heptaadecenoate (17:1n7); 10-nonadecenoate (19:1n9); ; 15-HETE; 1-arachidonoylglycerophosphoethanolamine; 1- arachidonoylglycerophosphoinositol; 1-arachidoylglycerophosphocholine; 1-eicosadienoylglycerophosphocholine; 1-heptadecanoylglycerophosphocholine; 1-heptadecanoylglycerophosphoethanolamine; 1-linoleoylglycerophosphocholine; 1-linoleoylglycerophosphoethanolamine; 1-myristoylglycerophosphocholine; 1-oleoylglycerol; 1-oleoylglycerophosphocholine; 1-oleoylglycerophosphoethanolamine; 1-oleoylglycerophosphoinositol; 1-oleoylglycerophosphoserine; 1-palmitoleoylglycerophosphocholine; 1-palmitoleoylglycerophosphoethanolamine; 1-palmitoylglycerol; 1-palmitoylglycerophosphocholine; 1-palmitoylglycerophosphoethanolamine 1-palmitoylglycerophosphoinositol; 1-palmitoylplasmenylethanolamine; 1-stearoylglycerol; 1-stearoylglycerophosphocholine; 1-stearoylglycerophosphoethanolamine; 1-stearoylglycerophosphoglycerol; 1-stearoylglycerophosphoinositol; 2-aminoadipate; 2-aminobutyrate; 2-arachidonoylglycerophosphocholine; 2-arachidonoylglycerophosphoethanolamine; 2-docosahexaenoylglycerophosphoethanolamine; 2-hydroxybutyrate; 2-hydroxyglutarate; 2-hydroxypalmitate; 2-hydroxystearate; 2-linoleoylglycerophosphocholine; 2-linoleoylglycerophosphoethanolamine; 2-methylbutyrylcarnitine; 2-oleoylglycerophosphocholine; 2-oleoylglycerophosphoethanolamine; 2-oleoylglycerophosphoserine; 2-palmitoylglycerophosphocholine; 2-palmitoylglycerophosphoethanolamine; 2-stearoylglycerophosphocholine; 3-(4-hydroxyphenyl)lactate; 3-aminoisobutyrate; 3-carboxy-4-methyl-5-propyl-2-furanpropanoate; 3-dehydrocarnitine; 3-dephosphocoenzyme-A; 3-hydroxybutyrate; 3-hydroxyhippurate; 3-indoxyl-sulfate; 3-phosphoglycerate; 4-acetamidobutanoate; 4-androsten-3beta_17beta-diol-disulfate-1; 4-hydroxybutyrate; 4-hydroxyhippurate; 4-methyl-2-oxopentanoate; 5,6-dihydrouracil; 5-alpha-androstan-3beta_17beta-diol-disulfate 5-methylthioadenosine; 5-oxoproline; 6-sialyllactose; 6-sialyl-N-acetyllactosamine; 7-alpha-hydroxy-3-oxo-4-cholestenoate; acetylcarnitine; acetylcholine; Ac-Ser-Asp-Lys-Pro; adenine; adenosine; adenosine 5'-diphosphate; adenosine 5'-monophosphate; adenosine 5'-diphosphoribose; adenosine 5-triphosphate; adenylosuccinate; adrenate (22:4n6); agmatine; alanine; alanylleucine; alanylphenylalanine; alanyltyrosine; alpha-glutamylvaline; alpha-hydroxyisovalerate; alpha-tocopherol; androsterone sulfate; arabitol; arabonate; arachidonate (20:4n6); arginine; ascorbate; asparagine; aspartate; aspartylleucine; aspartylphenylalanine; beta-alanine; beta-hydroxyisovalerate; betaine; butyrylcarnitine; caffeine; caproate (6:0); caprylate (8:0); carnitine; catechol-sulfate; C-glycosyltryptophan; chiro-inositol; cholesterol; choline; choline phosphate; cis-aconitate; cis-vaccenate (18:1n7); citrate; citrulline; coenzyme-A; creatine; creatinine; cysteine; cysteine-glutathione-disulfide; cysteinylglycine; cystine; cytidine; cytidine 5'-diphosphocholine; cytidine 5'-monophosphate; dehydroisoandrosterone sulfate; deoxycarnitine; dihomo-linoleate (20:2n6); docosadienoate (22:2n6); docosahexaenoate (22:6n3); docosapentaenoate (22:5n3); docosapentaenoate (22:5n6); docosatrienoate (22:3n3); eicosapentaenoate (20:5n3); ergothioneine; erythritol; erythronate; ethanolamine; flavin adenine dinucleotide; fructose; fucose; fumarate; galactose; gamma-aminobutyrate; gamma-glutamylalanine; gamma-glutamylglutamate; gamma-glutamylglutamine; gamma-glutamylleucine; gamma-tocopherol; gluconate; glucose; glucose 6-phosphate; glucose 1-phosphate; glutamate; glutamate, gamma-methyl ester; glutamine; glutarate; glutarylcarnitine; glutathione, oxidized; glutathione, reduced; glycerate; glycerol; glycerol 2-phosphate; glycerol 3-phosphate; glycerophosphoethanolamine; glycerophosphorylcholine; glycine; glycochenodeoxycholate; glycylisoleucine; glycylleucine; glycylproline; glycyltyrosine; glycylvaline; guanine; guanosine; guanosine-5-monophosphate; hexanoylcarnitine; hippurate; histamine; histidine; hydroxyisovaleroyl-carnitine; hypotaurine; hypoxanthine; inosine; inositol-1-phosphate; Isobar: 15-methylpalmitate, 2-methylpalmitate; Isobar: alpha-linolenate, gamma-linolenate (18:3n3 18:3n6); Isobar: dihomo-linolenate (20:3n3, 20:3n6); Isobar: dimethylarginine (ADMA, SDMA); Isobar: eicosenoate (20:1n9, 20:1n11); Isobar: fructose-1,6-diphosphate, glucose-1,6-diphosphate, myo-inositol-1,4-diphosphate, myo-inositol-1,3-diphosphate; Isobar: 13-HODE, 9-HODE; isobutyrylcarnitine; isocitrate; isoleucine; isoleucylisoleucine; isoleucylserine; isovalerylcarnitine; kynurenine; lactate; laurate (12:0); leucine; leucylglutamate; leucylleucine; leucylphenylalanine; leucylserine; linoleate (18:2n6); lysine; malate; maltose; maltotetraose; maltotriose; mannitol; mannose; margarate (17:0); mead acid (20:3n9); methionine; methyl-alpha-glucopyranoside; methylphosphate; myo-inositol; myristate (14:0); myristoleate (14:1n5); myristoylcarnitine; N1-methylguanosine; N2-methylguanosine; N-acetylalanine; N-acetylaspartate; N-acetyl-aspartylglutamate; N-acetylgalactosamine; N-acetylglucosamine; N-acetylglutamate; N-acetylmethionine; N-acetylneuraminate; N-acetylputrescine; N-acetyltryptophan; nicotinamide; nicotinamide adenine dinucleotide, reduced; nicotinamide adenine dinucleotide; nicotinamide ribonucleotide; nicotinamide riboside; nonadecanoate (19:0); octanoylcarnitine; oleate (18:1n9); oleoylcarnitine; ophthalmate; ornithine; palmitate (16:0); palmitoleate (16:1n7); palmitoylcarnitine; palmitoyl sphingomyelin; pantothenate; p-cresol sulfate; phenol sulfate; phenylacetylglutamine; phenylalanine; phenylalanylalanine; phenylalanylaspartate; phenylalanylglutamate; phenylalanylleucine; phenyllactate; phosphate; phosphoethanolamine; pipecolate; piperine; pregnen-diol-disulfate; pro-hydroxy-pro-proline; propionylcarnitine; prostaglandin I2; pseudouridine; putrescine; pyridoxate; pyroglutamine; pyroglutamylvaline; pyruvate; quinate; ribitol; riboflavin; ribose; ribulose; S-adenosylhomocysteine; sarcosine; scyllo-inositoll; serine; serotonin; serylleucine; serylphenylalanine; S-methylcysteine; sorbitol; spermidine; spermine; sphingosine ; stearate (18:0); stearoylcarnitine; stearoyl sphingomyelin; succinate; succinylcarnitine; taurine; theobromine; threonine; threonylisoleucine; threonylleucine; threonylphenylalanine; thymol sulfate; tiglyl carnitine; trans-4-hydroxyproline; tryptophan; tryptophan betaine; tyrosine; tyrsoylleucine; uracil; urate; urea; uridine; uridine 5'-monophosphate; valerylcarnitine; valine; valylmethionine; valyltyrosine; VGAHAGEYGAEALER; xanthine; xanthosine; xylitol; xylonate; xylulose;
|
Metabolites
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p<0.05
|
Tissue
|
23824564
|
1156
|
Peptide ID: 3495; 3506; 3621; 3992; 4437; 4679; 4697; 5180; 6832; 7661; 8698; 9483; 9645; 10502; 11899; 12083; 13995; 14592; 15331; 18990; 19773]
|
Protein
|
Humans
|
Upregulated in PCa [mean(case)/mean(control)]: Downregulated in PCa [mean(control)/mean (case)]: []
|
Diagnostic
|
Prostate Cancer and Benign Prostatic Hyperplasia Vs inflammatory and healthy prostate
|
p< 0.0137
|
Plasma
|
23826311
|
1157
|
Peptide ID: [7098; 8863; 9673; 10706; 24050]
|
Protein
|
Humans
|
Downregulated in PCa [mean(control)/mean (case)]: [Peptide ID: [7098 (3.3 fold) ; 8863 (7.7 fold) ; 9673(73.1 fold) ; 10706 (124.8 fold) ; 24050( 11.1 fold)]
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p< 0.0027
|
Plasma
|
23826311
|
1158
|
21PP + 5PP
|
Protein
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p=0.0001
|
Plasma
|
23826311
|
1160
|
Crystallin, alpha B (CRYAB)
|
mRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Cancerous Vs non cancerous conditions
|
p<0.01
|
Tissue
|
23840433
|
1161
|
Distal-less homeobox 1 (DLX1)
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Cancerous Vs non cancerous conditions
|
p<0.01
|
Tissue
|
23840433
|
1162
|
Serum deprivation response (SDPR)
|
mRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Cancerous Vs non cancerous conditions
|
p<0.01
|
Tissue
|
23840433
|
1163
|
Potassium large conductance calcium-activated channel, subfamily M, alpha member 1 (KCNMA1)
|
mRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Cancerous Vs non cancerous conditions
|
p<0.01
|
Tissue
|
23840433
|
1164
|
Prostate Cancer Antigen 3 (PCA3)
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Cancerous Vs non cancerous conditions
|
p<0.01
|
Tissue
|
23840433
|
1165
|
Aldo-keto reductase family 1, member C1/2 (AKR1C1/2)
|
mRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Cancerous Vs non cancerous conditions
|
p<0.01
|
Tissue
|
23840433
|
1166
|
Cyclin-dependent kinase 5, regulatory subunit 1 (CDK5R1)
|
mRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Cancerous Vs non cancerous conditions
|
p<0.01
|
Tissue
|
23840433
|
1167
|
Claudin 7 (CLDN7)
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Cancerous Vs non cancerous conditions
|
p<0.01
|
Tissue
|
23840433
|
1168
|
Activated leukocyte cell adhesion molecule (ALCAM)
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Cancerous Vs non cancerous conditions
|
p<0.01
|
Tissue
|
23840433
|
1169
|
RAS, dexamethasone-induced 1 (RASD1)
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Cancerous Vs non cancerous conditions
|
p<0.01
|
Tissue
|
23840433
|
1175
|
PCA3
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs No evidence of Maligancy
|
p <0.001
|
Urine
|
23861782
|
1176
|
Prostate Health Index (phi)
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs No evidence of Maligancy
|
p <0.001
|
Serum
|
23861782
|
1177
|
Genetic Risk score based on 41 SNPs (rs10187424, rs721048, rs1465618, rs13385191, rs12621278, rs2292884, rs4857841, rs6763931, rs10936632, rs17021918, rs12500426, rs7679673, rs2121875, rs12653946, rs130067, rs1983891, rs339331, rs9364554, rs10486567, rs6465657, rs1512268, rs1447295, rs6983561, rs16901979, rs10086908, rs12543663, rs620861, rs6983267, rs16902094, rs1016343, rs13252298, rs445114, rs10993994, rs4962416, rs10896449, rs11228565, rs12418451, rs10875943, rs9600079, rs4430796, rs11649743, rs1859962, rs8102476, rs17632542, rs2735839, rs9623117, rs5759167, rs5945619, rs5919432)
|
Mutation
|
Humans
|
Increased Score with Increased risk of Prostate Cancer
|
Diagnostic
|
Prostate Cancer Vs no Prostate Cancer
|
Univariate: p=0.014; Multivariate: 0.029
|
Blood
|
23891454
|
1179
|
Methylation Status of BNC1
|
Methylation
|
Humans
|
Hypermethylated in PCa (β atleast ≥ 0.2)
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
p =0.0476
|
Tissue
|
23896626
|
1180
|
Methylation Status of FZD1
|
Methylation
|
Humans
|
Hypermethylated in PCa (β atleast ≥ 0.2)
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
p =0.0363
|
Tissue
|
23896626
|
1181
|
Methylation Status of SYN2
|
Methylation
|
Humans
|
Hypermethylated in PCa (β atleast ≥ 0.2)
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
p =0.049
|
Tissue
|
23896626
|
1182
|
Methylation Status of ZNF783
|
Methylation
|
Humans
|
Hypermethylated in PCa (β atleast ≥ 0.2)
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
p =0.011
|
Tissue
|
23896626
|
1183
|
Methylation Status of CYB5R2
|
Methylation
|
Humans
|
Hypermethylated in PCa (β atleast ≥ 0.2)
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
p =0.0003
|
Tissue
|
23896626
|
1198
|
Angiogenin
|
Protein
|
Humans
|
Upregulated in Patients with PCa (median): [Cancer 487,500 vs. Non Cancer: 414,800)
|
Diagnostic
|
Prostate Cancer Vs Non Cancer
|
p = 0.008
|
Serum
|
23921786
|
1199
|
miR-210
|
miRNA
|
Humans
|
Upregulated in PCa [Cohort 1: 6.9 fold; Cohort 2: 3.1 fold]
|
Diagnostic
|
Controls Vs Metastatic Castration Resistant Prostate Cancer (mCRPC)
|
p=0.022
|
Serum
|
23935962
|
1200
|
miR-141
|
miRNA
|
Humans
|
Upregulated in PCa [Cohort 1: 27.9 fold; Cohort 2: 5.1 fold]
|
Diagnostic
|
Controls Vs Metastatic Castration Resistant Prostate Cancer (mCRPC)
|
Training: p<0.0001; Testing: p<0.001
|
Serum
|
23935962
|
1201
|
miR-200a
|
miRNA
|
Humans
|
Upregulated in PCa [Cohort 1: 6.1 fold; Cohort 2: 1.76 fold]
|
Diagnostic
|
Controls Vs Metastatic Castration Resistant Prostate Cancer (mCRPC)
|
Training: p=0.007; Testing: p=NS
|
Serum
|
23935962
|
1202
|
miR-200c
|
miRNA
|
Humans
|
Upregulated in PCa [Cohort 1: 22.4 fold; Cohort 2: 2.56 fold]
|
Diagnostic
|
Controls Vs Metastatic Castration Resistant Prostate Cancer (mCRPC)
|
Training: p=0.017; Testing: p=NS
|
Serum
|
23935962
|
1203
|
miR-375
|
miRNA
|
Humans
|
Upregulated in PCa [Cohort 1: 4.6 fold; Cohort 2: 11.27 fold]
|
Diagnostic
|
Controls Vs Metastatic Castration Resistant Prostate Cancer (mCRPC)
|
Training: p=0.009; Testing: p=0.021
|
Serum
|
23935962
|
1204
|
hsa-mir-31; hsa-mir-145; hsa-mir-455; hsa-mir-221; hsa-mir-222; hsa-mir-143; hsa-mir-221; hsa-mir-133b; hsa-mir-376c; hsa-mir-187; hsa-mir-139; hsa-mir-455; hsa-mir-224; hsa-mir-204; hsa-mir-505; hsa-mir-149; hsa-mir-222; hsa-mir-34a; hsa-mir-152; hsa-mir-30e; hsa-mir-377; hsa-mir-181c;
|
miRNA
|
Humans
|
Upregulated in PCa (log Fold Change): []
|
Diagnostic
|
Cancer Vs Benign
|
p < 0.0401
|
Tissue
|
23984644
|
1205
|
hsa-mir-33a; hsa-mir-25; hsa-mir-18b; hsa-mir-130b; hsa-mir-769; hsa-mir-182; hsa-mir-148a; hsa-mir-96;
|
miRNA
|
Humans
|
Downregulated in PCa (log Fold Change): []
|
Diagnostic
|
Cancer Vs Benign
|
p < 0.0401
|
Tissue
|
23984644
|
1206
|
Neuropeptideâ€Y (NPY)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs (Normal and BPH patients)
|
p = 0.0396
|
Plasma
|
23991666
|
1207
|
Neuropeptideâ€Y (NPY) + Prostate Specific Antigen (PSA)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs (Normal and BPH patients)
|
p = 0.0396
|
Plasma
|
23991666
|
1211
|
PSMA/PSA
|
Protein
|
Humans
|
Upregulated in PCa (PCa: 4.95 ± 0.83; BPH: 0.47 ± 0.02)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.0001
|
Tissue
|
24063616
|
1212
|
PSMA/PSA
|
Protein
|
Humans
|
Upregulated in PCa (PCa: 4.95 ± 0.83; NP: 1.22 ± 0.15)
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
p= 0.0001
|
Tissue
|
24063616
|
1213
|
Methylation Status of HIST1H4K
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
p<0.0001
|
Urine
|
24065480
|
1214
|
PCA3
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
NA
|
Urine
|
24080222
|
1215
|
PCA3 + Multiparametric MRI
|
Others
|
Humans
|
PCA3 Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
NA
|
Urine + Technique
|
24080222
|
1216
|
Cytochrome P450 family 24 subfamily A member 1 (CYP24A1)
|
mRNA
|
Humans
|
Upregulated in PCa (4 fold)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p = 0.03
|
Tissue
|
24081904
|
1217
|
Cytochrome P450 family 24 subfamily A member 1 (CYP24A1)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p = 0.03
|
Tissue
|
24081904
|
1221
|
β-Microseminoprotein
|
Protein
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Other Prostatic Conditions
|
p = 0.01
|
Urine
|
24115268
|
1222
|
β-Microseminoprotein + PSA
|
Protein
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Other Prostatic Conditions
|
β-Microseminoprotein: [p = 0.01]
|
Urine
|
24115268
|
1224
|
hsa-miR-367; hsa-miR-758; hsa-miR-190 hsa-miR-221; hsa-miR-205; hsa-miR-212; hsa-miR-99b; hsa-miR-214; hsa-miR-203; hsa-miR-127-3p; hsa-miR-130a; hsa-miR-335; hsa-miR-376; hsa-miR-10a; hsa-miR-589; hsa-miR-422a; hsa-miR-10b; hsa-miR-25; hsa-miR-210; hsa-miR-99a; hsa-miR-429; hsa-miR-92a; hsa-miR-100; hsa-miR-222; hsa-miR-484; hsa-miR-125b; hsa-miR-574-3p; hsa-miR-328; hsa-miR-483-5p; hsa-miR-331-3p; hsa-let-7c; hsa-miR-135a;
|
miRNA
|
Humans
|
miR-367, miR-758 and miR-190 were found to be upregulated in PCa; while, rest were Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Adjacent Normal
|
p ≤ 0.046
|
Tissue
|
24167554
|
1225
|
miR-205
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Adjacent Normal
|
p<0.0001
|
Tissue
|
24167554
|
1226
|
miR-214
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Adjacent Normal
|
p<0.0001
|
Tissue
|
24167554
|
1227
|
miR-221
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Adjacent Normal
|
p<0.001
|
Tissue
|
24167554
|
1228
|
miR-99b
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Adjacent Normal
|
p<0.0001
|
Tissue
|
24167554
|
1229
|
miR-205
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Healthy Controls
|
p<0.001
|
Urine
|
24167554
|
1230
|
miR-214
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Healthy Controls
|
p<0.001
|
Urine
|
24167554
|
1231
|
miR-205+ miR-214
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Healthy Controls
|
p<0.001
|
Urine
|
24167554
|
1233
|
Prostate Stem Cell Antigen (PSCA)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.05
|
Tissue
|
24183365
|
1234
|
Prostate Stem Cell Antigen (PSCA)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer VS HGPIN
|
p<0.05
|
Tissue
|
24183365
|
1235
|
Prostate Stem Cell Antigen (PSCA)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Gleason Score 6 Vs Gleason Score 8
|
p<0.05
|
Tissue
|
24183365
|
1236
|
Prostate Stem Cell Antigen (PSCA)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Gleason Score 7 Vs Gleason Score 8
|
p<0.05
|
Tissue
|
24183365
|
1237
|
Peroxisome proliferator activated receptors (PPAR) [PPARβ/δ]
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.001
|
Tissue
|
24189640
|
1238
|
cutaneous fatty acid-binding protein (C-FABP)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.001
|
Tissue
|
24189640
|
1240
|
Prostate cancer antigen 3 [PCA3]
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
NA
|
Urine
|
24211598
|
1241
|
PCA3 /PSA ratio (PCa antigen 3 [PCA3])
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
NA
|
Urine
|
24211598
|
1242
|
iXip: [IgM] + [tPSA]
|
Protein
|
Humans
|
Upregulated in PCa [PCa: 0.467 ± 0.160; Controls: 0.314 ± 0.098]
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p <0.001
|
Serum
|
24240583
|
1243
|
N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 (NAALADL2 )
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Tissue
|
p<0.0001
|
Tissue
|
24240687
|
1247
|
Anterior gradient 2 [AGR2]
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p = 0.026
|
Urine
|
24251762
|
1251
|
Active Hepatocyte Growth Factor [aHGF]
|
Protein
|
Humans
|
Upregulated in PCa: [Controls: 111.3; Localised PCa: 235.2]
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p = 0.003
|
Urine
|
24266816
|
1252
|
Insulin Like Growth Factor Binding Protein 3 (IGFBP3)
|
Protein
|
Humans
|
Upregulated in PCa: [Controls: 0.648; Localised PCa: 0.8862]
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p = 0.003
|
Urine
|
24266816
|
1255
|
ACACA; CDCA3; CEP55; CCNB1; CKS2; DLGAP5; SLC7A1;HMMR; HIG2; LOX; MMP10; MCOLN2; NLN; PDLIM5; PSD3; C20orf74; FAM80A; SDK1; STC2; SOX4; TMEM200A; TFF3; UBE2C; UBE2E3;
|
mRNA
|
Humans
|
Upregulated in PCa (log 2 PCa/Normal): []
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
NA
|
Tissue
|
24349376
|
1257
|
Occludin
|
mRNA
|
Humans
|
Downregulated in: [CAHPV-10 (19.08 fold); DU145 (3.2 fold); PC-3 (4.3 fold)]; Upregulated in LNCaP: (2.2 fold)
|
Diagnostic
|
CAHPV-10, DU145, PC-3, LNCaP Vs PNT2
|
CAHPV-10 (p= 0.001); DU145 (p=0.003); PC-3 (0.003); LNCaP: (p = 0.001)
|
Cell Lines
|
24358122
|
1258
|
Claudin 1
|
mRNA
|
Humans
|
Downregulated in: [CAHPV-10 (10 fold); LNCaP: (100 fold); DU145 (2.1 fold); PC-3 (3.8 fold)];
|
Diagnostic
|
CAHPV-10, DU145, PC-3, LNCaP Vs PNT2
|
p = 0.001
|
Cell Lines
|
24358122
|
1259
|
Claudin 7
|
mRNA
|
Humans
|
Downregulated in: [DU145 (5.3 fold); PC-3 (24.8 fold)];Upregulated in LNCaP: (4.63 fold)
|
Diagnostic
|
CAHPV-10, DU145, PC-3, LNCaP Vs PNT2
|
DU145 (p=0.004); PC-3 (p= 0.01); LNCaP (p = 0.001)
|
Cell Lines
|
24358122
|
1261
|
α-catenin
|
mRNA
|
Humans
|
Downregulated in: [DU145 (2.2 fold); PC-3 (33 fold)];
|
Diagnostic
|
CAHPV-10, DU145, PC-3, LNCaP Vs PNT2
|
p<0.001
|
Cell Lines
|
24358122
|
1263
|
β-catenin
|
mRNA
|
Humans
|
Downregulated in: [CAHPV-10 (3 fold)] ;Upregulated in [LNCaP: (3.8 fold) DU145 (2.2 fold); PC-3 (2.1 fold)]
|
Diagnostic
|
CAHPV-10, DU145, PC-3, LNCaP Vs PNT2
|
CAHPV-10 (p= 0.015); DU145 (p=0.001); PC-3 (p=0.001) LNCap: (p<0.001)
|
Cell Lines
|
24358122
|
1265
|
E-Cadherin
|
mRNA
|
Humans
|
Downregulated in: [CAHPV-10 (2.3 fold) ; DU145 (5.6 fold); PC-3 (7.25 fold)]
|
Diagnostic
|
CAHPV-10, DU145, PC-3, LNCaP Vs PNT2
|
CAHPV-10 (p= 0.004); DU145 (p<0.001); PC-3 (p<0.001);
|
Cell Lines
|
24358122
|
1266
|
Claudin 1
|
Protein
|
Humans
|
Downregulated in LNCaP (9.3 fold)
|
Diagnostic
|
CAHPV-10, DU145, PC-3, LNCaP Vs PNT2
|
p = 0.04
|
Cell Lines
|
24358122
|
1267
|
Claudin 7
|
Protein
|
Humans
|
Downregulated in LNCaP (1.1 fold); DU145 (1.1 fold); PC-3 (1.5 fold)
|
Diagnostic
|
CAHPV-10, DU145, PC-3, LNCaP Vs PNT2
|
p < 0.01
|
Cell Lines
|
24358122
|
1269
|
α-catenin
|
Protein
|
Humans
|
Downregulated in LNCaP (4.4 fold); DU145 (2 fold);
|
Diagnostic
|
CAHPV-10, DU145, PC-3, LNCaP Vs PNT2
|
LNCaP: p = 0.03; DU145: p=0.04
|
Cell Lines
|
24358122
|
1270
|
E-cadherin
|
Protein
|
Humans
|
Downregulated in CAHPV-10 (1.7 fold); DU145 (1.5 fold); Upregulated in LNCaP: (2.7 fold)
|
Diagnostic
|
CAHPV-10, DU145, PC-3, LNCaP Vs PNT2
|
p < 0.01
|
Cell Lines
|
24358122
|
1272
|
Integrin α3 [ITGA3]
|
Protein
|
Humans
|
Upregulated in Metastatic Prostate Cancer
|
Diagnostic
|
Metastasis Vs Prostate Cancer and BPH
|
p<0.005
|
Urine
|
24371517
|
1273
|
Integrin β1 [ITGB1]
|
Protein
|
Humans
|
Upregulated in Metastatic Prostate Cancer
|
Diagnostic
|
Metastasis Vs Prostate Cancer and BPH
|
p<0.01
|
Urine
|
24371517
|
1274
|
BTF3
|
Protein
|
Humans
|
Upregulated in PCa (2.5 fold)
|
Diagnostic
|
Benign Vs Malignant
|
p<0.0001
|
Tissue
|
24386364
|
1275
|
HINT1
|
Protein
|
Humans
|
Upregulated in PCa (2.3 fold)
|
Diagnostic
|
Benign Vs Malignant
|
p<0.0001
|
Tissue
|
24386364
|
1276
|
NDRG1
|
Protein
|
Humans
|
Upregulated in PCa (2.6 fold)
|
Diagnostic
|
Benign Vs Malignant
|
p<0.0001
|
Tissue
|
24386364
|
1277
|
ODC1
|
Protein
|
Humans
|
Upregulated in PCa (1.8 fold)
|
Diagnostic
|
Benign Vs Malignant
|
p<0.0001
|
Tissue
|
24386364
|
1278
|
BTF3 + HINT1
|
Protein
|
Humans
|
Upregulated in PCa [BTF3: 2.5 fold; HINT1: 2.3 fold]
|
Diagnostic
|
Benign Vs Malignant
|
p<0.0001
|
Tissue
|
24386364
|
1279
|
BTF3 + NDRG1
|
Protein
|
Humans
|
Upregulated in PCa [BTF3: 2.5 fold; NDRG1: 2.6 fold]
|
Diagnostic
|
Benign Vs Malignant
|
p<0.0001
|
Tissue
|
24386364
|
1280
|
BTF3 + ODC1
|
Protein
|
Humans
|
Upregulated in PCa [BTF3: 2.5 fold; ODC1: 1.8 fold]
|
Diagnostic
|
Benign Vs Malignant
|
p<0.0001
|
Tissue
|
24386364
|
1281
|
HINT1 + NDRG1
|
Protein
|
Humans
|
Upregulated in PCa [NDRG1: 2.6 fold; HINT1: 2.3 fold]
|
Diagnostic
|
Benign Vs Malignant
|
p<0.0001
|
Tissue
|
24386364
|
1282
|
HINT1 + ODC1
|
Protein
|
Humans
|
Upregulated in PCa [ODC1: 1.8 fold; HINT1: 2.3 fold]
|
Diagnostic
|
Benign Vs Malignant
|
p<0.0001
|
Tissue
|
24386364
|
1283
|
NDRG1 + ODC1
|
Protein
|
Humans
|
Upregulated in PCa [ODC1: 1.8 fold; NDRG1: 2.6 fold]
|
Diagnostic
|
Benign Vs Malignant
|
p<0.0001
|
Tissue
|
24386364
|
1284
|
PDCD6IP; EEF1A2; FASN; VPS28; PABPC1;YWHAB; ANXA2; ATP1A1; ATP1B1; ATP1B3; BSG; CLIC1; ITGA6; F11R; ACTA2; ATP12A; CTNNB1; ENO1; HSPA5; KPNB1; PKM2; TPI1; YWHAE; SLC3A2; ARF1; CXADR; EHD4; HSP90AB2P; HSP90AB3P; IQGAP1; KRT9; KRT2; MFGE8; PARK7; PGK1; PRDX1; RAB10; RAB1A;RAP1A; AHCY; TUBA1A; CCT5; UGDH;
|
Protein
|
Humans
|
Upregulated in PC346C cell lines (log2 fold):Downregulated in PC346C cell lines (log2 fold): []
|
Diagnostic
|
PC346C vs PNT2C2
|
p<0.05
|
Cell Lines
|
24391718
|
1285
|
PDCD6IP; EEF1A2; FASN; UBA52; VPS28; ACTR3B; CD9; YWHAB; ANXA2; ATP1A1; ATP1B1; ATP1B3; BSG; CLIC1; ITGA6 ;F11R; ATP12A; CTNNB1; ENO1;KPNB1; PKM2; TPI1; YWHAE; SLC3A2; EHD4; PTGFRN; HSP90AB2P; HBB; KRT9; KRT2; MFGE8; PARK7; RAB1A; RAC1; AHCY; CCT5;
|
Protein
|
Humans
|
Upregulated in PC346C cell lines (log2 fold):Downregulated in PC346C cell lines (log2 fold): []
|
Diagnostic
|
PC346C vs RWPE
|
p<0.05
|
Cell Lines
|
24391718
|
1286
|
PDCD6IP; UBA52; BCAM; PABPC1; YWHAB; ANXA2; ATP1A1; ATP1B1; ATP1B3; BSG; CLIC1; ITGA6; F11R; ACTA2; ATP12A; CTNNB1; ENO1; HSPA5; KPNB1; PKM2; TPI1; ARF1; CD151; CXADR; HSP90AB3P; IQGAP1; PGK1; PRDX1; RAB10; RAP1A; TUBA1A; UGDH;
|
Protein
|
Humans
|
Upregulated in VCaP cell lines (log2 fold): Downregulated in VCaP cell lines (log2 fold): []
|
Diagnostic
|
VCaP vs PNT2C2
|
p<0.05
|
Cell Lines
|
24391718
|
1287
|
PDCD6IP; EEF1A2; FASN; UBA52; VPS28; ACTR3B; BCAM; CD9;YWHAB; ANXA2; ATP1A1; ATP1B1; ATP1B3; BSG; CLIC1; ITGA6; F11R; ACTA2; HSPA5; YWHAQ; CD151; PTGFRN; HBB; RAC1;
|
Protein
|
Humans
|
Upregulated in VCaP cell lines (log2 fold): Downregulated in VCaP cell lines (log2 fold): []
|
Diagnostic
|
VCaP vs RWPE
|
p<0.05
|
Cell Lines
|
24391718
|
1321
|
miR-25; miR-101;miR-628-5p
|
miRNA
|
Humans
|
Differentially Expressed
|
Diagnostic
|
African Americans Vs Caucasian Americans with PCa
|
p<0.05
|
Serum
|
24477576
|
1322
|
miR-25
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
African Americans Vs Caucasian Americans with PCa
|
p= 0.0109
|
Serum
|
24477576
|
1323
|
miR-101
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
African Americans Vs Caucasian Americans with PCa
|
p= 0.0006
|
Serum
|
24477576
|
1324
|
miR-628-5p
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
African Americans Vs Caucasian Americans with PCa
|
p<0.0001
|
Serum
|
24477576
|
1327
|
Human Serum Albumin Complexed with Myristate and Aspirin; Apolipoprotein-D; Prostaglandin H2 D-isomerase; Ig A1 Bur; G-protein coupled receptor 115; Cadherin-1; α-N-acetylglucosaminidase; Pro-epidermal growth factor; Apolipoprotein-J precursor; Human Beta-Defensin-1; Matrilin-4; CD14 antigen; Chemo- kine-like factor superfamily-5 isoform a; Fibronectin precursor; Immunoglobulin-kappa light chain varia- ble region; SLURP1.
|
Protein
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
NA
|
Urine
|
24494028
|
1328
|
Cadherin -1
|
Protein
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
NA
|
Urine
|
24494028
|
1329
|
Fibronectin
|
Protein
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
NA
|
Urine
|
24494028
|
1330
|
TP53INP2
|
Protein
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
NA
|
Urine
|
24494028
|
1331
|
UAP1+ PDLIM5+ IMPDH2+ HSPD1+ PCA3+ TMPRSS2+ ERG+ GAPDH+ B2M+age+sPSA level
|
mRNA
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
NA
|
Urine + Plasma
|
24512523
|
1333
|
U78_x; SNORD78; U78_s; miR-182; U17b; miR-22; miR-34a*; miR-221*; miR-187; miR-221; miR-34c-3p;
|
miRNA
|
Humans
|
Upregulated in PCa: U78_x (3.8 fold); SNORD78 (3.6-fold); U78_s (3.7-fold); miR-182 (4.7-fold); U17b (2.7- fold)Downregulated in PCa: miR-224 (4.05-fold); miR-34a* (3-fold); miR-221* (3.3-fold); miR-187 (12-fold); miR-221 (2.2-fold); miR-34c-3p (1.7-fold)
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
p<0.05
|
Tissue
|
24518785
|
1334
|
miR-182
|
miRNA
|
Humans
|
Upregulated in PCa (4.7 fold)
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
0.717
|
Tissue
|
24518785
|
1335
|
miR-187
|
miRNA
|
Humans
|
Downregulated in PCa (12 fold)
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
0.052
|
Tissue
|
24518785
|
1336
|
PSA+PCA3+miR-187
|
miRNA
|
Humans
|
Downregulated in PCa (12 fold)
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
p<0.05
|
Tissue
|
24518785
|
1337
|
PCAT18
|
LncRNA
|
Humans
|
Upregulated in PCa (8.8-11.1 fold)
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
p<0.001
|
Tissue
|
24519926
|
1339
|
miR-1826; miR-1234; miR-1238; miR-191*; miR-484; miR-191; miR-451; miR-486-5p; miR-1913; miR-625*; miR-1825; miR-92a; miR-92b; miR-483-5p; miR-486-3p; miR-563; miR-940;
|
miRNA
|
Humans
|
Downregulated in PCa: miR-1826; miR-1234; miR-1238; miR-191*; miR-484; miR-191; miR-451; miR-486-5p; miR-1913; miR-625*; miR-1825; miR-92a; miR-92b; miR-486-3p; miR-563; miR-940; Upregulated in PCa: miR-483-5p
|
Diagnostic
|
Prostate Cancer Vs Healthy Controls
|
p<0.01
|
Urine
|
24563673
|
1340
|
miR-1825
|
miRNA
|
Humans
|
Downregulated in PCa vs BPH vs Healthy
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.01
|
Urine
|
24563673
|
1341
|
miR-484
|
miRNA
|
Humans
|
Downregulated in PCa vs BPH vs Healthy
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.01
|
Urine
|
24563673
|
1342
|
miR-1825 + miR-484
|
miRNA
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.01
|
Urine
|
24563673
|
1343
|
miR-1825 + miR-484 + PSA
|
miRNA
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.01
|
Urine
|
24563673
|
1395
|
GABRE
|
mRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Non Malignant
|
p=0.001
|
Tissue
|
24737792
|
1396
|
miR-224
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Non Malignant
|
p=0.000628
|
Tissue
|
24737792
|
1397
|
miR-452
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Non Malignant
|
p=0.000494
|
Tissue
|
24737792
|
1398
|
Methylation status of GABRE + miR-224 +miR-452
|
miRNA + Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs Non Malignant
|
p=0.001
|
Tissue
|
24737792
|
1416
|
ATRN; CATD; BTD; MTA1; NCAM1; PECA1;
|
Protein
|
Humans
|
Upregulated in PCa: [];Downregulated in PCa: []
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
NA
|
Tissue
|
24741114
|
1420
|
Macrophage Colony Stimulating Factor (M-CSF)
|
Protein
|
Humans
|
Upregulated in PCa: (> 2 fold)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.0001
|
Serum
|
24747338
|
1421
|
CC chemokine ligand 18 (CCL-18)
|
Protein
|
Humans
|
Upregulated in PCa: (> 2 fold)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.0001
|
Serum
|
24747338
|
1422
|
Insulin-Like Growth Factor-Binding Protein 6 (IGFBP-6)
|
Protein
|
Humans
|
Upregulated in PCa: (> 2 fold)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.0001
|
Serum
|
24747338
|
1423
|
Ttumor Necrosis Factor Receptor Superfamily Member 6 (TNFRSF6) [FAS/TNFRSF6]
|
Protein
|
Humans
|
Upregulated in PCa: (> 2 fold)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.0001
|
Serum
|
24747338
|
1426
|
PCA3
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Negative Vs Positive Biopsy for PCa
|
p<0.0001
|
Urine
|
24803095
|
1427
|
PCA3
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Controls Vs Positive Biopsy for PCa
|
p <0.0001
|
Urine
|
24803095
|
1444
|
Methylation status of genes (GSTM2; GSTP1; RARB; ALOX12; APC; PDGFRB; SCGB3A1; CFTR; MT1A; PENK; TERT; CCNA1; RARA; TAL1; ERG; MET; GFI1; MYCL2; SEPT9; COL18A1; KLK10; MFAP4; MMP14; TBX1; EYA4; NEU1; POMC; GADD45A; HTR1B; RASSF1; CDH13; PDGFRA; IRAK3; ASCL2; ESR1; HFE; IGFBP7; RARRES1; CAV1; THY1; BMP4;)
|
Methylation
|
Humans
|
Hypermethylated in Pca
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
NA
|
Tissue
|
24961912
|
1448
|
miR-361-3p
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p=0.004
|
Prostate Secretion Samples
|
24976077
|
1449
|
mir-221
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p=0.03
|
Prostate Secretion Samples
|
24976077
|
1450
|
mir-203
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p= 0.0002
|
Prostate Secretion Samples
|
24976077
|
1451
|
mir-133b
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p < 0.01
|
Prostate Secretion Samples
|
24976077
|
1452
|
miR-361-3p + miR-361-3p+ mir-221+ mir-203 + mir-133b
|
miRNA
|
Humans
|
Downregulated in PCa [miR-361-3p; miR-361-3p; mir-221; mir-133b]; Upregulated in PCa: [mir-203]
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
NA
|
Prostate Secretion Samples
|
24976077
|
1454
|
Prostate Health Index (phi)
|
Protein
|
Humans
|
Upregulated in PCa: [Prostate Volume ≤ 35: Negative Biopsy: 41.32 (31.30–64.23), Positive Biopsy: 64.93 (23.30–252.76) 36 ≤ Prostate Volume ≤ 50 : Negative Biopsy: 35.38 (20.69–49.80), PCa: 44.56 (21.88–132.72);Prostate Volume >50: 38.34 (19.23–72.63), PCa: 46.28 (24.33–80.34)]
|
Diagnostic
|
Negative Vs PCa (Segregated on the basis of Prostate Volume)
|
Prostate Volume ≤ 35:p= 0.001;36 ≤ Prostate Volume ≤ 50 : p= 0.011;Prostate Volume >50: 0.009
|
Serum
|
24978824
|
1458
|
Vascular Endothelial Growth Factor (VEGF)
|
Protein
|
Humans
|
Upregulated in PCa (PCa: 356.3±181.1; BPH: 147.5±80; Healthy: 124.9±50.8)
|
Diagnostic
|
Prostate Cancer Vs (Benign prostatic hyperplasia + Healthy Individuals)
|
p<0.001
|
Serum
|
25032132
|
1459
|
Vascular Endothelial Growth Factor (VEGF) + Prostate Specific Antigen (PSA)
|
Protein
|
Humans
|
Upregulated in PCa: [VEGF+ PSA]
|
Diagnostic
|
Prostate Cancer Vs (Benign prostatic hyperplasia + Healthy Individuals)
|
NA
|
Serum
|
25032132
|
1460
|
Receptor for advanced glycation end products (RAGE)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p=0.002
|
Tissue
|
25057439
|
1461
|
High Mobility Group Box 1 (HMGB1)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p=0.001
|
Tissue
|
25057439
|
1469
|
miR-135a
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer And Adjacent Normal
|
p<0.0001
|
Tissue
|
25065599
|
1479
|
miR-30c
|
miRNA
|
Humans
|
Downregulated in Malignant Samples (Benign: 0.621 ± 0.06; malignant: 0.438 ± 0.022)
|
Diagnostic
|
Benign Vs Malignant
|
p=0.014
|
Tissue
|
25075250
|
1480
|
miR-219
|
miRNA
|
Humans
|
Downregulated in Malignant Samples (Benign: 0.773 ± 0.082; malignant: 0.467 ± 0.019)
|
Diagnostic
|
Benign Vs Malignant
|
p=0.004
|
Tissue
|
25075250
|
1492
|
mir-23b
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p<0.0001
|
Tissue
|
25115396
|
1493
|
mir-27b
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p<0.0001
|
Tissue
|
25115396
|
1494
|
mir-24-1
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p<0.0001
|
Tissue
|
25115396
|
1509
|
Base model (Age and total PSA)
|
Protein
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
NA
|
Plasma
|
25151013
|
1510
|
Four-kallikrein panel (Kallikrein-related peptidase 2 [hK2]+ intact PSA+ free PSA [fPSA]+total PSA [tPSA])
|
Protein
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p<0.0001
|
Plasma
|
25151013
|
1511
|
Prostate Health Index (PHI)
|
Protein
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p<0.0001
|
Plasma
|
25151013
|
1512
|
Base model (Age and total PSA)
|
Protein
|
Humans
|
NA
|
Diagnostic
|
High-grade Prostate cancer
|
NA
|
Plasma
|
25151013
|
1513
|
Four-kallikrein panel (Kallikrein-related peptidase 2 [hK2]+ intact PSA+ free PSA [fPSA]+total PSA [tPSA])
|
Protein
|
Humans
|
NA
|
Diagnostic
|
High-grade Prostate cancer
|
p<0.0001
|
Plasma
|
25151013
|
1514
|
Prostate Health Index (PHI)
|
Protein
|
Humans
|
NA
|
Diagnostic
|
High-grade Prostate cancer
|
p<0.0001
|
Plasma
|
25151013
|
1519
|
Kallikrein-related peptidase 2 [hK2]+ intact PSA+ free PSA [fPSA]+total PSA [tPSA]
|
Protein
|
Humans
|
Upregulated 4K Score in Prostate Cancer
|
Diagnostic
|
Prostate Cancer Vs No Cancer
|
PSA >3ng/ml: p<0.01; All Patients: p<0.04
|
Serum
|
25168616
|
1520
|
PCA3
|
Protein
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Prostate Cancer Vs No Cancer
|
PSA >3ng/ml: p=0.01; All Patients: p<0.01
|
Serum
|
25168616
|
1521
|
Kallikrein-related peptidase 2 [hK2]+ intact PSA+ free PSA [fPSA]+total PSA [tPSA]+ PCA3
|
Protein
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Prostate Cancer Vs No Cancer
|
NA
|
Serum
|
25168616
|
1522
|
Oligophrenin-1 (OPHN1)
|
mRNA
|
Humans
|
Upregulated in Prostate Cancer (Tumor/nonneoplastic prostate (T/N ratio): > 3 fold)
|
Diagnostic
|
Prostate Cancer Vs Non Neoplastic Samples
|
NA
|
Tissue
|
25170626
|
1525
|
Yin Yang 1 (YY1)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs PIN
|
p<0.001
|
Tissue
|
25174820
|
1526
|
Death Receptor 5
|
Protein
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs PIN
|
p<0.001
|
Tissue
|
25174820
|
1529
|
8-hydroxydeoxyguanosine (8-OHDG)
|
Protein
|
Humans
|
Upregulated in Malignant Tissue
|
Diagnostic
|
Benign Vs Malignant
|
p<0.0001
|
Tissue
|
25175169
|
1530
|
cytoplasmic-nuclear factor erythroid 2-related factor 2 (c-Nrf-2)
|
Protein
|
Humans
|
Upregulated in Malignant Tissue
|
Diagnostic
|
Benign Vs Malignant
|
p=0.015
|
Tissue
|
25175169
|
1531
|
Nuclear-nuclear factor erythroid 2-related factor 2 (n-Nrf-2)
|
Protein
|
Humans
|
Upregulated in Malignant Tissue
|
Diagnostic
|
Benign Vs Malignant
|
p=0.016
|
Tissue
|
25175169
|
1534
|
miRNA-21
|
miRNA
|
Humans
|
Upregulated in PCa( BPH: 1.3 ± 3.6; PCa:4.5 ± 3.6)
|
Diagnostic
|
Prostata Cancer Vs Benign prostatic hyperplasia
|
p=0.003
|
Serum
|
25190021
|
1535
|
miRNA-221
|
miRNA
|
Humans
|
Upregulated in PCa( BPH: 1.2 ± 2.5; PCa: 6.9±4.6)
|
Diagnostic
|
Prostata Cancer Vs Benign prostatic hyperplasia
|
p=0.004
|
Serum
|
25190021
|
1538
|
C-Terminal Fragment of PSA
|
Protein
|
Humans
|
Upregulated in PCa (PCa: 117; Non PCa: 36.8)
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.0016
|
Urine
|
25233230
|
1539
|
Anterior gradient 2 Wild Type (AGR2wt)
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p<0.05
|
Tissue
|
25237833
|
1540
|
Anterior gradient 2 Slice Variant H (AGR2-SV-H)
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p<0.05
|
Tissue
|
25237833
|
1541
|
Anterior gradient 2 Wild Type (AGR2wt)
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p<0.001
|
Urine
|
25237833
|
1542
|
Anterior gradient 2 Slice Variant C (AGR2-SV-C)
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p≤0.001
|
Urine
|
25237833
|
1543
|
Anterior gradient 2 Slice Variant E (AGR2-SV-E)
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p<0.01
|
Urine
|
25237833
|
1544
|
Anterior gradient 2 Slice Variant F (AGR2-SV-F)
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p<0.01
|
Urine
|
25237833
|
1545
|
Anterior gradient 2 Slice Variant G (AGR2-SV-G)
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p≤0.001
|
Urine
|
25237833
|
1546
|
Anterior gradient 2 Slice Variant H (AGR2-SV-H)
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p≤0.001
|
Urine
|
25237833
|
1547
|
STEAP2 (Six transmembrane epithelial antigen of the prostate)
|
Protein
|
Humans
|
Upregulated in DU145 and PC3 (28 fold)
|
Diagnostic
|
Cancerous Vs Non Cancerous Cell Lines
|
p<0.001
|
Cell Lines
|
25248617
|
1548
|
STEAP1 (Six transmembrane epithelial antigen of the prostate)
|
mRNA
|
Humans
|
Upregulated in Low Risk PCa (4.45 fold)
|
Diagnostic
|
Low Risk PCa Vs Normal Tissue
|
p = 0.007
|
Tissue
|
25248617
|
1549
|
STEAP1 (Six transmembrane epithelial antigen of the prostate)
|
mRNA
|
Humans
|
Upregulated in High Risk PCa (8.15 fold)
|
Diagnostic
|
High Risk PCa Vs Normal Tissue
|
p=0.011
|
Tissue
|
25248617
|
1550
|
STEAP1 (Six transmembrane epithelial antigen of the prostate)
|
mRNA
|
Humans
|
Upregulated in Metastatic PCa (7.45 fold)
|
Diagnostic
|
Metastatic PCa Vs Normal Tissue
|
p=0.011
|
Tissue
|
25248617
|
1551
|
STEAP2 (Six transmembrane epithelial antigen of the prostate)
|
mRNA
|
Humans
|
Upregulated in Low Risk Localised PCa (5.77 fold)
|
Diagnostic
|
Low Risk Localised PCa Vs Normal Tissue
|
p=0.022
|
Tissue
|
25248617
|
1552
|
STEAP2 (Six transmembrane epithelial antigen of the prostate)
|
mRNA
|
Humans
|
Upregulated in Locally Advanced PCa (14.10 fold)
|
Diagnostic
|
Localy Advanced PCa Vs Normal Tissue
|
p=0.003
|
Tissue
|
25248617
|
1556
|
Chondroitin Sulfate
|
Protein
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Prostate Cancer Vs No Cancer
|
p<0.0001
|
Tissue
|
9815775
|
1558
|
Versican
|
Protein
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Prostate Cancer Vs No Cancer
|
p=0.0006
|
Tissue
|
9563891
|
1559
|
Decorin
|
Protein
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Prostate Cancer Vs No Cancer
|
p=0.0078
|
Tissue
|
9563891
|
1561
|
Linoleic
|
Metabolites
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Cancer
|
p=0.04
|
Tissue
|
8922296
|
1565
|
TMEFF2
|
mRNA
|
Humans
|
Upregulated in PCa (Log 2 Median Centered Intensity)
|
Diagnostic
|
Normal/ Benign Tissue Vs Primary/Localised Prostate Cancer
|
p<0.05
|
Tissue
|
31060542
|
1568
|
BUB1B; CDC45; CDK1; CENPI; CLSPN; ERCC6L; EXO1; NCAPG; NUSAP1; RAD51; RRM2;
|
mRNA
|
Humans
|
Upregulated in PCa (Log 2 Median Centered Intensity)
|
Diagnostic
|
Normal/ Benign Tissue Vs Primary/Localised Prostate Cancer
|
p<0.05
|
Tissue
|
31060542
|
1586
|
AF087978; uc002llc; EF177379; BC013821; uc001pyz; AK024556; AB116553; BC012900; LOC100506303; LOC100506922y; LOC100287482; XLOC_l2_009441; LOC154822; XLOC_010807; XLOC_002335; XLOC_l2_009136; XLOC_002871; ANKRD20A9Py; FLJ20444; XLOC_003734y; LOC100505666; LOC100506411; XLOC_007697; XLOC_003734y; XLOC_l2_000735; LOC100129480; XLOC_007162; LOC100506802; LOC100507025; XLOC_010813;
|
LncRNA
|
Humans
|
Upregulated in PC3 (Log Fold Change) [AF087978 (5.8 fold) ; uc002llc(4.8 fold) ; EF177379(4.3 fold) ; BC01382(3.8 fold)1 ; uc001pyz(3.7 fold) ; AK024556 (3.7 fold) ; AB116553 (3.5 fold) ; BC012900 (3.5 fold) ; LOC100506303(2.6 fold) ; LOC100506922(3.6 fold); LOC100287482 (3.0 fold); XLOC_l2_009441 (3.3 fold); LOC154822 (3.2 fold) ; XLOC_010807(3.5 fold) ; XLOC_002335 (3.4 fold); XLOC_l2_009136(2.1 fold); XLOC_002871 (2.3 fold); ANKRD20A9P ( 2.0 fold) ; FLJ20444 (4.1 fold); XLOC_003734( 4.0 fold); LOC100505666(2.1 fold); LOC100506411(4.1 fold); XLOC_007697(3.4 fold); XLOC_003734y(3.5 fold) XLOC_l2_000735(4.6 fold); LOC100129480(4.5 fold); XLOC_007162(3.1 fold); LOC100506802(3.4 fold); LOC100507025(5.7 fold); XLOC_010813(3.8 fold;]
|
Diagnostic
|
PC3 Cells Vs prostate epithelial cells
|
p<0.05
|
Cell Lines
|
25307116
|
1587
|
LOC100506303; LOC100506922; LOC100287482; XLOC_l2_009441; LOC154822; XLOC_010807; XLOC_002335; XLOC_l2_009136; XLOC_002871; ANKRD20A9Py; FLJ20444; XLOC_003734y; LOC100505666; LOC100506411; XLOC_007697; XLOC_003734y; XLOC_l2_000735; LOC100129480; XLOC_007162; LOC100506802; LOC100507025; XLOC_010813;
|
LncRNA
|
Humans
|
Upregulated in LNCaP (log fold change): [LOC100506303(5.1 fold); LOC100506922y(4.9 fold); LOC100287482(4.8 fold) ; XLOC_l2_009441(4.7 fold); LOC154822(4.6 fold); XLOC_010807 (4.5 fold) ; XLOC_002335( 4.5 fold) ; XLOC_l2_009136(4.4 fold) ; XLOC_002871( 4.2 fold) ; ANKRD20A9(4.0 fold); FLJ20444(4.0 fold); XLOC_003734(3.8 fold) ; LOC100505666(3.7 fold) ; LOC10050641( 3.5 fold)1; XLOC_007697(3.3 fold); XLOC_003734y(3.2 fold); XLOC_l2_000735(2.8 fold); LOC100129480(2.4 fold); XLOC_007162(2.2 fold); LOC100506802(2.1 fold) ; LOC100507025(2.1 fold) ; XLOC_010813(2.1 fold) ;]
|
Diagnostic
|
LNCaP Cells Vs prostate epithelial cells
|
p<0.05
|
Cell Lines
|
25307116
|
1588
|
XLOC_001699; XLOC_005327y; LOC400958; XLOC_008559y; LINC00340; XLOC_000495; RPS18; XLOC_012294; XLOC_l2_008560; XLOC_009911y;
|
LncRNA
|
Humans
|
Upregulated in PCa [Log2 (Tumor/Normal)]: [XLOC_001699 (4.3 fold) ; XLOC_005327y (4.1 fold); LOC400958 (3.9 fold); XLOC_008559y (3.7 fold) ; LINC00340 (3.6 fold) ; XLOC_000495 (3.6 fold) ; RPS18(3.3 fold) ; XLOC_012294 (3.3 fold); XLOC_l2_008560 (3.3 fold); XLOC_009911y (3.2 fold);
|
Diagnostic
|
Prostate Cancer Vs Adjacent Normal
|
p<0.05
|
Tissue
|
25307116
|
1589
|
SPRY4-IT1
|
LncRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Adjacent Normal
|
p<0.05
|
Tissue
|
25307116
|
1590
|
AK024556; XLOC_007697; LOC100287482; XLOC_005327; XLOC_008559; XLOC_009911;
|
LncRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Adjacent Normal
|
p<0.05
|
Urine
|
25307116
|
1591
|
uPA/PAI-1
|
Protein
|
Humans
|
Upregulated in PCa (PCa: 0.0479 ± 0.0060; BPH: (0.0332 ± 0.0023)
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p=0.0064
|
Tissue
|
25323935
|
1592
|
miRNA-483-5p
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Benign Vs Malignant
|
p=0.013
|
Urine
|
25445383
|
1593
|
miRNA-483-5p+ PSA
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Benign Vs Malignant
|
p=0.013
|
Urine
|
25445383
|
1595
|
Prostate Specific Antigen (PSA)
|
Protein
|
Humans
|
Upregulated in PCa [BPH: 7.2 (1.8-19.8); PCa: 7.7 (1.0-19.4)]
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p = 0.0407
|
Serum
|
26254378
|
1596
|
%fPSA
|
Protein
|
Humans
|
Downregulated in PCa [BPH: 16.7 (1.8-45.4); PCa:11.7 (4.1-31.7)]
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p<0.0001
|
Serum
|
26254378
|
1597
|
Prostate Health Index (phi)
|
Protein
|
Humans
|
Upregulated in PCa [BPH: 35.1 (13.1-155.6); PCa:61.6 (17.0-231.8)]
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p<0.0001
|
Serum
|
26254378
|
1598
|
−2proPSA
|
Protein
|
Humans
|
Upregulated in PCa [BPH: 16.0 (3.0-81.0); PCa: 21.0 (4.0-135.0)]
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p = 0.0004
|
Serum
|
26254378
|
1599
|
Methylation Status of IL-6
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.03
|
Blood
|
26265203
|
1600
|
Methylation Status of ICAM-1
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.02
|
Blood
|
26265203
|
1601
|
Methylation Status of IFN
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.02
|
Blood
|
26265203
|
1605
|
letâ€7c
|
miRNA
|
Humans
|
Downregulated in PCa (log 2 fold change: 0.7140)
|
Diagnostic
|
Prostate Cancer Vs Normal Adjacent
|
p<0.05
|
Tissue
|
31045265
|
1606
|
mir-145
|
miRNA
|
Humans
|
Downregulated in PCa (log 2 fold change: 0.4020)
|
Diagnostic
|
Prostate Cancer Vs Normal Adjacent
|
p<0.05
|
Tissue
|
31045265
|
1607
|
mir-221
|
miRNA
|
Humans
|
Downregulated in PCa (log 2 fold change: 0.5174)
|
Diagnostic
|
Prostate Cancer Vs Normal Adjacent
|
p<0.05
|
Tissue
|
31045265
|
1608
|
mir-21
|
miRNA
|
Humans
|
Upregulated in PCa (log 2 fold change: 0.6068)
|
Diagnostic
|
Prostate Cancer Vs Normal Adjacent
|
p<0.05
|
Tissue
|
31045265
|
1609
|
mir-182
|
miRNA
|
Humans
|
Upregulated in PCa (log 2 fold change: 0.8817)
|
Diagnostic
|
Prostate Cancer Vs Normal Adjacent
|
p<0.05
|
Tissue
|
31045265
|
1641
|
TGM4; SOSTDC1; MPO; SPRR1A; KLF4; RNU3B1; RNU3B3; RNU3B4; MT-ATP6; MT-ATP8; TMEM170A; LYNX1; IFNL3; PPP1R3G; GPR15; UGT2A3; MED13L; DNAJC10; NPY; XIST; LST1; WNT9A; LRRN3; GPR45; IFIT1; YWHAQ; KIR3DL1; EPPIN; CRLF1; MAL2; MAP3K15; H1FX;
|
mRNA
|
Mice
|
Upregulated in prostate cancer tissues compared with NA Pathway include: Genes were related to 12 pathways: (i) Aryl hydrocarbon receptor (AHR) signaling, (ii) Bone metamorphosis signaling, (iii) Wnt/GSK-3β signaling, (iv) Glucocorticoid receptor signaling, (v) Immune cell signaling, (vi) Gas signaling, (vii) iNOS signaling, (viii) Hypoxia signaling, (ix) Wnt/β-catenin signaling, (x) Cancer metastasis signaling (xi) p38MAPK signaling, and (xii) Oxidative phosphorylation TRAMP mice Vs Non-Transgenic Mice Diagnostic Twenty week old TRAMP mice and non-transgenic littermates tissues were harvested NA NA NA NA p<0.05 1640 Microarrays No NA NA Validated on human patient cohort
30972102 2019 TOX4; RPL38; LSM12; RPL5; HAX1; ALPI; TCTE3; RPL7; MRTO4; HDAC1; UBE2H; KRT26; TNFSF10; DPPA2; PNLDC1; MRPS11; PFDN6; STOML2; VDAC1; RPS8; TDGF1; UBE2E2; GKAP1; RPL10A; RPS15; UMOD; RPL9; RPL30; NPNT; NR1I2; KRTAP16-1; H3F3A; H3F3B; MRPL34; CSE1L; ST6GALNAC1; UBE2Q2; RPS17; RPL35; GMCL1; NIP7; MSL2; EIF4A1; LASP1; LUZP4; EIF1AD; TUBB3; RPL34; RPL17; RPL23; RPL28; KIR3DL2; LMO2; NA; AOC3; H2AFZ; RPL37; TMSB10; AMY2A; AMY2B; PPIA; PPIH; BEGAIN; NT5C3A; RPS28; RPL27; IL24; COPS9; NEK2; SOCS2; UBL5; UBE2D3; VHL; RPL23A; AICDA; LDHA; CNEP1R1; RPL29; SPCS1; RPL41; SP110; PMP22; ARCN1; UQCRB; SLC25A19; UBE2N; SNRPE; ACKR1; RPL21; LEFTY2; RPL31; RPL35A; RPL7A; RPL39; NACA; SP140; MRPL23; VDAC3; VDAC1P5; ATP5L; DIMT1; GMCL1P1; ARFGAP2; RPL22;' NA Expression Based mRNA Tissue Mice normal tissues
|
Diagnostic
|
TRAMP mice Vs Non-Transgenic Mice
|
p<0.05
|
Tissue
|
30972102
|
1642
|
ATP5L; ARFGAP2; DIMT1; GMCL1; MRPL34; RPL22; SP140; VDAC3
|
mRNA
|
Mice
|
Upregulated in Gleason Grade 5
|
Diagnostic
|
TRAMP mice Vs Non-Transgenic Mice
|
p<0.01
|
Tissue
|
30972102
|
1643
|
KLF4; MPO; SOStdc1; SPRR1A; TGM4
|
mRNA
|
Mice
|
Downregulated in TRAMP
|
Diagnostic
|
TRAMP mice Vs Non-Transgenic Mice
|
p<0.01
|
Tissue
|
30972102
|
1644
|
TNFSF; RPL22; EIF4; SLC2A; LMO2/3; KRT; RPS21; RPS19; RPL21; NEK; PPP1R3;
|
mRNA
|
Humans
|
Upregulated in TRAMP
|
Diagnostic
|
prostate cancer vs. benign prostate
|
p<0.05
|
Tissue
|
30972102
|
1645
|
GPR15; GPR45; TME; TGM4; KLF4; LRRN3; WNT; SPRR1A; TMEM;
|
mRNA
|
Humans
|
Upregulated in TRAMP
|
Diagnostic
|
prostate cancer vs. benign prostate
|
p<0.05
|
Tissue
|
30972102
|
1657
|
MMP2 (Matrix Metalloproteinase-2)
|
mRNA
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
p<0.05
|
Tissue
|
30917169
|
1658
|
BASP1 (Brain Abundant Membrane Attached Signal Protein 1)
|
mRNA
|
Humans
|
Downregulated in High Grade PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
p<0.05
|
Tissue
|
30917169
|
1659
|
SNHG6 (small nucleolar RNA host gene 6)
|
LncRNA
|
Humans
|
Upregulated in High Grade PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
p<0.05
|
Tissue
|
30911973
|
1663
|
SNHG6 (small nucleolar RNA host gene 6)
|
LncRNA
|
Humans
|
Upregulated in T2 PCa and T3+T4 PCa
|
Diagnostic
|
Normal Cell Lines Vs PCa Cell Lines
|
p<0.001
|
Cell Lines
|
30911973
|
1664
|
SNHG6 (small nucleolar RNA host gene 6)
|
LncRNA
|
Humans
|
Upregulated in GS 6,7,8,9+10
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
p<0.05
|
Tissue
|
30911973
|
1665
|
PLZF (Promyelocytic leukemia zinc finger protein)
|
Protein
|
Humans
|
High expression associated with shorter disease-free survival time
|
Diagnostic
|
Normal Vs Primary and Metastatic PCa
|
NA
|
Tissue
|
25807461
|
1666
|
tPSA
|
Protein
|
Humans
|
Upregulated in PCa Cell Lines
|
Diagnostic
|
PCa Vs No PCa
|
p<0.001
|
Serum
|
25847734
|
1667
|
%fPSA
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
PCa Vs No PCa
|
p<0.001
|
Serum
|
25847734
|
1668
|
p2PSA
|
Protein
|
Humans
|
Downregulated in Primary and Metastatic PCa
|
Diagnostic
|
PCa Vs No PCa
|
p<0.001
|
Serum
|
25847734
|
1669
|
%p2PSA
|
Protein
|
Humans
|
Upregulated in PCa (PCa: 6.7; No PCa: 6.01)
|
Diagnostic
|
PCa Vs No PCa
|
p<0.001
|
Serum
|
25847734
|
1670
|
PHI (Prostate Health Index)
|
Protein
|
Humans
|
Downregulated in PCa (PCa in %: 13.5; No PCa in %: 17.6)
|
Diagnostic
|
PCa Vs No PCa
|
p<0.001
|
Serum
|
25847734
|
1671
|
tPSA + fPSA
|
Protein
|
Humans
|
Upregulated in PCa (PCa: 14.92; No PCa: 11.79)
|
Diagnostic
|
PCa Vs No PCa
|
p<0.001
|
Serum
|
25847734
|
1672
|
tPSA + %fPSA
|
Protein
|
Humans
|
Downregulated in PCa (PCa in %: 20.5 ; No PCa in %: 15.5)
|
Diagnostic
|
PCa Vs No PCa
|
p<0.001
|
Serum
|
25847734
|
1673
|
fPSA + p2PSA
|
Protein
|
Humans
|
Upregulated in PCa (PCa: 48.62; No PCa: 33.35)
|
Diagnostic
|
PCa Vs No PCa
|
p<0.001
|
Serum
|
25847734
|
1674
|
%fPSA + %p2PSA
|
Protein
|
Humans
|
NA
|
Diagnostic
|
PCa Vs No PCa
|
p<0.001
|
Serum
|
25847734
|
1675
|
PSA + %fPSA + %p2PSA
|
Protein
|
Humans
|
NA
|
Diagnostic
|
PCa Vs No PCa
|
p<0.001
|
Serum
|
25847734
|
1687
|
TIMP1 (Tissue Inhibitor Of Metalloproteinase 1)
|
Protein
|
Humans
|
NA
|
Diagnostic
|
PCa Vs No PCa
|
p=0.003
|
Serum
|
25967040
|
1688
|
sE-Cadherin
|
Protein
|
Humans
|
NA
|
Diagnostic
|
PCa Vs No PCa
|
p<0.001
|
Serum
|
25967040
|
1689
|
Clusterin
|
Protein
|
Humans
|
NA
|
Diagnostic
|
PCa Vs No PCa
|
p=0.004
|
Serum
|
25967040
|
1690
|
MMP9
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
PCa Vs No PCa
|
p<0.001
|
Serum
|
25967040
|
1691
|
Galectin
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
PCa Vs No PCa
|
p=0.01
|
Serum
|
25967040
|
1694
|
TTTY15-USP9Y
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Positive Vs Negative Biopsy
|
p<0.001
|
Urine
|
26008593
|
1695
|
TTTY15-USP9Y + PSA
|
mRNA
|
Humans
|
Downregulated in Gleason Pattern 4 and 5
|
Diagnostic
|
Positive Vs Negative Biopsy
|
p<0.001
|
Urine
|
26008593
|
1696
|
TTTY15-USP9Y
|
mRNA
|
Humans
|
Downregulated in Gleason Upgrade Patients
|
Diagnostic
|
Positive Vs Negative Biopsy
|
p<0.001
|
Urine
|
26008593
|
1697
|
hsa-miR-518a
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p< 0.001
|
Urine
|
26126436
|
1698
|
hsa-miR-3605
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p=0.033
|
Urine
|
26126436
|
1699
|
hsa-miR-16
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p=0.04
|
Urine
|
26126436
|
1700
|
RUN6-2
|
miRNA
|
Humans
|
Downregulated in PCa (BPH: 4098.6; PCa: 2670.6)
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p< 0.001
|
Urine
|
26126436
|
1701
|
hsa-miR-615-3p
|
miRNA
|
Humans
|
Downregulated in PCa (BPH: 8842.4; PCa: 2781.7)
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p< 0.001
|
Urine
|
26126436
|
1702
|
hsv1-miR-H18
|
miRNA
|
Humans
|
Downregulated in PCa (BPH: 1030.7; PCa: 619.2)
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p< 0.001
|
Urine
|
26126436
|
1703
|
hsv2-miR-H9-5p
|
miRNA
|
Humans
|
Downregulated in PCa (BPH: 1030.7; PCa: 619.2)
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p< 0.001
|
Urine
|
26126436
|
1704
|
hsv1-miR-H18
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
Tissue, Urine: p<0.001; Serum: p=0.004
|
Tissue+Urine+Serum
|
26126436
|
1705
|
hsv2-miR-H9-5p
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
Tissue, Urine: p<0.001; Serum: p=0.002
|
Tissue+Urine+Serum
|
26126436
|
1706
|
hsa-miR-615-3p
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
Tissue: p<0.001;
|
Tissue+Urine+Serum
|
26126436
|
1707
|
hsa-miR-BARTA-4
|
miRNA
|
Humans
|
Upregulated in PCa (Tissue, Serum, Urine)
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
Tissue: p<0.001;
|
Tissue+Urine+Serum
|
26126436
|
1708
|
hsa-miR-4316
|
miRNA
|
Humans
|
Upregulated in PCa (Tissue, Serum, Urine)
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
Tissue: p<0.001; Urine: p=0.022
|
Tissue+Urine+Serum
|
26126436
|
1709
|
hsv1-miR-H18
|
miRNA
|
Humans
|
Upregulated in PCa (Tissue)
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p<0.05
|
Tissue+Urine
|
26126436
|
1710
|
hsv2-miR-H9-5p
|
miRNA
|
Humans
|
Upregulated in PCa (Tissue)
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p<0.05
|
Tissue+Urine
|
26126436
|
1714
|
TEP1 (Telomerase Associated Protein 1) [SNP: rs1760904 GG/AA]
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.003
|
Blood
|
26238235
|
1715
|
TEP1 (Telomerase Associated Protein 1) [SNP: rs1760904 AG/AA]
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.005
|
Blood
|
26238235
|
1720
|
FOXM1 (Forkhead Box M1)
|
Protein
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p<0.001
|
Tissue
|
30719174
|
1723
|
Zn/PSA
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.0001
|
Serum
|
30672309
|
1726
|
HA: Hyaluronic acid
|
Metabolites
|
Humans
|
Upregulated in PCa (PCa: 239.6 (145.1–357.7); No PCa: 150.8 (51.8–264.1))
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.004
|
Serum
|
30516927
|
1729
|
SERPINA5; MFSD2A; ACSL6; MCF2; EMX2; HOXB8; CLDN2; AKR1B1; SPINK2; CYP19A1;
|
mRNA
|
Humans
|
Upregulated in PCa: (PCa: 39.68 ± 30.00; No PCa: 15.04 ± 7.11)
|
Diagnostic
|
Prostate Cancer Vs Normal Adjacent
|
p<0.05
|
Tissue
|
30286759
|
1730
|
EMX2OS; LINC02137; LINC01116; LINC00839; AL161645.1; AC012123.1; AL354793.1; LINC02385; HOXBâ€AS3; AC005674.1;
|
LncRNA
|
Humans
|
Upregulated in High Risk PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Adjacent
|
p<0.05
|
Tissue
|
30286759
|
1731
|
hsaâ€mirâ€891a; hsaâ€mirâ€892a; hsaâ€mirâ€1224; hsaâ€mirâ€93; hsaâ€mirâ€23c; hsaâ€mirâ€1251; hsaâ€mirâ€204; hsaâ€mirâ€323b; hsaâ€mirâ€200c; hsaâ€mirâ€96;
|
miRNA
|
Humans
|
Downregulated after surgery (Before Surgery: 31.05 ± 21.01; After Surgery: 23.14 ± 11.1)
|
Diagnostic
|
Prostate Cancer Vs Normal Adjacent
|
p<0.05
|
Tissue
|
30286759
|
1733
|
Methylation Status of cg12799885
|
Methylation
|
Humans
|
Differentially Expressed [Log Fold Change: EMX2OS: (-5.98142); LINC02137 (-5.28623); LINC01116 (-3.59594); LINC00839: (- 4.30616); AL161645.1: (-4.9543); AC012123.1: (-4.63826); AL354793.1 (-5.45876); LINC02385: (-5.3465); HOXBâ€AS3 (-5.22943); AC005674.1: (-3.98991);]
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p < 0.001
|
Tissue
|
30866497
|
1734
|
Methylation Status of DOCK2
|
Methylation
|
Humans
|
Differentially Expressed [Log Fold Change: hsaâ€mirâ€891a (-4.8); hsaâ€mirâ€892a (-5.14); hsaâ€mirâ€1224 (-3.66); hsaâ€mirâ€93 (1.79); hsaâ€mirâ€23c (-2.96); hsaâ€mirâ€1251 (-2.76); hsaâ€mirâ€204 (-1.84); hsaâ€mirâ€323b (-2.31); hsaâ€mirâ€200c (1.58); hsaâ€mirâ€96 (1.98);]
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p < 0.001
|
Tissue
|
30866497
|
1735
|
Methylation Status of FBXO30
|
Methylation
|
Humans
|
Differentially Expressed [Log Fold Change: SERPINA5: (-6.78954); MFSD2A (− 5.97025); ACSL6: (− 4.99597); MCF2: (−5.26855); EMX2: (− 6.79059); HOXB8: (− 6.24965); CLDN2: (−7.91887); AKR1B1: (− 3.87736); SPINK2: (−7.41992); CYP19A1: (−5.40444;]
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p < 0.001
|
Tissue
|
30866497
|
1736
|
Methylation Status of GRASP
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p < 0.001
|
Tissue
|
30866497
|
1737
|
Methylation Status of HIF3A
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p < 0.001
|
Tissue
|
30866497
|
1738
|
Methylation Status of MOB3B
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p < 0.001
|
Tissue
|
30866497
|
1739
|
Methylation Status of PFKP
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p < 0.001
|
Tissue
|
30866497
|
1740
|
Methylation Status of TPM4
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p < 0.001
|
Tissue
|
30866497
|
1747
|
miR-1260
|
miRNA
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p=0.00001
|
Tissue
|
30250996
|
1748
|
miR-1274a
|
miRNA
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p=0.00001
|
Tissue
|
30250996
|
1759
|
AHNAK2; ANKRD30A; ANKRD36C; APOB; ATP13A5; BAI3; CACNA1A; CACNA1E; CDH23; CNTNAP5; EPB41L3; FAM47C; FAT2; FAT4 ;FBN3; FLG2; FRG1B; HSPG2; KMT2D; KRTAP4-9; LPHN3; MUC16; SACS; MUC4; SALL1; MYH11; SCN5A; MYT1L; SPOP; NOD1; SRCAP; PCDHA12; TP53; PIK3CA; TRPM6; PTEN; USH2A; PTH2; ZNF208; PTPRC; ZNF91;RYR1; MUC2;
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
NA
|
NA
|
29158798
|
1760
|
PSA concentration+Gleason grade+clinical T stage+ AHNAK2; ANKRD30A; ANKRD36C; APOB; ATP13A5; BAI3; CACNA1A; CACNA1E; CDH23; CNTNAP5; EPB41L3; FAM47C; FAT2; FAT4 ;FBN3; FLG2; FRG1B; HSPG2; KMT2D; KRTAP4-9; LPHN3; MUC16; SACS; MUC4; SALL1; MYH11; SCN5A; MYT1L; SPOP; NOD1; SRCAP; PCDHA12; TP53; PIK3CA; TRPM6; PTEN; USH2A; PTH2; ZNF208; PTPRC; ZNF91;RYR1; MUC2;
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
NA
|
NA
|
29158798
|
1762
|
miR-1825
|
miRNA
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p<0.001
|
Serum
|
30324582
|
1763
|
miR-484
|
miRNA
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p<0.001
|
Serum
|
30324582
|
1764
|
miR-205
|
miRNA
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p<0.001
|
Serum
|
30324582
|
1765
|
miR-141
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p<0.001
|
Serum
|
30324582
|
1766
|
let-7b
|
miRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p<0.001
|
Serum
|
30324582
|
1770
|
PCA3
|
mRNA
|
Humans
|
Upregulated in Stage T3-T4
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
NA
|
Blood
|
30334974
|
1771
|
hK2
|
mRNA
|
Humans
|
Downregulated in Stage T3-T4
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
NA
|
Blood
|
30334974
|
1772
|
miR-141
|
miRNA
|
Humans
|
Upregulated in Bone Metastasis
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
NA
|
Blood
|
30334974
|
1773
|
tPSA+ hK2+ PCA3+ miR-141
|
miRNA
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
NA
|
Blood
|
30334974
|
1774
|
Small HDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00070
|
Blood
|
30352818
|
1775
|
VLDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00056
|
Blood
|
30352818
|
1776
|
Cholesterol esters in medium LDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00058
|
Blood
|
30352818
|
1777
|
Cholesterol esters to total lipids ratio in medium LDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00062
|
Blood
|
30352818
|
1778
|
Cholesterol esters in small HDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00002
|
Blood
|
30352818
|
1779
|
Cholesterol esters to total lipids ratio in small HDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00111
|
Blood
|
30352818
|
1780
|
Cholesterol esters in small LDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00107
|
Blood
|
30352818
|
1781
|
Cholesterol esters to total lipids ratio in small LDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00139
|
Blood
|
30352818
|
1782
|
Free cholesterol in IDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00057
|
Blood
|
30352818
|
1783
|
Free cholesterol in large LDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00080
|
Blood
|
30352818
|
1784
|
Free cholesterol in medium LDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00060
|
Blood
|
30352818
|
1785
|
Free cholesterol to total lipids ratio in medium HDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00055
|
Blood
|
30352818
|
1786
|
Total cholesterol in HDL3
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00109
|
Blood
|
30352818
|
1787
|
Total cholesterol in medium LDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00095
|
Blood
|
30352818
|
1788
|
Total cholesterol to total lipids ratio in medium LDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00105
|
Blood
|
30352818
|
1789
|
Total cholesterol in small HDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p<0.00001
|
Blood
|
30352818
|
1790
|
Total cholesterol to total lipids ratio in small HDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00106
|
Blood
|
30352818
|
1791
|
Total cholesterol in small LDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00132
|
Blood
|
30352818
|
1792
|
Total cholesterol to total lipids ratio in small LDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00107
|
Blood
|
30352818
|
1793
|
Total cholesterol to total lipids ratio in small VLDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00105
|
Blood
|
30352818
|
1794
|
Phospholipids in IDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00092
|
Blood
|
30352818
|
1795
|
Phospholipids to total lipids ratio in medium LDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00046
|
Blood
|
30352818
|
1796
|
Phospholipids to total lipids ratio in medium VLDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p<0.00001
|
Blood
|
30352818
|
1797
|
Phospholipids in very small VLDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00103
|
Blood
|
30352818
|
1798
|
Phospholipids to total lipids ratio in very small VLDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00013
|
Blood
|
30352818
|
1799
|
Total lipids in small HDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00035
|
Blood
|
30352818
|
1800
|
Triglycerides to total lipids ratio in medium VLDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00064
|
Blood
|
30352818
|
1801
|
Triglycerides to total lipids ratio small VLDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00055
|
Blood
|
30352818
|
1802
|
Ratio of omega-6 Fatty Acids to total Fatty Acids
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00080
|
Blood
|
30352818
|
1803
|
Ratio of saturated Fatty acids to total Fatty acids
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00006
|
Blood
|
30352818
|
1804
|
Isoleucine
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00008
|
Blood
|
30352818
|
1805
|
Leucine
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00027
|
Blood
|
30352818
|
1806
|
Tyrosine
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00003
|
Blood
|
30352818
|
1807
|
Valine
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00139
|
Blood
|
30352818
|
1808
|
Albumin
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00065
|
Blood
|
30352818
|
1809
|
AMACR (Alpha methylacyl A coenzyme racemase)
|
Protein
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
NA
|
Semen
|
30337219
|
1810
|
AMACR (Alpha methylacyl A coenzyme racemase) + Age
|
Protein
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
NA
|
Semen
|
30337219
|
1811
|
PHI (Prostate Health Index)
|
Protein
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
NA
|
Serum
|
30926382
|
1812
|
PHID (Prostate Health Index Density)
|
Protein
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
NA
|
Serum
|
30926382
|
1813
|
APC; HOXD3; TGFβ2; GSTP1; KLK10
|
Methylation
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs Benign
|
p<0.05
|
Urine
|
30470249
|
1814
|
APC
|
Methylation
|
Humans
|
NA
|
Diagnostic
|
Benign Vs High CAPRA Score
|
p<0.01
|
Urine
|
30470249
|
1815
|
HOXD3
|
Methylation
|
Humans
|
NA
|
Diagnostic
|
Benign Vs High CAPRA Score
|
p<0.01
|
Urine
|
30470249
|
1816
|
TGFβ2
|
Methylation
|
Humans
|
Methylated in PCa
|
Diagnostic
|
Benign Vs High CAPRA Score
|
p<0.05
|
Urine
|
30470249
|
1817
|
GSTP1
|
Methylation
|
Humans
|
Methylated in PCa
|
Diagnostic
|
Benign Vs High CAPRA Score
|
p<0.01
|
Urine
|
30470249
|
1818
|
KLK10
|
Methylation
|
Humans
|
Methylated in PCa
|
Diagnostic
|
Benign Vs High CAPRA Score
|
p<0.001
|
Urine
|
30470249
|
1819
|
TBX15
|
Methylation
|
Humans
|
Methylated in PCa
|
Diagnostic
|
Benign Vs High CAPRA Score
|
p<0.05
|
Urine
|
30470249
|
1820
|
HOXD3+GSTP1
|
Methylation
|
Humans
|
Methylated in PCa
|
Diagnostic
|
Benign Vs High CAPRA Score
|
p<0.001
|
Urine
|
30470249
|
1821
|
AMBP; (cDNA FLJ50830, highly similar to AMBP); (unnamed protein product); (Isoform 2 of Calmodulin-regulated spectrin-associated protein 1-like 1 (CAMSAP1L1); cDNA FLJ51445, highlysimilar to AMBP protein; Ribosomal RNA upstream binding transcription factor (Fragment, UBTF); Basementmembrane-specific heparan sulfate proteoglycan coreprotein (HSPG2); Ferritin heavy chain (FTH1); Transthyretin; 13 kDa protein; Unknown (protein for IMAGE:3934797); Putative beta-actin-like protein 3 F7 Factor VII active sitemutant immunoconjugate; C11orf54 Aminoacylase-1 (ACY1); Ferritin Light chain (FTL) Coactosin-like protein (COTL1);
|
Protein
|
Humans
|
Methylated in PCa
|
Diagnostic
|
Prostate Cancer Vs Controls and Benign Prostatic Hyperplasia
|
p<0.05
|
Urine
|
30610587
|
1839
|
HEATR5B (HEAT repeat containing 5B); DDC (Dopa decarboxylase, transcript variant 6); TAS1R3 (Taste 1 receptor member 3); XIAP (X-linked inhibitor of apoptosis, transcript variant 2);
|
mRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Adjacent
|
p<0.05
|
Tissue
|
30890858
|
1840
|
GABPB1-AS1 (GABPB1 antisense RNA 1); DDC (Dopa decarboxylase, transcript variant 6); HEATR5B (HEAT repeat containing 5B); CARD11 (Caspase recruitment domain family member 11, transcript variant 2);
|
mRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Adjacent
|
p<0.05
|
Tissue
|
30890858
|
1841
|
GABPB1-AS1 (GABPB1 antisense RNA 1); KRT5 (Keratin 5); NCS1 (Neuronal calcium sensor 1, transcript variant 2); COL17A1 ( Collagen type XVII alpha 1 chain); ANXA1 (Annexin A1); LGALS3BP (Galectin 3 binding protein);
|
mRNA
|
Humans
|
Downregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Adjacent
|
p<0.05
|
Tissue
|
30890858
|
1849
|
miR-30c-5p
|
miRNA
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p<0.05
|
Urine
|
30728149
|
1850
|
miR- 222-3p*+ miR-24-3p+ miR-30c-5p
|
miRNA
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p<0.05
|
Urine
|
30728149
|
1851
|
miR- 222-3p*+ miR-24-3p+ miR-30c-5p+PSA
|
miRNA
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
p<0.05
|
Urine
|
30728149
|
1852
|
miR-425-5p
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Adjacent Normal
|
p<0.001
|
Tissue
|
30720162
|
1853
|
miR-425-5p
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Adjacent Normal
|
p<0.001
|
Cell Lines
|
30720162
|
1858
|
PDGF-BB (Platelet Derived Growth Factor-BB)
|
Protein
|
Humans
|
Upregulated in Recurrent PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.04
|
Urine
|
30374275
|
1859
|
PDGF-BB/Cr (Platelet Derived Growth Factor-BB/creatinine)
|
Protein
|
Humans
|
Upregulated in Recurrent PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.016
|
Urine
|
30374275
|
1860
|
Promoter methylation of: miR-193b+ miR-34b/c
|
Methylation
|
Humans
|
Upregulated in Recurrent PCa
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p<0.05
|
Tissue
|
30373654
|
1861
|
Methlyation Status of APC, GSTP1 RARβ2
|
Methylation
|
Humans
|
Upregulated in PCa (Non PCa: 1504.7 Vs PCa: 1657.1)
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p<0.05
|
Tissue
|
30373654
|
1862
|
Promoter methylation of: miR-193b+ miR-34b/c
|
Methylation
|
Humans
|
Upregulated in PCa (Non PCa: 1504.7 Vs PCa: 1657.1)
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p<0.05
|
Urine
|
30373654
|
1863
|
Methlyation Status of APC, GSTP1 RARβ2
|
Methylation
|
Humans
|
Methylated in PCa
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p<0.05
|
Urine
|
30373654
|
1864
|
Methlyation Status of APC, GSTP1 RARβ2
|
Methylation
|
Humans
|
Methylated in PCa
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p<0.05
|
Urine
|
30373654
|
1875
|
KNG1 (Kininogen-1);
|
Protein
|
Humans
|
Methylated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic hyperplasia
|
p<0.05
|
Urine
|
30237853
|
1882
|
Keratin, type II cytoskeletal 2 epidermal; Serum amyloid Pâ€component;Keratin, type II cytoskeletal 1; Keratin, type I cytoskeletal 9; Isoform 2 of Filamin A; Isoform 3 of Vitamin Dâ€binding protein; Ig kappa chain Vâ€II region Cum; soform 2 of Eukaryotic translation initiation 1.8 factor 2â€alpha kinase 4; Ig alphaâ€1 chain C region; Afamin;
|
Protein
|
Humans
|
Increased in Progression Free survival
|
Diagnostic
|
Prostate Cancer in African American Men Vs Normal African American Men
|
p<0.05
|
Serum
|
30623593
|
1883
|
Complement component C8 alpha chain; Apolipoprotein Aâ€I; Plasminogen; Complement component C7;Isoform 2 of Interâ€alphaâ€trypsin inhibitor heavy chain H4;Interâ€alphaâ€trypsin inhibitor heavy chain H1; Complement C1s subcomponent; Ig heavy chain Vâ€III region BRO; Ig gammaâ€2 chain C region; Ig gammaâ€3 chain C region;
|
Protein
|
Humans
|
Decreased in Progression Free Survival
|
Diagnostic
|
Prostate Cancer in African American Men Vs Normal African American Men
|
p<0.05
|
Serum
|
30623593
|
1884
|
Complement component C8 alpha chain; Apolipoprotein Aâ€I; Plasminogen; Complement component C7;Isoform 2 of Interâ€alphaâ€trypsin inhibitor heavy chain H4;Interâ€alphaâ€trypsin inhibitor heavy chain H1; Complement C1s subcomponent; Ig heavy chain Vâ€III region BRO; Ig gammaâ€2 chain C region; Ig gammaâ€3 chain C region;
|
Protein
|
Humans
|
Decreased in Overall Survival
|
Diagnostic
|
Prostate Cancer in Caucasian American Men Vs Normal Caucasian American Men
|
p<0.05
|
Serum
|
30623593
|
1885
|
SCOâ€spondin; Complement component C7;Isoform 2 of Ankyrin repeat and SOCS box protein 18; Gelsolin; Serum amyloid Pâ€component; g heavy chain Vâ€I region V35; Complement C1q subcomponent subunit C; Complement component C8 alpha chain; Isoform 2 of Filamin A; Inter-alpha trypsin inhibitor heavy chain H2;
|
Protein
|
Humans
|
Upregulated in PCa (Keratin, type II cytoskeletal 2 epidermal (64 fold); Serum amyloid Pâ€component (39 fold) ;Keratin, type II cytoskeletal 1 (13 fod) ; Keratin, type I cytoskeletal 9 (12 fold) ; Isoform 2 of Filamin A (2.6 fold) ; Isoform 3 of Vitamin Dâ€binding protein (2.4 fold); Ig kappa chain Vâ€II region Cum (2.4 fold) ; Isoform 2 of Eukaryotic translation initiation 1.8 factor 2â€alpha kinase 4 (1.8 fold) ; Ig alphaâ€1 chain C region (1.7 fold) ; Afamin (1.5 fold);
|
Diagnostic
|
Prostate Cancer in Caucasian American Men Vs Normal Caucasian American Men
|
p<0.05
|
Serum
|
30623593
|
1886
|
Isoform 2 of Eukaryotic translation initiation factor 2â€alpha kinase 4; Keratin type I cytoskeletal 10; SCO†spondin; Serum amyloid Pâ€component; Apolipoprotein(a); Keratin, type I cytoskeletal 9; Ig kappa chain Vâ€IV region; Isoform 2 of Filamin A; Keratin, type II cytoskeletal 1; Keratin, type II cytoskeletal 2 epidermal;
|
Protein
|
Humans
|
Downregulated in PCa [Complement component C8 alpha chain (0.07 fold); Apolipoprotein Aâ€I (0.04 fold); Plasminogen (0.08 fold); Complement component C7 (0.1 fold); Isoform 2 of Interâ€alphaâ€trypsin inhibitor heavy chain H4 (0.2 fold); Interâ€alphaâ€trypsin inhibitor heavy chain H1 (0.2 fold); Complement C1s subcomponent (0.2 fold); Ig heavy chain Vâ€III region BRO (0.2 fold); Ig gammaâ€2 chain C region (0.2 fold); Ig gammaâ€3 chain C region (0.2 fold);]
|
Diagnostic
|
African American men with PCa (PAA) Vs Caucasian men with PCa (PCC)
|
p<0.05
|
Serum
|
30623593
|
1887
|
Ig heavy chain Vâ€III region BRO; Alphaâ€1â€antitrypsin; Plasminogen (0.1†fold); Ig heavy chain Vâ€III region TIL, Hemopexin; Afamin; Interâ€alphaâ€trypsin inhibitor heavy chain H1; Protein AMBP; Alphaâ€1Bâ€glycoprotein; Complement component C8 alpha chain;
|
Protein
|
Humans
|
Upregulated in PCa [Alphaâ€1â€acid glycoprotein 1 (13.6â€fold); Alphaâ€1Bâ€glycoprotein (11.6â€fold); von Willebrand factor (5.0â€fold); Ig heavy chain Vâ€II region NEWM (6.0â€fold); Ig heavy chain Vâ€III region BRO (5.7â€fold); Afamin (5.4â€fold); Apolipoprotein Aâ€I (4.9â€fold); Isoform 3 of Vitamin Dâ€binding protein (4.3â€fold); Complement C1r subcomponent (4.3†fold); Angiotensinogen (4.1â€fold);
|
Diagnostic
|
African American men with PCa (PAA) Vs Caucasian men with PCa (PCC)
|
p<0.05
|
Serum
|
30623593
|
1888
|
4-(3,4-dihydro-2,2,4-trimethyl-2H-1-benzopyran-4-yl)-phenol; Estradiol; Ethyl à-hydroxymyristate trisiloxane; 1-(2,4-Dimethylphenyl)-3-(tetrahydrofuryl-2)propane; 2-amino-Imidazole-5-carboxylic acid; 1,1,3,3,5,5,7,7,9,9-decamethyl-pentasiloxane; 1,1,1,5,5,5-hexamethyl-3,3-bis[(trimethylsilyl)oxy]-Trisiloxane; Phthalic acid, bis(7-methyloctyl) ester; 4-Nitro-4’-chlorodiphenylsulfoxide; 1-Propylpentachlorotriphosphazene; 2,6-di-t-butyl-4-hydroxymethylene-2,3,5,6-detetrahydrocyclohexanone
|
Metabolites
|
Humans
|
Downregulated in PCa [SCOâ€spondin (0.1 fold); Complement component C7 (0.1â€fold); Isoform 2 of Ankyrin repeat and SOCS box protein 18 (0.3â€fold); Gelsolin (0.3â€fold); Serum amyloid P-component (0.4â€fold); Ig heavy chain Vâ€I region V35 (0.5â€fold); Complement C1q subcomponent subunit C (0.5â€fold); Complement component C8 alpha chain (0.6â€fold); Isoform 2 of Filamin A (0.6â€fold); and Inter-alpha-trypsin inhibitor heavy chain H2 (0.7â€fold);]
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p<0.05
|
Urine
|
30853355
|
1910
|
HSP27; prohibitin; GSTP1; fibrinogen β chain; ALDH6A1; A1AT; HSP60;
|
Protein
|
Humans
|
Downregulated in Metastatic PCa
|
Diagnostic
|
Metastatic Prostate Cancer Vs No Prostate Cancer
|
NA
|
Tissue
|
30396985
|
1917
|
CAV1; TP53; MAGEA11; CALM1; EGFR; UBE2I; CALR; SMAD3; FHL2; HDAC1; APP; MYC; JUN; ESR1; GNB2L1; HIPK3; SMAD2; APPBP2; CDC2; BRCA1; RB1; SMAD1;PXN; XRCC6; IL6ST; STAT3; DLG1; AES; TRAF6; FLNA; TRIM29; PCAF; REPS2; AKT1; PRKCA; RAF1; HLA-B; TRAF2; SMARCA4; MAPK1; CHGB; RANBP9; CCND1; GSK3B; HSPA1A; BCL2; VCL; RAI17; TGFBR1; SELENBP1;
|
Protein
|
Humans
|
Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);]Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);]
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
NA
|
Tissue
|
22654636
|
1919
|
miR-17*
|
miRNA
|
Humans
|
Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);]
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic hyperplasia
|
p=0.040
|
Serum
|
25786615
|
1920
|
miR-200b*
|
miRNA
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic hyperplasia
|
p=0.045
|
Serum
|
25786615
|
1921
|
miR-210
|
miRNA
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic hyperplasia
|
p=0.003
|
Serum
|
25786615
|
1922
|
miR-297
|
miRNA
|
Humans
|
Upregulated in PCa [mean PC/mean]: (2.27 fold)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic hyperplasia
|
p=0.031
|
Serum
|
25786615
|
1923
|
miR-375
|
miRNA
|
Humans
|
Upregulated in PCa [mean PC/mean]: (2.13 fold)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic hyperplasia
|
p=0.009
|
Serum
|
25786615
|
1924
|
miR-501-3p
|
miRNA
|
Humans
|
Upregulated in PCa [mean PC/mean]: (2.02 fold)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic hyperplasia
|
p=0.015
|
Serum
|
25786615
|
1925
|
miR-551b
|
miRNA
|
Humans
|
Upregulated in PCa [mean PC/mean]: (2.30 fold)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic hyperplasia
|
p=0.017
|
Serum
|
25786615
|
1926
|
miR-562
|
miRNA
|
Humans
|
Upregulated in PCa [mean PC/mean]: (14.66 fold)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic hyperplasia
|
p=0.01
|
Serum
|
25786615
|
1927
|
miR-562+ miR-210
|
miRNA
|
Humans
|
Upregulated in PCa [mean PC/mean]: (2.12 fold)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic hyperplasia
|
NA
|
Serum
|
25786615
|
1928
|
miR-562+ miR-210+ miR-501-3p
|
miRNA
|
Humans
|
Upregulated in PCa [mean PC/mean]: (17.39 fold)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic hyperplasia
|
NA
|
Serum
|
25786615
|
1929
|
miR-562+ miR-210+ miR-501-3p+ miR-375
|
miRNA
|
Humans
|
Upregulated in PCa [mean PC/mean]: (2.72 fold)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic hyperplasia
|
NA
|
Serum
|
25786615
|
1930
|
miR-562+ miR-210+ miR-501-3p+ miR-375+ miR551b
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic hyperplasia
|
NA
|
Serum
|
25786615
|
1943
|
Methylation status of A0X1
|
Methylation
|
Humans
|
Upregulated in PCa [mean PC/mean]: (2.34 fold)
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1944
|
Methylation status of CYBA
|
Methylation
|
Humans
|
Upregulated in PCa [mean PC/mean]: (2.34 fold)
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1945
|
Methylation status of EDG3
|
Methylation
|
Humans
|
Upregulated in PCa [mean PC/mean]: (2.34 fold)
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1946
|
Methylation status of ELF4
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1947
|
Methylation status of EPB41L3
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1948
|
Methylation status of FLJ12056
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1949
|
Methylation status of FLJ90650
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1950
|
Methylation status of FLT4
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1951
|
Methylation status of GAS6
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1952
|
Methylation status of GRASP
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1953
|
Methylation status of GSTP1
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1954
|
Methylation status of HAAO
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1955
|
Methylation status of HIF3A
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1956
|
Methylation status of HOXC11
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1957
|
Methylation status of LEP
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1958
|
Methylation status of MGC39606
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1959
|
Methylation status of MOBKL2B
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1960
|
Methylation status of RAB34
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1961
|
Methylation status of RARb
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1962
|
Methylation status of RHCG
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1963
|
Methylation status of RND2
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1964
|
Methylation status of SLC34A2
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1965
|
Methylation status of SPATA6
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1966
|
Methylation status of TPM4
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
1967
|
Methylation status of ZNF154
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
2025
|
LPC(18∶1)
|
Metabolites
|
Humans
|
Methylated in systemic Recurrence
|
Diagnostic
|
Patients Vs Controls
|
2.63E-09
|
Plasma
|
23152813
|
2026
|
LPC(20∶4)
|
Metabolites
|
Humans
|
Methylated in systemic Recurrence
|
Diagnostic
|
Patients Vs Controls
|
1.71E-15
|
Plasma
|
23152813
|
2027
|
PC(40∶7)
|
Metabolites
|
Humans
|
Methylated in systemic Recurrence
|
Diagnostic
|
Patients Vs Controls
|
4.37E-11
|
Plasma
|
23152813
|
2028
|
LPC(18∶0)
|
Metabolites
|
Humans
|
Upregulated with fold change of 2.7
|
Diagnostic
|
Patients Vs Controls
|
3.00E-08
|
Plasma
|
23152813
|
2029
|
LPC(16∶0)
|
Metabolites
|
Humans
|
Upregulated with fold change of 3.2
|
Diagnostic
|
Patients Vs Controls
|
2.03E-06
|
Plasma
|
23152813
|
2030
|
ePC(38∶4)
|
Metabolites
|
Humans
|
Upregulated with fold change of 2.2
|
Diagnostic
|
Patients Vs Controls
|
3.01E-08
|
Plasma
|
23152813
|
2031
|
PC(38∶4)
|
Metabolites
|
Humans
|
Upregulated with fold change of 2.5
|
Diagnostic
|
Patients Vs Controls
|
3.65E-05
|
Plasma
|
23152813
|
2032
|
PC(38∶5)
|
Metabolites
|
Humans
|
Upregulated with fold change of 2.8
|
Diagnostic
|
Patients Vs Controls
|
8.50E-06
|
Plasma
|
23152813
|
2033
|
SM(18∶1)
|
Metabolites
|
Humans
|
Upregulated with fold change of 2.1
|
Diagnostic
|
Patients Vs Controls
|
1.05E-09
|
Plasma
|
23152813
|
2034
|
SM(16∶1)
|
Metabolites
|
Humans
|
Upregulated with fold change of 2.1
|
Diagnostic
|
Patients Vs Controls
|
6.71E-09
|
Plasma
|
23152813
|
2035
|
DSM(16∶0)
|
Metabolites
|
Humans
|
Upregulated with fold change of 2.2
|
Diagnostic
|
Patients Vs Controls
|
3.85E-19
|
Plasma
|
23152813
|
2036
|
SM(16∶0)
|
Metabolites
|
Humans
|
Upregulated with fold change of 3
|
Diagnostic
|
Patients Vs Controls
|
1.20E-06
|
Plasma
|
23152813
|
2037
|
ePC(36∶1)
|
Metabolites
|
Humans
|
Upregulated with fold change of 2.5
|
Diagnostic
|
Patients Vs Controls
|
6.30E-10
|
Plasma
|
23152813
|
2038
|
SM(18∶0)
|
Metabolites
|
Humans
|
Upregulated with fold change of 22.7
|
Diagnostic
|
Patients Vs Controls
|
1.72E-06
|
Plasma
|
23152813
|
2039
|
ePC(36∶2)
|
Metabolites
|
Humans
|
Upregulated with fold change of 2.5
|
Diagnostic
|
Patients Vs Controls
|
1.72E-07
|
Plasma
|
23152813
|
2040
|
LPC(18:1)+LPC(20:4)
|
Metabolites
|
Humans
|
Upregulated with fold change of 2.4
|
Diagnostic
|
Patients Vs Controls
|
<0.001
|
Plasma
|
23152813
|
2041
|
LPC(18:1)+LPC(20:4)+PC(40:7)
|
Metabolites
|
Humans
|
Upregulated with fold change of 2.8
|
Diagnostic
|
Patients Vs Controls
|
<0.001
|
Plasma
|
23152813
|
2042
|
LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)
|
Metabolites
|
Humans
|
Upregulated with fold change of 2
|
Diagnostic
|
Patients Vs Controls
|
<0.001
|
Plasma
|
23152813
|
2043
|
LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)
|
Metabolites
|
Humans
|
Upregulated with fold change of more than 2
|
Diagnostic
|
Patients Vs Controls
|
<0.001
|
Plasma
|
23152813
|
2044
|
LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4)
|
Metabolites
|
Humans
|
Upregulated with fold change of more than 3
|
Diagnostic
|
Patients Vs Controls
|
<0.001
|
Plasma
|
23152813
|
2045
|
LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4)+PC(38:4)
|
Metabolites
|
Humans
|
Upregulated with fold change of more than 4
|
Diagnostic
|
Patients Vs Controls
|
<0.001
|
Plasma
|
23152813
|
2046
|
LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4)+PC(38:4)+PC(38:5)
|
Metabolites
|
Humans
|
Upregulated with fold change of more than 5
|
Diagnostic
|
Patients Vs Controls
|
<0.001
|
Plasma
|
23152813
|
2047
|
LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4)+PC(38:4)+PC(38:5)+SM(18:1)
|
Metabolites
|
Humans
|
Upregulated with fold change of more than 6
|
Diagnostic
|
Patients Vs Controls
|
<0.001
|
Plasma
|
23152813
|
2048
|
LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4)+PC(38:4)+PC(38:5)+SM(18:1)+SM(16:1)
|
Metabolites
|
Humans
|
Upregulated with fold change of more than 7
|
Diagnostic
|
Patients Vs Controls
|
<0.001
|
Plasma
|
23152813
|
2049
|
LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4)+PC(38:4)+PC(38:5)+SM(18:1)+SM(16:1)+DSM(16:0)
|
Metabolites
|
Humans
|
Upregulated with fold change of more than 8
|
Diagnostic
|
Patients Vs Controls
|
<0.001
|
Plasma
|
23152813
|
2050
|
LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4)+PC(38:4)+PC(38:5)+SM(18:1)+SM(16:1)+DSM(16:0)+SM(16:0)
|
Metabolites
|
Humans
|
Upregulated with fold change of more than 9
|
Diagnostic
|
Patients Vs Controls
|
<0.001
|
Plasma
|
23152813
|
2051
|
LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4)+PC(38:4)+PC(38:5)+SM(18:1)+SM(16:1)+DSM(16:0)+SM(16:0)+ePC(36:1)
|
Metabolites
|
Humans
|
Upregulated with fold change of more than 10
|
Diagnostic
|
Patients Vs Controls
|
<0.001
|
Plasma
|
23152813
|
2052
|
LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4)+PC(38:4)+PC(38:5)+SM(18:1)+SM(16:1)+DSM(16:0)+SM(16:0)+ePC(36:1)+SM(18:0)
|
Metabolites
|
Humans
|
Upregulated with fold change of more than 11
|
Diagnostic
|
Patients Vs Controls
|
<0.001
|
Plasma
|
23152813
|
2053
|
LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4)+PC(38:4)+PC(38:5)+SM(18:1)+SM(16:1)+DSM(16:0)+SM(16:0)+ePC(36:1)+SM(18:0)+ePC(36:2)
|
Metabolites
|
Humans
|
Upregulated with fold change of more than 12
|
Diagnostic
|
Patients Vs Controls
|
<0.001
|
Plasma
|
23152813
|